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Hemolytic disease of the fetus and newborn (HDFN), in earlier times known as 
erythroblastosis fetalis, is a condition in which fetal and neonatal red cells are destructed 
by the action of IgG antibodies derived from the mother by placental transfer. Maternal 
alloimmunization usually occurs after fetal-maternal hemorrhage at the time of delivery or 
during pregnancy when fetal red cells which express paternally derived antigens enter the 
maternal circulation.1 In contrast to fetal and neonatal alloimmune thrombocytopenia, first 
pregnancies in HDFN are usually not affected because fetomaternal hemorrhage is too small 
or too late to cause formation of IgG antibodies.1,2 Maternal immunization may also result 
from a blood transfusion and partly for that reason primigravida can still be affected.3  
Over 50 red blood cell antigens can cause HDFN, however only Rh D, Kell (K1) and Rh c 
alloimmunization are frequently associated with severe fetal disease.4 When fetal disease is 
left untreated, this can lead to progressive fetal anemia, fetal hydrops and fetal death. Fetal 
hydrops consists of abnormal fluid accumulation in fetal compartments, including ascites, 
pleural effusion, pericardial effusion, and skin edema. It is assumed that immune fetal 
hydrops results from congestive heart failure due to severe anemia.5-7
After birth, placental transfer of antibodies stops, but already derived antibodies can remain 
in the circulation for several months. As a consequence, hemolysis continues leading to 
neonatal hyperbilirubinemia and anemia which can be present up to three months of 
age.8 Hyperbilirubinemia is usually not present in the fetal period because fetal bilirubin is 
transferred through the placenta and excreted by the mother. Neonatal hyperbilirubinemia 
arises from a transient deficiency of conjugation in the liver (exacerbated in premature 
neonates) and increased red cell turnover.9 
HDFN is a complex disorder and disease severity seems to depend on many factors. 
These factors include: concentration, specificity, subclass, and glycosylation of antibodies; 
density, structure, and tissue distribution of antigens; efficiency of placental transport; 
functional maturity of the fetal spleen; macrophage Fc receptor function and the presence 
of HLA-related inhibitory antibodies.10 In Kell HDFN for example, hyperbilirubinemia is 
usually not severe because anti-Kell antibodies cause suppression of erythropoiesis rather 
than hemolysis of erythrocytes.11-13
Prevalence
The exact prevalence of HDFN is difficult to determine because it depends on how HDFN is 
defined and the population in which it is measured. Reported prevalence of severe HDFN 
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varies from 3/100.000 to 80/100.000 pregnancies in developed countries.14 In low income 
countries, prevalence of Rh negativity is lower than in North America and Europe. However, 
from data from three low income countries it is estimates that the prevalence of Rh HDFN 
varies from around 200/100.000 to around 340/100.000 births. In those countries there is a 
lack of Rh D prophylaxis leading to more neonates at risk.15
Prevention
Primary prevention of HDFN consists of extended matching of red blood cell (RBC) 
transfusions and the administration of Rh D immunoprophylaxis. In addition to ABO and 
Rh D matching of RBC transfusions, Dutch guidelines recommend matching for K, Rh c and 
Rh E for women below 45 years of age.16 However, in many other countries this extensive 
matching is not routine practice. Rh D immunoprophylaxis has been licensed in Europe 
and North America since 1968. As a consequence, Rh D immunization rate decreased from 
13.2% to 0.14% per Rh D positive pregnancy in Rh D negative mothers.17 Nevertheless, 
maternal sensitization from fetomaternal hemorrhages will continue due to insufficient 
administration of Rh D immunoprophylaxis and the unavailability of immunoprophylaxis to 
prevent sensitization to non-Rh D antigens.
Antenatal management
Fetuses at risk are identified by maternal antibody screening and titration, determination 
of paternal antigen status, and determination of fetal antigen status.18 The latter can be 
done by amniocentesis or noninvasively using free fetal DNA in maternal plasma. This 
noninvasive fetal blood group typing was first reported by Lo et al. in 1998.19 Fetuses at risk 
were used to be monitored by amniotic fluid bilirubin measurements and cordocentesis 
to determine fetal anemia. However, currently noninvasive detection of fetal anemia by 
Doppler assessments of peak systolic velocity in the fetal middle cerebral artery is used 
predominantly.20-22 
Treatment of fetal anemia by intrauterine intraperitoneal RBC transfusion was introduced 
in 1963.23 In the 1980s intravascular transfusion via umbilical vessels became practice.24,25 
With improvement of this intravascular technique, nowadays overall perinatal survival 
rates in experienced centers vary between 89% and 92%.26,27 Other proposed antenatal 
treatment options include maternal or fetal administration of intravenous immunoglobulin 
and maternal administration of phenobarbital.29-32 However, further studies are needed to 




After birth, diagnosis of HDFN can be confirmed by blood group and Rh typing, measuring 
antibodies and bilirubin, and performing direct antibody (Coombs’) test.33 
Neonatal treatment of HDFN mainly consists of treatment of hyperbilirubinemia with 
phototherapy and exchange transfusion and correction of anemia. Severe (unconjugated) 
hyperbilirubinemia can lead to acute bilirubin encephalopathy and chronic bilirubin 
encephalopathy, also known as kernicterus.34 Phototherapy, which was introduced in the 
1970s, can prevent severe hyperbilirubinemia by photo-oxidation of bilirubin in the skin 
which converts it to a water-soluble substance. In the late 1940s treatment of neonatal 
hyperbilirubinemia with exchange transfusion (ET) was introduced.35 ET not only removes 
bilirubin from the circulation to prevent kernicterus, but also maternal antibodies limiting 
further hemolysis. In addition, ET also corrects the associated anemia. ET is a high-risk 
invasive procedure and several alternative treatment options have been studied to reduce 
the need for ET, including intravenous immunoglobulin (IVIg), albumin, phenobarbarbital 
and metalloporphyrins. The use of the latter three options is not recommended since there 
is not sufficient evidence.34 A Cochrane review on the use of IVIg in neonates with HDFN 
in 2002 concluded that IVIg was effective in reducing ET requirements. However, authors 
commented that evidence was limited due to small size and low quality of the studies and 
that routine use cannot be recommended.34,36 Despite this advice, the guidelines of the 
American Academy of Pediatrics of 2004 advocate the routine use of IVIg in neonates with 
HDFN and consequently the use of it became widespread.33,34 
Top-up transfusions, also known as simple or RBC transfusions, are used to treat anemia 
up to three months of age. In addition, several medicaments are used to stimulate 
erythropoiesis. These treatment options and the management of other hematological 
complications of HDFN are reviewed in this thesis. 
Outline of the thesis
The Leiden University Medical Center (LUMC) is a tertiary center and the national referral 
center for intrauterine treatment of pregnancies complicated by red cell alloimmunization. 
Yearly around 35 neonates with HDFN due to red cell alloimmunization are admitted to the 
neonatal intensive care unit in the LUMC.
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Implementation of Rhesus (D) immunoprophylaxis in 1965 has led to a drastic decrease 
in incidence of hemolytic disease of the fetus and newborn (HDFN). Nevertheless, due to 
failure of pregnant women to obtain the prophylaxis and in a minor extent due to failure of 
the prophylaxis itself, anti-D is still the most commonly implicated antibody in HDFN. Other 
clinically relevant antibodies associated with severe HDFN are anti-Kell and anti-c.1  
Antenatal management of HDFN is based on the treatment of fetal anemia and prevention 
of fetal hydrops with intrauterine red cell transfusions (IUT). Since the introduction 
of IUT in 1963 by Sir William Liley, perinatal survival in HDFN has nowadays increased 
up to 90%.2 Postnatal management in neonates with HDFN is based on the treatment 
of hyperbilirubinemia and prevention of kernicterus and includes mainly the use of 
phototherapy and exchange transfusions. In the last decade the use of intravenous 
immunoglobulin (IVIg) is increasingly being advocated. Postnatal treatment also consists 
of treating or preventing early and late anemia using top-up transfusions and supplements 
such as folic acid and iron. The additional use of erythropoietin treatment has also been 
studied in several small studies. In addition to anemia, other hematological complications 
such as thrombocytopenia, coagulation disturbances, leucopenia and iron overload have 
been reported. This review provides an overview of the hematological morbidity in HDFN 
due to red cell alloimmunization and summarizes the neonatal treatment options.
Anemia
Early versus late anemia: etiology
In red cell alloimmunization, anemia develops due to hemolysis of fetal red blood cells by 
maternal IgG antibodies directed against a paternal derived antigen which the mother is 
lacking. Maternal antibodies can persist for several months in the infants’ circulation after 
birth causing ongoing hemolysis up to several months after birth. In neonates with HDFN 
early onset (within 7 days after birth) and late onset anemia are distinguished. Early onset 
anemia is caused by antibody dependent hemolysis of red blood cells. Late-onset anemia 
can be subdivided in “late hyporegenerative anemia” which is characterized by ineffective 
erythropoiesis and “late anemia of hemolytic disease” with an active bone marrow and 
appropriate levels of reticulocytes.3 It should be noted that these types of anemia can occur 
simultaneously. More information on the types of anemia in HDFN is presented in table 1. 
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2) marrow suppression by 
IUTs and postnatal RBC-
transfusions; 
3) erythropoietin deficiency;
4) shortened half-life of 
transfused RBCs;  
5) expanding intravascular 
volume of growing infant
1) antibody-dependent 
hemolysis of RBCs; 
2) shortened half-life of 
transfused RBCs; 
3) natural decline of Hb 
levels; 
4) expanding intravascular 
volume of growing infant 
Bilirubin level Elevated Normal Usually elevated
Reticulocyte 
count 
Normal or high Low or absent Normal or high
RBC = red blood cell; IUT = intrauterine red cell transfusion; Hb = hemoglobin
Late anemia is a common problem in infants with HDFN. Al-Alaiyan et al. found an incidence 
of late anemia (hemoglobin <8 g/dL = 5 mmol/L) in 83% (30/36) in term and late-preterm 
infants with HDFN.3 Because of the risk for prolonged anemia, a full work-up including 
invasive diagnostic tests (such as bone marrow aspirations) to exclude other causes of 
anemia is generally not necessary and should only be considered in select cases with an 
abnormal or persistent course.
Although late anemia was already described before the use of IUT, treatment with IUT 
seems to increase and prolong the risk of anemia, probably by reducing erythropoiesis.4 
A high persistent antibody titer in Rhesus D hemolytic disease can also contribute to 
prolonged anemia.5 In contrast, in Kell HDFN antibody titer does not correspond well with 
the severity of anemia. Anemia in Kell HDFN seems to result from reduced erythropoiesis 
caused by destruction of progenitor red blood cells rather than hemolysis of erythrocytes.6 
Although fetal anemia in Kell HDFN is often more severe necessitating more often IUT 
treatment compared to Rhesus D HDFN, in the neonatal period no significant differences 
Chapter 2
20
Table 2. Information on studies (published in English) on rhEPO administration to neonates with HDFN 
due to red cell alloimmunization













Top-ups after start 
rhEPO




Scaradavou/ 199315 4 35.5-37 Rhesus D 2-5 / 0-3 / 0 200 U/kg 3×/wk 7-52
Stopped in case 
of reticulocytosis 
+ Hb increase of 
≥1 g/dL
none iron, folic acid 0,1,1,1
Zuppa/ 199917 6 28-38 Rhesus 1-9 / 0 / 0-3 200 U/kg/d 14-17 3 weeks none
iron, folic acid, 
vitamin E
0,2,1,0,2,3
Ovaly/ 1996 (RPCT)14 10/10 ≥35 Rhesus
rhEPO group: 2.4 * / 2 cases** / 1 case**;
control group: 2.0* / 3 cases** / 1case**
200 U/kg 3×/wk 14 6 weeks none








iron, folic acid 0
Dhodapkar/ 200110 1 35 Kell 0 / 0 / 0 150-200 U/kg 3×/wk*** 14 9 weeks none iron 0
Nicaise/ 200212 2 35
Rhesus;
Rhesus D
both 4 IUET/ both 2 / 0 250 U/kg 3×/wk 73; 71 6 and 3.4 weeks NS




Pessler/ 200220 1 35 Rhesus D 4 / 2 / 0 200 U/kg 3×/wk 8 5 weeks (iron overload) iron 4
Ovaly/ 2003 (Letter)19 103 NS NS NS 200 U/kg 3×/wk 14 6 weeks NS IVIg 1.5* (55% none)
Manoura/ 200711 1 36 Kell (Ku) Regular IUTs / 0 / 0 300 U/kg 3×/wk 15 8 weeks NS iron 0
Zuppa/ 201018 25 33 ± 3* Rhesus
In 14 of 25 IUT(s): 3 ± 2* / 4 cases of ET for 
anemia / 20 (incl.4 for anemia) cases ≥1 ET
400 U/kg/d (except first 
6 neonates: 200 U/kg/d)
11 ± 4* 26 ± 14* d none
iron, folic acid 
and vitamin E
only in IUT treated 
neonates: 1.8 ± 0.7*
Masumoto/ 201044 1 37 Jra 0 / 0 / 0
NS (7×rhEPO from d 
20-60)
20 6 weeks NS iron 0
rhEPO = recombinant human erythropoietin; HDFN = hemolytic disease of the fetus and newborn; 
GA = gestational age; top-ups = top-up transfusions; ET = exchange transfusion; NS = not specified; 
IVIg = intravenous immunoglobulin; RPCT = randomized placebo controlled trial; IUET = intrauterine 
exchange transfusion; * mean (± standard deviation); ** number of transfusions not specified; *** 200 
U/kg/d (3×/wk) for 4 weeks, then 150 U/kg/d (3×/wk) for 5 weeks
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in top-up transfusion requirements are seen.6 Due to the low incidence of antibodies other 
than anti-Rhesus D and anti-Kell, studies in non-Rhesus D and non-Kell HDFN with sufficient 
sample size to make reliable conclusions on the risk of (late) anemia are lacking.
Top-up transfusions
Top-up transfusions (or simple or erythrocyte transfusions) to treat postpartum anemia can 
be necessary up to the third month of life.7 Approximately 80% of infants with HDFN treated 
with IUT require at least one top-up transfusion for late anemia (hemoglobin <5 mmol/L 
= <8 g/dL) during the first 3 months.3,7,8 In infants with HDFN who did not receive IUTs, 
around 65% require at least one top-up transfusion.3 Median number of top-up transfusions 
required in Rhesus D HDFN and Kell HDFN are two (IQR 0-2) and one transfusion (IQR 0-2), 
respectively. However, in some cases up to six top-up transfusions are necessary to treat 
late anemia.6  
International guidelines for top-up transfusions including transfusion triggers during 
the first months of life are not available. Various protocols based on clinical condition, 
respiratory support, oxygen supplementation, postnatal age, hemoglobin and hematocrit 
levels and weight gain are used.9 In our centre top-up transfusion triggers in term neonates 
with HDFN include: hemoglobin levels <8.0 g/dL (5.0 mmol/L) or <9.6 g/dL (6.0 mmol/L) 
when clinical symptoms of anemia are present like need of extra oxygen, poor feeding, 
tachycardia and/or tachypnea. 
The vast majority of top-up transfusions given to neonates with HDFN consist of 10-20 
ml/kg (weight on day of transfusion) ABO/Rhesus type-specific and antigen-negative (for 
maternal antibodies) red blood cells. Due to an incompletely developed immune system in 
(premature) neonates, irradiation of cellular blood components and cytomegalovirus and 
parvo-B19 virus risk reduction are important safety measures.9 Furthermore, the use of 
satellite packs (one unit of donor blood divided in smaller aliquots) is valuable for reducing 
donor exposure. 
Erythropoietin
Some authors advocate the use of Erythropoietin (EPO) to prevent late anemia in 
neonates with HDFN.10-19 EPO is a glycoprotein hormone responsible for fetal and neonatal 
erythropoiesis and increases on hypoxic stimuli. The normal EPO-level in the non-anemic 
full-term infants at 7-50 days of age was estimated to be 30 mU/ml.3 In the fetal period EPO 
is produced in the liver and does not cross the placenta and after birth production shifts to 
the kidneys. In HDFN EPO-production can be insufficient for the degree of anemia.18 
Since 1992 several reports on the use of recombinant human erythropoietin (rhEPO) in 
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neonates with HDFN have been published (table 2). Most reports showed beneficial effects 
of rhEPO treatment without any side effects except for two cases. However, reported 
studies were small case series or case reports and only one small randomized controlled 
trial has been performed. In addition, gestational ages in these studies varied between 
28 weeks and 40 weeks and protocols varied greatly in the timing, duration and dosages 
of rhEPO and top-up transfusion triggers. In the study of Zuppa et al. only IUT treated 
neonates needed top-up transfusions after rhEPO treatment.18 Theoretically, this could 
be due to an insufficient dose of rhEPO to compensate for the reduced endogenous EPO-
production caused by transfused adult hemoglobin (HbA) which provides more oxygen to 
tissues.18 In addition, Pessler et al. suggested that rhEPO treatment might be ineffective 
when antibody titers are high.20
Unfortunately effective rhEPO treatment can only be administered subcutaneously and 
intravenously. 
Long-acting erythropoietin
In three small pharmacokinetic and pharmacodynamic studies in premature infants long-
acting erythropoietin (darbepoetin) which can be applied once weekly was considered as 
a reasonable alternative to rhEPO with a shorter half-life, but larger randomized trials are 
needed before darbepoetin can be recommended for routine clinical use in neonates.21-23   
Supplements to support erythropoiesis
For effective erythropoiesis sufficient amounts of iron, folic acid and vitamin B12 are 
required. Folate and vitamin B12 are essential for proliferation of erythroblasts during their 
differentiation and iron is required for hemoglobin synthesis by erythroblasts. Deficiency of 
one these nutrients results in ineffective erythropoiesis.24 
Folic acid 
Folic acid is frequently supplemented although limited data are available on its beneficial 
effect on erythropoiesis in infants with HDFN. Gandy and Jacobson demonstrated 
prospectively that oral folic acid supplementation (2.5-5 mg/d) has a beneficial effect on 
growth and serum folate levels, but not on hemoglobin levels in erythroblastotic infants.25 
Strelling et al. did found a hematological response in two severely anemic infants after daily 
administration of intramuscular folic acid.26
Although adverse effects of severe maternal folate deficiency on the motor and mental 
development of infants have been reported, the role of low serum folate levels during the 
first year of life on neurodevelopmental outcome is unclear. 
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Folic acid dosages reported in the literature vary from 0.025 to 5 mg/d and side effects 
(such as rash, fever) are uncommon. 
Even though high-leveled evidence is lacking, in our centre we routinely supplement 0.05 
mg/d orally to infants with HDFN during the first three months of life.
Iron
Iron supplementation is also used to support erythropoiesis in anemic neonates with 
HDFN. However, neonates with HDFN usually do not lack iron. On the contrary, in Rhesus 
HDFN ferritin levels (which reflects total body iron stores) in fetal and cord blood are 
highly elevated.27,28 Moreover, in HDFN blood transfusions are frequently necessary and 
with each top-up transfusion, iron is transfused as well. Multiple intrauterine and/or 
postnatal blood transfusions can lead to iron overload that exceeds transferrin binding 
capacity. Non-tranferrin bound iron can lead to the formation of hydroxyl radicals which can 
damage lipids, proteins, sugars and DNA.27 Additionally, iron overload can cause damage 
to the liver, heart and endocrine organs and also can alter immune response and increase 
susceptibility to infection.29 Nevertheless, iron is crucial for early brain growth and function 
and iron deficiency as well as iron overload have been associated with neurodevelopmental 
impairment.29 
The incidence and morbidity of iron overload and long-term neurodevelopmental outcome 
in HDFN is unclear. Therefore, iron supplementation should be withheld, especially in 
transfused infants with HDFN, unless ferritin levels are in the low/normal ranges. More 
research is necessary to define indications for chelation therapy, which occasionally is used 
to treat iron overload in HDFN.30
Vitamin E
Occasionally vitamin E is supplemented to neonates with HDFN. Vitamin E is an antioxidant 
which reduces oxidative stress to the red blood cell membrane. Therefore vitamin E 
deficiency can generate a shorter life span of red blood cells. Serum vitamin E (tocopherol) 
concentrations in newborns are abnormally low compared to adult concentrations and 
administration of vitamin E to newborns protects against hemolysis by hydrogen peroxide 
in vitro.31 In contrast, addition of a large amount of vitamin E analogue did not inhibit the 
peroxidation process in three neonates with rhesus hemolytic disease.27 These limited data 
are inconclusive to routinely advise on the use of vitamin E in HDFN.
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Exchange transfusion 
Exchange transfusions (ET) in HDFN due to red cell alloimmunization are performed to wash 
out the increased bilirubin and maternal red blood cell antibodies. In addition to removal 
of antibodies, the neonatal red blood cells are replaced by immunologically compatible 
cells which survive in the blood stream, hence reducing the hemolytic process and the 
risk of neonatal anemia.8 Another favorable effect of ET is a fall in ferritin and iron plasma 
concentrations. 
However, ET are also known to be associated with adverse effects such as catheter 
related infections, thrombosis and hemorrhage.7 In 2004 more restrictive ET guidelines 
were published by the American Academy of Pediatrics (AAP) and led consequently to a 
reduction in the use of ET.8 This reduction in ET has led to an increased need of top-up 
transfusions caused by the ongoing hemolysis and remaining antibodies.8
Treatment with intravenous immunoglobulin (IVIg)
Although the mechanism of intravenous immunoglobulin in HDFN is incompletely 
understood, IVIg is applied to reduce the need for ET in case of failure of phototherapy to 
treat hyperbilirubinemia. In small randomized controlled trials IVIg reduced the need for ET 
and duration of phototherapy in neonates with Rhesus HDFN, but the need for late top-up 
transfusions was increased. However, these studies were restricted by several important 
methodological limitations. In 2002, a Cochrane review was published and concluded that 
more well-designed trials are needed before routine use of IVIg can be recommended for 
treatment of HDFN.32 In 2006, Nasseri et al. described a reduction in the number of ETs and 
duration of phototherapy after a 3-dose treatment with IVIg in neonates with Rhesus and 
ABO hemolytic disease.33  Although it seems a randomized controlled trial (RCT), they did 
not describe the randomization process and whether the study was blinded, and moreover 
the number of neonates with Rhesus HDFN was small. In addition, the 100% need for 
ET in the control group of Rhesus HDFN indicates a suboptimal postnatal treatment with 
phototherapy.33  
In 2011, Elalfy et al. performed an RCT on the use of early IVIg in 90 term (>38 weeks’ 
gestation) neonates with Rhesus HDFN not formerly treated with IUT. They concluded that 
IVIg administration at 12 h after birth was effective in reducing duration of phototherapy 
and the need for ET.34 However, in this unblinded study the randomization process was also 
not specified and parents were even allowed to choose whether their child would receive 
IVIg and in which dose after randomization was performed. In contrast, our study group 
recently concluded a double-blind randomized placebo controlled trial on the prophylactic 
use of IVIg in Rhesus HDFN and demonstrated that IVIg does not reduce the need for ET 
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nor the rates of other adverse neonatal outcomes.35 Recently, a research group from Brazil 
finalized a similar RCT on IVIg for neonates with Rhesus hemolytic disease and also found 
no difference between both groups on the rate of ET.36 A new meta-analysis of all recently 
performed RCTs is required to determine the efficacy and safety of IVIg in HDFN due to red 
cell alloimmunization. In view of the absence of beneficial effects and because of potential 
(but rare) adverse effects associated with the use of IVIg such as transfusion-transmitted 
diseases, anaphylaxis, hypersensitivity, thrombosis, pulmonary emboli, and renal failure, we 
do not recommend the routine use of IVIg.35
Thrombocytopenia 
Incidence of thrombocytopenia in HDFN
The association between thrombocytopenia and red cell alloimmunization was first 
described more than 50 years ago.37 However, since then, the prevalence, severity and risks 
of thrombocytopenia in the neonatal period have not been investigated. In a small study in 
Rhesus HDFN by Koenig et al., all of the severely diseased (hydropic, n = 5) and moderate 
severely diseased (non-hydropic but requiring ET, n = 6) infants but none of the mildly 
diseased (not treated with ET, n = 9) infants had thrombocytopenia.38  
Two recent studies demonstrated that thrombocytopenia (platelet count <150 × 109/L) 
is present in the fetal period in 26% and 10% of neonates treated with IUT for Rhesus D 
and Kell HDFN, respectively.39,40 In Rhesus D but not in Kell HDFN, hydrops was associated 
with fetal thrombocytopenia. In surviving fetuses with Rhesus HDFN, significantly more 
fetuses with severe thrombocytopenia (platelet count <50 × 109/L) had an intracranial 
bleeding on cranial ultrasound in the first week of life compared to fetuses without severe 
thrombocytopenia.39 
To elucidate the incidence, etiology and complications of neonatal thrombocytopenia in red 
cell alloimmunization further research is necessary. We recently performed a retrospective 
observational study on the incidence and severity of thrombocytopenia in red cell 
alloimmunization and results will be awaited soon.
Etiology of thrombocytopenia in HDFN 
Based on hematopoietic progenitor cell studies, it appears that because of increased 
erythropoiesis in fetuses with severe Rhesus HDFN neutrophil and platelet production 
can be suppressed.38 In addition to a decreased production, increased destruction or 
consumption and dilution may also play a role. Thrombocytopenia is a known complication 
of ET caused by platelet-poor blood and/or catheter-related thrombi.41 Bilirubin toxicity to 
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platelets leading to changes in platelet morphology and possibly to platelet destruction is 
described, but seems irrelevant since it has only been seen in very high levels of bilirubin.38 
Coagulation
Thirty years ago prospective studies on coagulation status showed a coagulation failure in 
neonates with severe HDFN. A platelet count of less than 150 × 109/L and severe deficiency 
of multiple coagulation factors were described.42 The severely diseased neonates with 
coagulation failure died of bleeding complications in longs or brain. The authors presumed 
that the very low vitamin-K dependent factor levels in the cord blood were the result of 
liver damage in utero. Vitamin-K prophylaxis was administered at birth and in some cases 
in subsequent days. Use of ET seemed to correct the factor deficiency temporarily and 
platelet count decreased in neonates with platelets >50 × 109/L and increased in neonates 
with platelet counts <50 × 109/L. Coagulation tests at birth (including prothrombin and 
thrombin time) appeared to identify the neonates at risk of bleeding complications.42 Since 
intrauterine treatment has improved greatly over the years, severe hemolytic disease with 
hydrops is rare nowadays. However, in case of severe hydropic disease there is still a risk for 
serious coagulation failure with subsequent risk for bleeding complications.
Leucopenia
Very limited data are available on leucopenia in neonates with HDFN due to red cell 
alloimmunization. Koenig et al. reported that of 20 patients with Rhesus HDFN, all 5 
neonates with severe Rhesus HDFN, two of six with moderately severe disease, and two 
of nine with mild disease had neutropenia.38 It appears that the incidence of neutropenia 
increases if Rhesus HDFN is more severe. Segal et al. described two neonates with Rhesus 
incompatibility, hydrops fetalis, and neutropenia who were successfully treated with 
recombinant human granulocyte colony-stimulating factor (rhG-CSF) without any side 
effects.43 These limited data are insufficient to be conclusive on the incidence and morbidity 




•• In the majority of neonates with HDFN late anemia is present necessitating top-up 
transfusions up to three months after birth.  
•• Iron supplementation should be withheld, especially in transfused infants with HDFN, 
until ferritin levels are normalized.
•• IVIg does not reduce the need for ET in neonates with Rhesus HDFN and the routine 
use of IVIg should therefore be discouraged.
Research directions 
•• More studies are needed to determine the incidence and risk factors of iron overload 
in infants with HDFN treated with and without IUT.
•• To elucidate the prevalence and morbidity of neonatal thrombocytopenia and the 
efficacy of prophylactic platelet transfusions in HDFN, further research is required. 
•• Larger well-designed trials are needed to recommend on the use of rhEPO therapy in 
neonates with HDFN.
•• Studies on the use of folic acid in neonates with HDFN are needed to determine if and 
in which dosage this therapy could be beneficial.
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To study the effect of a restrictive guideline for exchange transfusion (ET) on the number of 
top-up transfusions in neonates with Rhesus hemolytic disease.
Study design
Retrospective study of all (near)-term neonates with Rhesus hemolytic disease admitted to 
our center between 2000 and 2008. In December 2005, policy changed from using liberal ET 
criteria to more restrictive ET criteria. We recorded the number of ETs and the number of 
top-up transfusions in the group of neonates before (group I, n = 156) and after (group II, n 
= 27) the guideline change.
Results
The percentage of neonates requiring an ET decreased from 66% (103/156) in group 
I to 26% (7/27) in group II (p = <0.01). The percentage of neonates receiving a top-up 
transfusion increased from 68% (105/154) in group I to 81% (22/27) in group II (p = 0.25). 
The median number of top-up transfusions increased from 1 (interquartile range 0-2) in 
group I to 2 (interquartile range 1-3) in group II (p = 0.01).
Conclusion
In this study, restrictive ET criteria in neonates with Rhesus hemolytic disease lead to 
a reduction of the rate of ET but an increase in the number of top-up transfusions for 
neonatal anemia.
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Introduction
The mainstay of antenatal treatment for hemolytic disease of the fetus and newborn 
due to Rhesus alloimmunization (HDFN) is intrauterine transfusions (IUT) to treat 
severe fetal anemia. The mainstay of postnatal treatment for hemolytic disease of the 
newborn (HDN) secondary to Rhesus alloimmunization is (1) intensive phototherapy 
and exchange transfusion (ET) to treat hyperbilirubinemia and prevent kernicterus, and 
(2) top-up transfusions to treat neonatal anemia. Neonatal anemia secondary to Rhesus 
alloimmunization can be divided into two types: “hyporegenerative anemia” characterized 
by depressed erythropoiesis and “late anemia of hemolytic disease” caused by persisting 
hemolysis by remaining antibodies.1 Both causes of anemia contribute to the necessity 
of top-up transfusions during the first months of life. The percentage of infants with HDN 
secondary to Rhesus alloimmunization requiring top-up transfusions for neonatal anemia 
varies from 27 to 83%.2,3
Several risk factors for neonatal anemia secondary to Rhesus alloimmunization have been 
reported, including IUT (due to suppression of fetal erythropoiesis)2 and severity of HDN.1,4,5 
Use of ET during the neonatal period has been reported to protect against neonatal 
anemia.3 In addition to removing excess bilirubin, ET also removes antibody-coated 
erythrocytes and maternal antibodies, hence reducing the risk for continuing hemolysis and 
neonatal anemia.3,6 However, the protective role of ET for neonatal anemia has only been 
demonstrated in one small study.3
In December 2005, we implemented a new guideline for the management of neonatal 
hyperbilirubinemia and HDN secondary to Rhesus alloimmunization based on the guidelines 
from the American Academy of Pediatrics (AAP).7 The new guideline for ET was more 
restrictive than the previous ones and led to a more than 50% decrease in the rate of ET. 
Restrictive ET criteria may hypothetically lead to an increase in top-up transfusions ascribed 
to ongoing hemolysis due to antibody coated cells not being removed from the circulation. 
Whether the reduction in ET indeed resulted in an increased rate of top-up transfusions was 
not clear. 
The aim of this study was to evaluate the effect of this new guideline on the number of 
top-up transfusions and determine if neonates with hemolytic disease of the newborn 





All neonates with a gestational age ≥35 weeks with HDN secondary to Rhesus D, C, c or E 
antibodies admitted between January 2000 and November 2008 to the neonatal division 
of the Leiden University Medical Center (LUMC) were included in this retrospective 
observational study. LUMC is the national referral center for the management and 
intrauterine treatment of red cell alloimmunization in the Netherlands. Neonates with 
Kell, Jka or Cw red cell alloimmunization, and neonates receiving transfusions for unrelated 
pathology were excluded from this study. We also excluded neonates participating in an 
ongoing randomized double-blind placebo-controlled trial for the use of immunoglobulin 
in RHD, which started in August 2006 at our institution (the LIVIN-study: http://www.
trialregister.nl/trialreg/admin/rctview.asp?TC=832)
In December 2005, we implemented a new guideline for the management of neonatal 
hyperbilirubinemia and HDN secondary to Rhesus alloimmunization based on the guidelines 
from the American Academy of Pediatrics (AAP).7 The differences in phototherapy 
thresholds before and after introduction of the new guideline are shown in figure 1. The 
guideline for phototherapy administration at our neonatal division has previously been 
described.2 The bilirubin thresholds for ET in the new guideline were higher than in the 
previous one. The differences in ET thresholds of total serum bilirubin before and after 
guideline change are shown in figure 2. The criteria for ET before December 2005 included 
a total serum bilirubin level at birth >3.5 mg/dL (measured in neonatal blood at birth or in 
a few cases in umbilical cord blood), (early criterion) and/or a total serum bilirubin level 
above ET thresholds (rise of bilirubin value >0.5 mg/dL/hr despite intensive phototherapy).2 
In neonates not treated with IUT, a hemoglobin level at birth of <12.9 g/dL was also 
considered as an early criterion for ET.2 Bilirubin levels were measured in all neonates every 
2 to 3 hours during the first few days after birth.
Early criteria for ET were abandoned after the guideline change. The criteria for ET after 
December 2005 were: (1) total serum bilirubin above (new) ET thresholds7 (fig 2) and/or (2) 
rise of bilirubin >0.5 mg/dL/hr despite intensive phototherapy, and/or (3) clinical symptoms 
of acute bilirubin encephalopathy regardless of bilirubin level. ET was performed with 
double-volume transfusion (160 mL/kg) using irradiated and leukocyte-depleted compatible 
erythrocytes. 
After initial discharge from the LUMC, top-up transfusions were performed when 
hemoglobin levels were <8.0 g/dL or <9.6 g/dL if clinical symptoms of neonatal anemia 
(lethargy, feeding problems, need for oxygen or failure to thrive) were present. The volume 
used for top-up transfusions during the study period was 15 ml/kg bodyweight. The volume 
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Figure 1. Phototherapy thresholds before and after guideline change in neonates with Rh hemolytic disease
Figure 2. Exchange transfusion thresholds before and after guideline change in neonates with Rh 
hemolytic disease
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and criteria for top-up transfusion were the same in both groups. Neonatal anemia, often 
referred to as “late anemia” in previous studies3,5,8,9 was defined as a hemoglobin level 
below thresholds requiring a top-up transfusion during the first three months of life. Folic 
acid 50 mcg/day was administered orally during the first three months of life to all neonates 
with RHD. According to our management guidelines, neonates with RHD were not treated 
with erythropoietin. 
We recorded the following obstetric and neonatal data: fetal hemoglobin at first IUT and 
number of IUTs, gestational age at birth, birth weight, hemoglobin level and reticulocyte 
count at birth, bilirubin level at birth, maximum bilirubin level during admission, duration 
of phototherapy (days), number of ETs required, number of top-up red blood cell 
transfusions received during the first 3 months of life and hemoglobin levels prior to the 
top-up transfusion. Obstetric data were gathered using a dedicated database for Rhesus 
complicated pregnancies in which data are prospectively collected. Neonatal data were 
collected using medical files. Data on top-up transfusions and hemoglobin levels prior to 
the top-up transfusion in infants who received follow-up outside the LUMC were gathered 
through correspondence with the local pediatrician or blood transfusion department. 
Primary outcome was the number of top-up transfusions in the group of neonates admitted 
before (group I) and after (group II) the new guideline implementation in December 2005.
Data are reported as means and standard deviations (SD) or as medians and interquartile 
range (IQR), as appropriate. Statistical analysis was performed using Student-t-test and 
Mann-Whitney test for continuous variables. Chi square and Fisher’s exact test were used 
for categorical variables, as appropriate. To assess the relationship between the number 
of ETs and the number of top-up transfusions, Spearman correlations were calculated. A 
p-value <0.05 was considered statistically significant. Statistical analysis was executed with 
SPSS 16.0 (SPSS Inc, Chicago, IL).
Results
During the study period 270 infants with hemolytic disease born at ≥35 weeks’ gestation 
were admitted to our neonatal division. Fifty neonates were excluded because of 
participation in a randomized double-blind placebo-controlled trial for the use of 
intravenous immunoglobulin. Thirty-six neonates were excluded due to hemolytic disease 
caused by Kell (n = 34), Jka (n = 1) or Cw (n = 1). One neonate requiring major cardio-
thoracic surgery for congenital heart disease was also excluded. A total of 183 patients 
were included in this study, of whom 156 in the group before (group I) and 27 in the group 
after (group II) the implementation of the new guideline in December 2005. Baseline 
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characteristics in both groups are summarized in Table 1. 






Neonates treated with IUT, n (%) 99 (63) 15 (56) 0.52
Number of IUTs per neonatea 2 (0 - 3) 1 (0 - 2) 0.29
Gestational age at first IUT, weeksa 30 (24 – 33) 31 (23 - 32) 0.70
Hemoglobin level at first IUT, g/dLa 6.6 (5.1 – 7.7) 5.8 (5.0 – 7.4) 0.70
Gestational age at birth, weeksa 37 (36 - 37) 37 (36 - 37) 0.89
Birth weight, gramsb 3020 ± 445 2940 ± 396 0.40
Male, n (%) 87 (56) 21 (78) 0.04
Neonates with Rhesus D, n (%) 140 (90) 21 (78) 0.10
Neonates with Rhesus c, n (%) 13 (8) 4 (15) 0.29
Neonates with Rhesus C, n (%) 2 (1) 0 (0) 1.00
Neonates with Rhesus E, n (%) 1 (1) 2 (7) 0.06
a Value given as median (IQR), b Value given as mean ± SD
The use of IUT, phototherapy and ET
Detailed information on the use of IUT is presented in Table 1 and on the use of 
phototherapy and ET in group I and group II is presented in Table 2. Serial IUTs were 
performed in 99 (63%) infants in group I and 15 (56%) in group II (p = 0.52). At least one 
ET was required in 66% (103/156) of the patients in group I compared to 26% (7/27) of 
the patients in group II (p = <0.01). The rate of ET performed on day 1 dropped from 96% 
(94/103) in group I to 57% (4/7) in group II (p = <0.01). The median number of ETs was 1 in 
group I (IQR 0-1, range 0-5) and 0 in group II (IQR 0-1, range 0-2) (p = <0.01). No significant 
relationship was found between the number of IUTs and the number of ETs (Spearman 
correlation coefficient = -0.009; p = 0.90). 
The use of top-up transfusions
Complete information on the number of top-up red cell transfusions was obtained for 98% 
(180/183) of neonates. Detailed information on the use of top-up transfusions in group 
I and group II is presented in Table 3. The percentage of neonates in group I and group II 
receiving a top-up transfusion was 68% (105/154) and 81% (22/27), respectively (p = 0.25). 
The median number of top-up transfusions per infant in group I and II was 1 (IQR 0-2, range 
0-6) and 2 (IQR 1-3, range 0-5) (p = 0.01). 
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Combining group I and II, we found a negative correlation between the number of ETs 
and the number of top-up blood transfusions (Spearman correlation coefficient -0.183; p 
= 0.01). This correlation between a lower number of ETs and a higher number of top-up 
transfusions was present mainly in the subgroup of neonates treated with IUT (n = 114) 
(Spearman correlation coefficient = -0.340; p = <0.01). In the subgroup of neonates without 
IUT (n = 69), the correlation between the number of ETs and the number of top-up blood 
transfusions was not significant (Spearman correlation coefficient = 0.011; p = 0.93). Of the 
110 neonates that received an ET 73 neonates (66%) were treated with IUT.






Hemoglobin level at birth, g/dL a 11.6 ± 2.58 12.6 ± 3.40 0.25
Bilirubin level at birth, mg/dLa 6.0 ± 2.70 6.2 ± 2.85 0.89
Reticulocyte count at birth, ‰b,c 21 (3 - 61) 47.5 (3 - 106) 0.19
Maximum bilirubin, mg/dLb 13.6 (10.3 – 16.8) 15.4 (13.2 -18.0) 0.03
Neonates treated with phototherapy, n (%) 150 (96) 27 (100) 0.59
Phototherapy, daysa 4.1 ± 1.88 4.7 ± 1.59 0.11
Neonates treated with ET, n (%) 103 (66) 7 (26) <0.01
Number of ETs per neonateb 1 (0 -1) 0 (0 -1) <0.01
ETs performed on day 1, n (%) 94 (96) 4 (57) <0.01
Duration of admission at our center, daysa 6.0 ± 3.3 6.3 ± 3.9 0.47
a Value given as mean ± SD, b Value given as median (IQR), c Assessed in 75 and 20 patients of group I 
and II, respectively






Neonates receiving top-up transfusions, n (%) 105/154 (68) 22/27 (81) 0.25
Number of top-up transfusions per infanta 1 (0-2)c 2 (1-3) 0.01
Neonates receiving:  1 top-up transfusion, n (%)
                                      2 top-up transfusions, n (%)
                                      3 top-up transfusions, n (%)
                                      4 top-up transfusions, n (%)
                                      5 top-up transfusions, n (%)



















Days after birth until first top-up transfusiona 19.5 (1 - 34.8)c 10 (2.5 – 23.0)d 0.23
Hemoglobin level at first top-up transfusion, g/dLb 8.3 ± 1.5e 8.2 ± 1.3f 0.72
a Value given as median (IQR) , b Value given as mean ± SD, c Assessed in 153/156 neonates, 
d Assessed in 17/22 neonates, e Assessed in 95/105 neonates, f Assessed in 16/22 neonates
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Discussion
This study shows that after implementation of a more restrictive guideline for ET in 
neonates with RHD, the rate of ETs decreased considerably from 66% to 26%. The reduction 
in ET rate was associated with a significant increase in the number of top-up transfusions 
for neonatal anemia. Neonates in group II required twice more top-up transfusions than 
neonates in group I. Since the criteria for top-up transfusions remained unchanged before 
and after the ET guideline changes, our findings suggest that neonatal anemia in neonates 
with RHD is more likely to occur if restrictive ET criteria are used.
Our findings are in accordance with a previous study by al-Alaiyan et al. in a small group 
of 36 (near-) term neonates with RHD treated with IUT.3 Al-Alaiyan et al. reported a similar 
association between ET rate and top-up transfusions.3 The risk of neonatal anemia in 
neonates treated with and without ET was 36% and 92%, respectively (p = 0.04).3
The reduced rate of top-up transfusions in infants treated with ET can be attributed to the 
removal of antibodies and IgG coated erythrocytes during ET, hence reducing the hemolytic 
process and the risk of neonatal anemia.3,6 However, the effect of ET on the antibody titer 
on the short term is limited. Since the antibodies are distributed in the intravascular as 
well as the extravascular fluid, ET reduces the antibody titer only by about 25 percent.4,10 
The beneficial effect of ET lies in replacing nearly all of the Rhesus positive red cells by 
immunologically compatible cells, hence surviving cells in the blood stream.4
In contrast with previous studies2,8 we found a significant negative correlation between 
the number of ETs and top-up transfusions. This negative correlation was found only in 
neonates treated with IUT, but was not found in neonates without IUT treatment. Since 
fetuses requiring IUT treatment are more severely affected by RHD than fetuses without 
IUT treatment, we speculate that the beneficial effect of ET in reducing the number of top-
up transfusions occurs primarily in severely affected neonates with high titer antibodies. 
Washing out antibodies and replacing Rhesus positive cells through ET treatment may be 
particularly more effective in severely affected neonates. 
The pathogenesis of neonatal or late anemia in RHD is not completely clarified and can 
be due to either depressed erythropoiesis (“hyporegenerative anemia”) or persisting 
reduction in half-life of the Rhesus positive erythrocytes caused by remaining antibodies 
(“late anemia of hemolytic disease”) if age-appropriate or elevated reticulocytes are 
present.11,12 “Hyporegenerative anemia” occurs in particular after IUT due to suppression 
of the erythropoiesis.2,9 An alternative explanation for failing compensatory reticulocytosis 
is destruction of bone marrow precursors and reticulocytes by antibodies.4,13 Other 
contributing factors to neonatal anemia are reduced survival of transfused red blood cells5, 
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natural decline of the hemoglobin level toward the physiological nadir, and the increasing 
intravascular volume of the growing neonate.1 Finally, erythropoietin deficiency can be a 
possible contributing factor to neonatal anemia.12 Treatment with erythropoietin has been 
suggested to reduce the number of top-up transfusions, but the evidence to recommend 
routine use of erythropoietin is very limited.14 
The data in this study should be interpreted with care due to the retrospective design of 
the study which may have led to a selection bias and influenced by changing transfusion 
attitudes over time. Although both groups were similar in terms of severity of fetal anemia, 
need of IUT, and hemoglobin levels at birth, it is conceivable that neonates in group II were 
more severely affected than neonates in group I, hence requiring more top-up transfusions.2 
Importantly, the percentage of male infants in group II was higher than in group I. Male 
infants have a higher prevalence of HDN secondary to Rhesus alloimmunization,15 a higher 
neonatal death rate from kernicterus16 and appear to be more severely affected than 
females in terms of need for IUT, development of hydrops fetalis and perinatal mortality.17 
A larger study is required to determine if this sex difference in baseline characteristic may 
have influenced our results.   
In conclusion, this study shows that the number of ETs in neonates with HDN secondary 
to Rhesus alloimmunization decreased significantly after the introduction of restrictive ET 
criteria. Reduction of ET rate resulted in a doubling of the number of top-up transfusions. 
Restrictive ET criteria in HDN secondary to Rhesus alloimmunization during the neonatal 
period may thus lead to an increased rate of neonatal anemia. Nevertheless, the risk of 
adverse events associated with ETs (in particular catheter-related complications) is high 
(7%)18 compared to the transfusion-related risks of blood transfusion in general (<0.04%).19 
A reduction in ETs, despite an increase in top-up transfusions may therefore be more 
beneficial for neonates with HDN secondary to Rhesus alloimmunization, although the long-
term effects on neurodevelopmental outcome requires longer follow-up.
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Exchange transfusion (ET) is a high risk procedure. Type and rate of complications in 
neonatal red cell alloimmune hemolytic disease exclusively is not clear.
Objective
Our aim was to study type and rate of complications associated with ET in a large series 
of neonates with hemolytic disease of the fetus and newborn (HDFN) due to red cell 
alloimmunization.
Methods
All neonates with HDFN due to red cell alloimmunization admitted to our center between 
January 2001 and June 2011 were eligible for this study. We recorded the number and 
rate of complications during admission in the group of neonates treated with (ET-group) 
and without ET (no-ET-group). Multivariate logistic regression analysis was performed to 
measure independent risk of complications of ET treatment.
Results
A total of 347 infants with red cell alloimmune hemolytic disease were included, 39% 
(134/347) was treated with at least one ET (ET-group) and 61% (213/347) did not require ET 
(no-ET-group). Comparison between ET-group and no-ET-group showed that ET treatment 
was independently associated with: proven sepsis (8% versus 1% respectively, odds ratio 
(OR) 8.3, 95% confidence interval (CI) 1.7-40.3, p = 0.009), leukocytopenia (88% versus 23% 
respectively, OR 36.0, 95% CI 17.5-73.8, p = <0.001), severe thrombocytopenia (platelet 
count <50 × 109/L) (63% versus 8% respectively, OR 31.4, 95% CI 14.0-70.4, p = <0.001), 
hypocalcemia (22% versus 1% respectively, OR 27.4, 95% CI 5.9-126.8, p = <0.001) and 
hypernatremia (8% versus 0% respectively, p = <0.001). Neonatal death did not occur in the 
ET-group.
Conclusion
ET in neonates with HDFN is associated with increased risk of sepsis, leukocytopenia, 
thrombocytopenia, hypocalcemia and hypernatremia.
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Introduction
Hemolytic disease of the fetus and newborn (HDFN) due to red cell alloimmunization 
may lead to excessive unconjugated hyperbilirubinemia. Neonatal treatment consists 
of intensive phototherapy and exchange transfusion (ET) to prevent kernicterus. After 
introduction in the late 1940s1 neonatal treatment with ET became one of the most 
commonly performed procedures. However, ET is a high-risk invasive procedure requiring 
the use of central lines and is associated with a significant rate of adverse events. Although 
the contemporary mortality rate is reported to be less than 2%, rates of morbidity and ET-
related adverse events can reach 74%.2-9 Reported adverse events include catheter-related 
complications, complications related to the use of blood products, metabolic derangements 
and cardio-respiratory reactions.2-9
In nearly all previous studies a heterogeneous group of infants with HDFN treated with 
ET was included, varying from HDFN due to red cell alloimmunization to HDFN due to 
ABO-incompatibility.2-4,6,8,9 Hemolysis caused by ABO-incompatibility is usually less severe 
compared to red cell alloimmunization and therefore associated with a reduced rate of 
neonatal morbidity. Furthermore, different indications for ET were used2,8,9 and most studies 
were limited by a relative small number of included patients or were not case-controlled.2-9
The aim of this study was to evaluate type and rate of complications associated with ET in a 
large series of neonates with HDFN due to red cell alloimmunization exclusively.
Patients and Methods
All term and preterm neonates with HDFN due to maternal red cell alloimmunization 
treated with or without ET, admitted to our center between January 2001 and June 2011 
were eligible for this retrospective observational study. The Leiden University Medical 
Center (LUMC) is the national referral center for the management and intrauterine 
treatment of HDFN in the Netherlands. Neonatal outcome in part of this group was 
reported in previous studies.10-14 In the Netherlands no formal ethical approval by the 
Medical Ethics Committee or written informed consent is necessary for retrospective 
studies.
Guidelines for ET used in our neonatal center were revised in December 2005.10,11 Before 
December 2005, criteria for ET included: (1) bilirubin level at birth >3.5 mg/dL and/or (2) 
total serum bilirubin level above ET thresholds (rise of bilirubin value >0.5 mg/dL/h despite 
intensive phototherapy). In neonates not treated with IUT, a hemoglobin level at birth of 
<12.9 g/dL was also considered as a criterion for ET. Criteria for ET after December 2005 
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were: (1) total serum bilirubin above (higher) ET thresholds and/or (2) rise of bilirubin >0.5 
mg/dL/h despite intensive phototherapy, and/or (3) clinical symptoms of acute bilirubin 
encephalopathy regardless of bilirubin level.15 
ET was performed with double-volume transfusion (160 mL/kg) with citrated plasma (citrate 
12-19 mEq/L) from a non-transfused male donor, lacking irregular erythrocyte-antibodies, 
added to irradiated, leukocyte-depleted (<1 × 106/L) and thrombocyte-reduced red cell 
concentrate, compatible with maternal antibodies. Citrated plasma contains nearly no free 
calcium, physiologic levels of potassium and glucose and an increased concentration of 
sodium (168 mEq/L) (Sanquin Bloodbank, The Netherlands). According to our guidelines no 
standard calcium supplementation is used during ET.
Primary outcome of this study was the rate of complications during admission in the group 
treated with ET (ET-group) and without ET (no-ET-group).
 
The following adverse events (complication occurring during admission) were recorded: 
hypocalcemia (<8 mg/dL), hypoglycemia (<46.8 mg/dL), hyperkalemia (>6.5 mEq/L), 
hypokalemia (<3.0 mEq/L), hypernatremia (>150 mEq/L), hyponatremia (<130 mEq/L), 
metabolic acidosis (pH <7.25, bicarbonate <22 mEq/L requiring treatment with 
bicarbonate), respiratory failure (respiratory support with continuous positive airway 
pressure and/or mechanical ventilation), apnea (cessation of respiration >20 seconds), 
pulmonary hemorrhage, cardiac arrest, hypertension (requiring antihypertensive 
medication), hypotension (requiring intravenous fluids or vasopressors), necrotizing 
enterocolitis,16 proven sepsis (clinical and/or biochemical signs of infection (leukocytes 
<24 hours after birth <9 × 109/L and >24 hours <5 × 109/L or leukocytes >25 × 109/L and/
or band forms >20% of leukocytes and/or C reactive protein >10mg/L) with positive blood 
culture), suspected sepsis (clinical and/or biochemical signs of infection without positive 
blood culture), disseminated intravascular coagulation (DIC) (requiring fresh frozen plasma), 
seizures (treated with anti-epileptic medication), leukocytopenia (<24 hours after birth <9 
× 109/L and >24 hours <5 × 109/L) thrombocytopenia (<150 × 109/L; severe if platelet count 
<50 × 109/L and very severe if platelet count <20 × 109/L), intraventricular hemorrhage17, 
or other cerebral hemorrhage and neonatal death. Platelet transfusions are given when 
platelets are: 1) <100 × 109/L before planned ET and 2) <50 × 109/L after ET.
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of intrauterine red cell transfusions (IUT), gestational age at birth, birth weight, 
presence of hydrops at birth, hemoglobin level, reticulocyte count, leukocyte count and 
bilirubin level at birth, days of admission on our neonatal intensive care unit, occurrence 
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of complications during admission and time of occurrence in relation to ET, number of ETs 
and presence of umbilical venous catheter (UVC). Before ET-guideline change in 2005 a 
UVC was inserted directly after birth in all neonates. After 2005 a UVC was inserted when 
bilirubin levels increased towards ET-threshold. UVCs were left in place until bilirubin levels 
were decreased towards or below phototherapy threshold. According to our guidelines 
ultrasound to detect portal vein thrombosis (PVT) after ET was not performed standard but 
only in the presence of clinical signs of thrombosis.
 
Data are reported as means and standard deviations (SD) or as medians and interquartile 
ranges (IQR). Statistical analysis was performed using Student-t test and Mann-Whitney 
test for continuous variables. Chi-square and Fisher’s-exact test were used for categorical 
variables. A p-value <0.05 was considered to indicate statistical significance. Of all 
statistically significant complications identified with univariate analysis a multivariate 
logistic regression analysis was performed to measure independent effect of ET(s). Results 
of logistic regression models were expressed as odds ratios (OR) and 95% confidence 
intervals (CI). Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
During this 10-year study, 348 neonates with HDFN due to red cell alloimmunization were 
admitted to our nursery. We excluded one preterm neonate (29 weeks’ gestation) because 
he died immediately after caesarean section due to severe perinatal asphyxia following 
unsuccessful IUT. 347 Patients were included, 134 (39%) in the ET-group and 213 (61%) in 
the no-ET-group. Baseline characteristics are summarized in Table 1. The total number of 
ETs in the ET-group was 207 and the median (range) number of ETs was 1 (1-9).
In the ET-group 93/134 (69.4%) neonates needed one or more top-up transfusions 
compared to 162/213 (76.1%) in the no-ET-group.
Complications




Table 1. Baseline characteristics in ET-group and no-ET-group





Type of red cell alloimmunization
  Rh D, n (%) 122 (91) 138 (65) <0.001
  Rh c, n (%) 11 (8) 16 (8) 0.813
  Kell, n (%) 1 (1) 46 (22) <0.001
  Other types than Rh D, Rh c or Kell, n (%) 0 (0) 13 (6)
Neonates treated with IUT, n (%) 99 (74) 141 (66) 0.131
Number of IUTs per neonatea 2 (2-3) 3 (2-4) 0.009
Gestational age at first IUT, weeksa 30 (25-33) 26 (23-31) 0.001
Birth weight, kgb 2.9 ± 0.6 2.9 ± 0.6 0.591
Gestational age at birth, weeksa 36 (36-37) 36 (36-37) 0.247
Male, n(%) 89 (66) 130 (61) 0.311
Hydrops at birth, n (%) 2 (2) 4 (2) 1.000
Hemoglobin level at birth, g/dLb 11.6 ± 2.6 12.7 ± 2.9 <0.001
Reticulocyte count at birth, ‰a,c 49 (6.8-83.3) 39 (3-75.5) 0.089
Leukocyte count at birth, 109/Lb,d 14.1 ± 5.6 13.4 ± 5.7 0.270
Thrombocytopenia at birth, n (%) 39 (29) 48 (23) 0.169
Bilirubin level at birth, mg/dLb 7.1 ± 3.1 4.8 ± 2.3 <0.001
Umbilical venous catheter, n (%) 133 (99) 64 (30) <0.001
Days of admission on NICUb 6.6 ± 3.8 6.2 ± 3.9 0.009
a Value given as median (IQR), b Value given as mean ± SD, c assessed in 78/134 and 149/213 neonates, 
d assessed in 130/134 and 207/213 neonates, NICU = neonatal intensive care unit
Univariate analysis
Metabolic derangements/complications
Hypocalcemia (22% versus 1%) and hypernatremia (8% versus 0%) occurred significantly 
more in the ET-group. Four of 31 (13%) neonates with hypocalcemia needed calcium 
supplementation and 3/11 (27%) needed treatment (additional sodium-free intravenous 
fluid) for hypernatremia. Severe symptoms of hypernatremia (seizures) did not occur.
Cardio-respiratory complications
No significant differences were seen in respiratory support, apneas, cardiac arrest and 
hypotension (Table 2). No cases of cardiac rhythm disorders, pulmonary hemorrhage and 
hypertension occurred. 
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Table 2. Complications during admission in ET-group and no-ET-group






OR (95% CI) p-value OR (95% CI) p-value
Hypocalcemia 29 (21.6) 2 (0.9) 29.1 (6.8-124.5) <0.001 27.4 (5.9-126.8) <0.001
Hypoglycemia 14 (10.4) 28 (13.1) 0.453 0.848
Hyperkalemia 1 (0.7) 0 0.386 NC
Hypokalemia 3 (2.2) 1 (0.5) 0.303 0.220
Hypernatremia 11 (8.2) 0 NC <0.001 NC NC
Hyponatremia 1 (0.7) 2 (0.9) 1.000 0.949
Metabolic aci-
dosis
2 (1.5) 7 (3.3) 0.491 0.103
Respiratory 
support
17 (12.7) 18 (8.5) 0.202 0.425
Apneas 7 (5.2) 3 (1.4) 0.050 0.137
Cardiac arrest 0 2 (0.9) 0.525 NC
Hypotension 2 (1.5) 4 (2) 1.000 0.356
NEC 1 (0.7) 2 (1.9) 1.000 1.000
Proven sepsis 11 (8.2) 3 (1.4) 6.3 (1.7-22.9) 0.002 8.3 (1.7-40.3) 0.009
Suspected 
sepsis
9 (6.7) 16 (7.5) 0.780 0.466
Leukocytopenia 118 (88.1) 49 (23.0) 24.7 (13.4-45.5) <0.001 36.0 (17.5-73.8) <0.001
Thrombocyto-
penia 
     Severe 



















DIC 0 1 (0.5) 1.000 0.982
Seizures 2 (1.5) 1 (0.5) 0.562 0.931
Death 0 1 (0.5) 1.000 NC
Values in columns 2 and 3 represent n (%). Respiratory support = continuous positive airway pressure 
and/or mechanical ventilation, NEC = necrotizing enterocolitis, DIC = disseminated intravascular 




Proven sepsis and leukocytopenia occurred significantly more often in the ET-group (8% 
versus 1% and 88% versus 23%, respectively). All ET-treated neonates with proven sepsis 
had leukocytopenia during admission and in 55% (6/11) leukocytopenia occurred after ET.
In the 14 neonates from both groups with proven sepsis, bacterial cultures were positive 
for Staphylococcus aureus (7/14), coagulase-negative Staphylococcus (3/14), beta-
hemolytic Streptococcus (1/14), Klebsiella pneumonia (1/14), Escherichia coli (1/14) and 
Bacillus cereus (1/14). This last patient developed a sepsis with brain abscesses after an ET 
performed through a UVC.18
Hematological complications
The rate of thrombocytopenia was significantly higher in the ET-group (99% versus 32%). 
Seventy-five of 134 ET-treated neonates were treated with at least one platelet transfusion. 
One near-term neonate (36 weeks’ gestation) received a platelet transfusion after ET on 
day one because of post-ET platelet count 39 × 109/L. On day 2 cranial ultrasonography 
showed a hemorrhage in the right parieto-occipital periventricular white matter, which was 
not observed antenatally. Magnetic resonance imaging (MRI) showed no sinus thrombosis 
and coagulation was normal. At one year of age, the infant had no neurologic sequelae. In 
the no-ET-group 3 neonates had intracerebral hemorrhage on cranial ultrasound and/or 
MRI of whom one neonate had severe thrombocytopenia for which he received 4 platelet 
transfusions. This neonate died during admission (see below).
In both study-groups no cases of bilirubin encephalopathy or PVT were observed.
Neonatal mortality
Only one of 347 neonates died during admission. This neonate from the no-ET-group (30 
weeks’ gestation) had severe fetal hydrops. On day 2 bilirubin levels increased above ET 
threshold, however due to intravenously access problems ET could not be performed. 
Subsequently, bilirubin levels decreased below ET threshold with phototherapy. He died 
on day 11 due to respiratory failure, pulmonary hypertension, bilateral intraventricular 
hemorrhage grade 2 and renal failure. 
ET guideline change
To measure the possible effect of ET guideline change10 on the rate of the previously 
mentioned complications we performed a sub-analysis of ET-treated neonates before and 
after guideline change. Rates of complications were not significantly different between both 
groups (data not shown). 
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Multivariate analysis
Complications during entire admission 
We corrected for the following covariates: hemoglobin level at birth, type of red cell 
alloimmunization, days of admission and gestational age at birth. We corrected for the 
first two because of significant differences at baseline (Table 1) and for the latter because 
preterm neonates are more susceptible for ET-related complications.8,19 Since the presence 
of UVC and ET are correlated (Spearman correlation coefficient r = 0.680, p = <0.001), we 
did not correct for the presence of a UVC. Proven sepsis (OR 8.3), severe thrombocytopenia 
(OR 31.4), leukocytopenia (OR 36.0) and hypocalcemia (OR 27.4), had a higher incidence in 
the ET-group. 
Complications after first ET 
Since our main interest is in ET-related complications, we performed a sub-analysis 
excluding all complications in the ET-group that were observed before (first) ET (adjusted-
ET-group, Table 3). Similar to the entire data set, neonates undergoing ET were more likely 
to experience sepsis, leukocytopenia, thrombocytopenia, hypocalcemia and hypernatremia.
Table 3. Complications during admission in Adjusted Exchange Transfusion (ET) and No Exchange 
Transfusion group







OR (95% CI) p-value OR (95% CI) p-value
Hypocalcemia 25 (18.7) 2 (0.9) 24.2 (5.6-104.1) <0.001 21.9 (4.7-101.7) <0.001
Hypernatremia 10 (7.5) 0 NC <0.001 NC NC
Proven sepsis 8 (6.0) 3 (1.4) 4.4 (1.6-17.1) 0.030 5.30 (1.0-27.1) 0.046
Leukocytopenia 91 (70.5)b 49 (23.0) 8.0 (4.9-13.2) <0.001 9.0 (5.1-15.9) <0.001
Thrombocyto-
penia
     Severe 



















Values in columns 2 and 3 represent n (%). For the adjusted ET group, only complications which 




This study demonstrates that treatment with ET in neonates with HDFN is associated 
with an increased risk of sepsis, thrombocytopenia, leukocytopenia, hypocalcemia and 
hypernatremia. Treatment with ET was not associated with neonatal death in our cohort.
Several studies have been published on neonatal morbidity due to treatment with ET.2-9 One 
of the known risk factors associated with ET is development of invasive bacterial infections. 
The reported incidence of ET-related sepsis ranges from 0% to 11%.4,6,8 The incidence of 
proven sepsis detected in this study (8%) is in accordance with these previous reports. 
We found that the independent risk of sepsis was more than eight times higher in the ET-
group. The exact cause of increased risk of infection is not fully understood, but is most 
probably related to the use of UVCs for ET. UVCs are a well-known risk factor for nosocomial 
infection.20 Sepsis in the ET-group may also be caused by administration of infected blood 
products. Although the current risk of transmission of infectious diseases is relatively low, 
it is not completely negligible.5,21 Furthermore, ET-related wash out of leukocytes may also 
play a role in the higher incidence of sepsis in the ET-group, since in double volume ET more 
than 90% of circulating blood is replaced by leukocyte-depleted donor-blood.21,22 Finally, 
limited data on leukocytopenia in neonates with HDFN due to red cell alloimmunization 
show that the risk of leukocytopenia is increased in severe Rhesus HDFN.23,24 In this study 
86% (12/14) of neonates with proven sepsis had leukocytopenia of whom 11 were treated 
with ET. In 55% (6/11) leukocytopenia occurred after treatment with ET. In the remaining 
45% leukocytopenia might be caused by bone marrow suppression due to increased 
erythropoiesis.
Another important ET-related complication is PVT. Risk factors for PVT include umbilical 
catheterization and ET.25 However, none of the included infants in our study was diagnosed 
with PVT, probably because in this retrospective study no standard ultrasound to detect PVT 
after umbilical catheterization and/or ET has been performed. 
Another reported risk associated with ET is thrombocytopenia due to the use of 
a thrombocyte-free blood product.26 Previous studies reported incidences of ET-
related thrombocytopenia ranging from 6% to 44%.2-4,6,8,9 In our study, the incidence of 
thrombocytopenia in the ET-group was much higher, almost all neonates (99%) had low 
platelet counts and 63% had severe thrombocytopenia. Differences in incidence can be 
explained by differences in methodology and study population. We only included neonates 
with red cell alloimmune HDFN which is known to be associated with an increased risk for 
thrombocytopenia, even without ET.14,27,28 Because other studies included neonates with 
ABO-incompatibility, their incidence of thrombocytopenia should be lower. In this study, 
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the risk of severe thrombocytopenia is 21-fold higher in the ET-group. Neonatologists must 
be aware of this potentially devastating complication as massive hemorrhage may arise 
after ET. Complications can be prevented by prophylactic platelet transfusion. In our study, 
platelet transfusions were administered in 57% of neonates before, during or after ET. 
A further complication of ET is hypocalcemia, resulting from the use of citrated blood 
which contains almost no free calcium.26,29 Previous studies reported incidences ranging 
from 3% to 42%.4,8,10,11 In our study, 22% of neonates in the ET-group had hypocalcemia, 
and 13% needed replacement therapy. Treatment with ET was independently associated 
with an almost 30-fold increased risk of hypocalcemia. If left untreated, hypocalcemia can 
lead to potentially devastating complications such as seizures and cardiac arrhythmias. It is 
therefore crucial to measure calcium levels during the ET-procedure and act accordingly.  
Another metabolic complication related to ET is hypernatremia.  Hypernatremia probably 
results from an increased level of sodium in citrated blood. Only few studies have reported 
on hypernatremia resulting from ET, and the exact incidence is unknown.30,31 Because 
hypernatremia can lead to serious complications we recommend frequent measurements 
of serum sodium levels during and after ET.
Finally, previous studies have reported that ET may also lead to neonatal death. Neonatal 
mortality attributable to ET ranges between 0.5% and 2%.2,6-8 In accordance with our 
findings, three recent studies reported no ET-related deaths.3,4,9 However, these studies (as 
well as ours) were not powered to detect a difference in neonatal mortality. Differences 
between reported rates can be explained by methodological differences such as different 
sizes of study cohorts and differences in disease-severity between cohorts. Neonates 
included in previous studies were often more premature than our study-population.7-9 
Another explanation could be that our center is the national referral center for intrauterine 
treatment of red cell alloimmunization. Consequently all severely affected neonates with 
HDFN are born and treated in our center. As a result, ET is a frequently performed and 
standardized procedure and part of routine practice. We speculate that this may have 
contributed to the low level of severe morbidity and mortality in the ET-group. Operator’s 
experience (‘learning curve’) could also be a factor in the reduction of morbidity and 
mortality in the ET-group. 
Future alternative treatments for hyperbilirubinemia might theoretically further reduce the 
rate of ET and consequently decrease morbidity and mortality rates.32
In conclusion, sepsis, leukocytopenia, thrombocytopenia, hypernatremia and hypocalcemia 
are common complications in neonates with HDFN due to red cell alloimmunization treated 
with ET. In experienced hands severe permanent morbidity and mortality rates due to ET-
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Despite limited data, international guidelines recommend the use of intravenous 
immunoglobulin (IVIg) in neonates with Rhesus hemolytic disease. 
Objective
To test whether prophylactic use of IVIg reduces the need for exchange transfusions in 
neonates with Rhesus hemolytic disease.
Design and setting
We performed a randomized, double-blind, placebo-controlled trial in neonates with 
Rhesus hemolytic disease. After stratification for treatment with intrauterine transfusion, 
neonates were randomly assigned for IVIg (0.75 g/kg) or placebo (glucose 5%). The primary 
outcome was the rate of exchange transfusions. Secondary outcomes were duration of 
phototherapy, maximum bilirubin levels, and the need for top-up red cell transfusions.
Results
Eighty infants were included, of whom 53 (66%) were treated with intrauterine 
transfusion(s). There was no difference in the rate of exchange transfusions between the 
IVIg and placebo groups (17% (7 of 41) versus 15% (6 of 39), p = 1.00) and in number of 
exchange transfusions per patient (median (range): 0 (0-2) versus 0 (0-2), p = 0.90), or in 
duration of phototherapy (4.7  ± 1.8 versus 5.1 ± 2.1 days, p = 0.34), maximum bilirubin 
levels (14.8 ± 4.7 versus 14.1 ± 4.9 mg/dL, p = 0.52) and proportion of neonates requiring 
top-up red cell transfusions (83% (34 of 41) versus 87% (34 of 39), p = 0.76). 
Conclusion
Prophylactic IVIg does not reduce the need for exchange transfusion or the rates of other 
adverse neonatal outcomes. Our findings do not support the use of IVIg in neonates with 
Rhesus hemolytic disease.
RCT on IVIg in neonatal Rh hemolytic disease
65
Introduction
Rhesus hemolytic disease of the neonate (HDN) may lead to excessive hyperbilirubinemia 
and permanent brain damage due to kernicterus. Traditional neonatal treatment of Rhesus 
HDN consists of intensive phototherapy and exchange transfusion (ET). Phototherapy 
lowers bilirubin through photo-oxidation, whereas ET removes bilirubin and hemolytic 
antibodies, and corrects anemia.1 However, ET is a high-risk invasive procedure associated 
with a significant rate of adverse effects. Although the mortality rate associated with ET is 
nowadays reported to be less than 0.3% in term infants, the morbidity rates can reach 24% 
and includes catheter-related complications, sepsis, thrombocytopenia and hypocalcemia.1-7 
Neonatal treatment with intravenous immunoglobulin (IVIg) has been suggested as an 
alternative therapy for ET in Rhesus HDN.8 In many Western countries, including the 
Netherlands, IVIg is widely used.9 A few small randomized controlled trials (RCT) reported 
that IVIg combined with phototherapy reduces serum bilirubin levels and the need for 
ET in neonates with Rhesus HDN compared to phototherapy alone.10-13 In these studies, 
treatment with IVIg reduced the duration of phototherapy and length of hospitalization, but 
increased the need for top-up red cell transfusions. 
Recommendations for the routine use of IVIg are controversial due to various 
methodological limitations of the studies. A Cochrane review suggested in 2002 that the 
results of further trials of higher quality should be awaited.14 The American Academy 
of Pediatrics (AAP) recommended in 2004 the use of IVIg (0.5–1 g/kg) in Rhesus HDN in 
case of failure of phototherapy, based on the same limited data.8 Given these conflicting 
recommendations, a well-designed RCT for the use of IVIg in Rhesus HDN was urgently 
needed. We hypothesized that IVIg reduces the need for ET and we designed an RCT to 
address this question.  
Patients and Methods
We performed a randomized single-center double-blind placebo-controlled trial (http://
www.trialregister.nl/trialreg/admin/rctview.asp?TC=832). The Leiden University Medical 
Center (LUMC) is the national referral center for the management and intrauterine 
treatment of red cell alloimmunization in the Netherlands. All neonates of 35 or more 
weeks of gestation with Rhesus HDN, born between 2006 and 2010 and admitted to the 
neonatal nursery of the LUMC were eligible. Rhesus HDN was defined as (1) Maternal 
Antibody Dependent Cellular Cytotoxicity-test (ADCC) >50%, a validated functional test 
predicting severe hemolysis and comparable with a titer of >1:6415 and (2) positive direct 
Chapter 5 
66
antiglobulin test caused by anti-Rhesus D (RhD)  or c antibodies in the  fetus/neonate of a 
RhD or c negative mother. We excluded all neonates (1) with perinatal asphyxia (defined as 
an Apgar score at 5 minutes less than 3 and/or umbilical cord arterial pH less than 7.0), (2) 
with hemolytic disease other than RhD or c and (3) with Rhesus HDN presenting >4 hours 
after birth.
Written informed parental consent was obtained before birth. After stratification into 
two groups (with and without IUT), infants were assigned at birth to the IVIg treatment 
group (IVIg-group) or placebo control group (placebo-group) through pharmacy-controlled 
randomization. Method of treatment allocation was computer-generated randomization 
sequence, with randomization code kept by the chief pharmacist. The block size for 
randomization was 4 in the IUT-group and 2 in the group without IUT (because of the 
expected smaller proportions of infants in the non-IUT-group). The hospital pharmacy 
provided identical coded drug boxes and infusion solutions were delivered in sequentially-
numbered identical vials containing either IVIg or placebo. To prevent discrepancy between 
two children of the same family, in case of twins the same vial was used for both children. 
Clinicians, nurses and parents were blinded to the randomization and allocation.
In the IVIg-group, patients received conventional intensive phototherapy plus prophylactic 
IVIg as a single dose of 0.75 g/kg (administered in approximately 5-6 hours) starting within 
the first 4 hours after birth. In the placebo-group, patients received conventional intensive 
phototherapy plus an equal amount of glucose 5% intravenous infusion.
The IVIg product used in this trial (Nanogam®, Sanquin Amsterdam, The Netherlands) is 
treated with solvent-detergent to inactivate enveloped viruses and subjected to filtration 
through a 15 nanometer filter to remove non-enveloped viruses, including Parvo B19. 
Nanogam® contains more than 95% monomeric IgG and no aggregates.
All infants with Rhesus HDN admitted to our neonatal nursery receive intensive 
phototherapy directly after birth using white light with an intensity of 12-20 µW/cm/nm 
given by air shield and Ohmeda lamps, in combination with a bilirubin-blanket providing 
blue light 30 µW/cm/nm. During phototherapy, extra fluids (10 ml/kg) are administered. 
Phototherapy and ET were performed according to the latest AAP guidelines.8 The criteria 
for ET were: (1) total serum bilirubin above (higher) ET thresholds and/or (2) rise of bilirubin 
>0.5 mg/dL/hr despite intensive phototherapy, and/or (3) clinical symptoms of acute 
bilirubin encephalopathy regardless of bilirubin level. ET criteria were not based on fixed 
bilirubin thresholds, but were derived from the nomograms of AAP and varied according 
to postnatal age (hours/days) of the neonate. ET was performed with double-volume 
transfusion (160 mL/kg) using irradiated and leukocyte-depleted compatible erythrocytes. 
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We recorded the following obstetric and neonatal data: fetal hemoglobin (Hb) 
concentration and gestational age at first IUT, number of IUTs, gestational age at birth, birth 
weight, Hb concentration, reticulocyte count and bilirubin level from cord blood at birth, 
maximum bilirubin level during admission, duration of phototherapy and admission (days), 
number of ETs required, number of top-up red blood cell transfusions received during the 
first 3 months of life and Hb levels prior to top-up transfusion. Hb levels were measured 
routinely every week up to three months of age. After discharge from our center, top-up 
transfusions were performed in referring hospitals when Hb levels were <8.0 g/dL, or <9.6 
g/dL in the presence of clinical symptoms of anemia (such as lethargy, feeding problems, 
need for oxygen or failure to thrive). Folic acid (50 mcg/day) was administered orally during 
the first three months of life to all neonates. Data on the number of top-up transfusions and 
Hb levels in infants managed (after discharge) outside our center were collected through 
correspondence with the local pediatrician or blood transfusion department.
Primary outcome was the rate of ET and the number of ETs per infant. Secondary outcomes 
were duration of phototherapy and hospital stay, maximum serum bilirubin levels and the 
need for top-up red cell transfusions in the first three months of life.
Statistical analysis
Based on the available literature, we calculated that a minimum of 40 infants in each study 
arm was required to demonstrate a 5-fold reduction in need for ET between the placebo-
group and the IVIg-group (30% versus 6%) with a significance of 0.05 and a power of 80%, 
by two-tailed analysis. The expected rate (30%) of ET in the placebo-arm was derived from 
the recorded incidence on ET at our department in 2005-2006. The expected rate (6%) 
of ET in the IVIg-group was calculated from the reported data in the literature (Gottstein 
and Cooke)11. According to the meta-analysis from Gottstein and Cooke, the use of IVIg in 
neonates with Rhesus HDN could lead to a 5-fold reduction in the incidence of ET (relative 
risk (RR) 0.21, 95% confidence intervals (CI) 0.10 to 0.45).
Data are reported as means and standard deviations (SD) or as median and ranges, as 
appropriate. Statistical analysis was performed using Student-t-test and Mann-Whitney 
test for continuous variables. Chi square and Fisher’s exact test were used for categorical 
variables, as appropriate. A p-value <0.05 was considered statistically significant. Statistical 




A total of 121 neonates with Rhesus hemolytic disease were born in the study period, of 
whom 41 (34%) were excluded (Figure 1). We enrolled 80 patients in the study, 41 patients 
in the IVIg-group and 39 in the placebo-group. One pair of twins was included in the IVIg-
group. Both children received IVIg from the same vial according to the protocol. During 
infusion of the study medication no potential side-effects such as hypotension, tachycardia 
or allergic reactions were reported. The baseline characteristics of the two treatment 
groups were similar (Table 1). 
Figure 1. Flow diagram of study participants
Neonatal outcome: phototherapy and ET
All neonates were treated with intensive phototherapy directly after birth. The mean 
number (SD) of days of phototherapy in neonates in the IVIg-group and placebo group was 
4.7 (1.8) and 5.1 (2.1), respectively (p = 0.34). At least one ET was required in 17% (7/41) of 
the neonates in the IVIg-group compared to 15% (6/39) in the placebo-group (p = 1.00). The 
median number of ETs in the IVIg-group and placebo-group was 0 (range 0-2) and 0 (range 
0-2), respectively (p = 0.90). Median time from birth to (first) ET was 44 hours (range 9-60) 
in the IVIg-group and 31 hours (range 22-66) in the placebo-group. IVIg or placebo was 
administered within the first 4 hours after birth.
121 neonates assessed for eligibility
80 randomly assigned
41 excluded:
6 gestational age < 35 weeks
16 hemolytic disease other than 
Rhesus D or c
19 refused to participate
41 assigned to IVIg-group
41 included in analysis 39 included in analysis
39 assigned to placebo-group
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Gestational age at birth, weeksa 36.7 ± 1.0 36.5 ± 0.6 0.23
Birth weight, gramsa 2994 ± 485 2953 ± 424 0.68
Male, n (%) 29 (71) 25 (64) 0.64
Neonates treated with IUT, n (%) 27 (66) 26 (67) 0.99
Number of IUTs per neonateb 1 (0-4) 1 (0-6) 0.47
Gestational age at first IUT, weeksa 29 ± 4 28 ± 6 0.44
Hemoglobin level at first IUT, g/dLa 6.9 ± 2.2 6.5 ± 2.3 0.44
Rhesus D immunization, n (%) 36 (88) 35 (90) 0.59
Hemoglobin level at birth, g/dLa 12.2 ± 2.9 11.9 ± 2.6 0.52
Reticulocyte count at birth, ‰a 64 ± 51 52 ± 57 0.31
Bilirubin level at birth, mg/dLa 7.0 ± 3.9 5.7 ± 2.3 0.07
a Value given as mean ± SD, b Value given as median (range)
Maximum mean bilirubin levels during admission were similar in both groups (14.8 ± 
4.7 versus 14.1 ± 4.9 mg/dL, respectively (p = 0.52). Similar results for the primary and 
secondary outcomes were observed for the sub-groups of neonates after stratification for 
treatment with or without IUT. Detailed information on neonatal treatment and outcome in 
both groups, overall and after stratification for IUT, is presented in Table 2. 
One included patient developed a Bacillus cereus sepsis with brain abscesses a few days 
after an ET performed through an umbilical venous catheter. Because of this serious adverse 
event the randomization code for the patient was opened and showed that the infant 
had received IVIg. Sterility tests on the used IVIg batches were subsequently performed 
and found to be sterile. In addition, cultures of all donor blood products used for the IUTs 
and ET were examined and found to be sterile. Therefore the cause of infection remained 
unclear and may have been related to the umbilical venous catheterization and ET. Detailed 
information on this exceptional case can be found in a case report.16
 
Top-up transfusions
The percentage of neonates requiring a top-up transfusion in the IVIg-group and placebo-
group was 83% (34/41) and 87% (34/39), respectively (p = 0.76). The median number of 
top-up transfusions per neonate in the IVIg-group and placebo-group was 2 (range 0-6) and 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































median number of days until first top up transfusion were similar in both groups. Detailed 
information on the use of top-up transfusions in the IVIg-group and the placebo-group is 
presented in Table 3.
Discussion
In this RCT we have shown that prophylactic treatment with IVIg in neonates with Rhesus 
hemolytic disease did not reduce the need for ET or the rates of other adverse neonatal 
outcomes. Our results do not support the recommendation to give IVIg in Rhesus hemolytic 
disease, as stated in recent AAP guidelines8. Our study adds to the Cochrane analysis that 
there is no evidence to recommend routine use of IVIg.14
In the past, several studies have suggested a positive effect of IVIg in reducing the rate of 
hemolysis in Rhesus hemolytic disease.10,12,13,17-19 Although the exact mechanism of action 
of IVIg remains unclear, IVIg has been reported to block Fc-receptors on macrophages, 
resulting in a decreased removal of anti-Rh antibody coated erythrocytes from the 
circulation. IVIg might increase IgG catabolism, resulting in a shorter half-life of antibodies 
(including anti-Rh antibodies). A third hypothesis is the presence of anti-idiotypic antibodies 
in IVIg neutralizing anti-Rh antibodies.12,20-22
Our results are in contrast with the most recent recommendations of the AAP to use 
0.5-1.0 g/kg IVIg in Rhesus hemolytic disease in case of failure of phototherapy.8 These 
guidelines were published in 2004 and based on a limited number of small RCTs. Several 
important methodological limitations hampered the interpretation of these studies, 
including sub-optimal study-designs and the wide range of inclusion criteria.18,19 The 
Cochrane Collaboration performed a review on three studies, in which a total of 189 
infants were included.10,12-14 Rubo et al.10 included 32 infants with Rhesus hemolytic 
disease in a multicenter RCT. No details on IUT and gestational age were given. Several 
years later Dagoglu et al.13 included 29 preterm and 12 term infants in an RCT. Cut-off for 
prematurity and criteria for top-up red cell transfusions were not defined. In 1999 Alpay 
et al.12 enrolled 116 infants, predominantly with ABO incompatibility (n = 93), but also 
neonates with Rhesus hemolytic disease (n = 16) and both Rh and ABO incompatibility (n 
= 7) were included. However, results were not given for each group separately. None of 
the studies described detailed phototherapy guidelines and none of them used a placebo 
in the control-group or described any method of blinding the intervention after allocation 
concealment. According to the Cochrane review, none of the trials fulfilled criteria for 
high quality study. Our study is the first well-designed randomized double-blind placebo-
controlled trial on this topic.  
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In 4 other studies, infants with ABO incompatibility were included.12,17,18,23 In general, 
compared to Rhesus immunization, ABO incompatibility causes less severe hemolysis and 
therefore less neonatal morbidity.24 For that reason, we included only neonates with Rhesus 
disease. These important methodological differences between our study and the previous 
ones may explain the discordant results. 
Several other explanations can be envisaged to explain the lack of effect of IVIg in our 
study. A possible explanation could be the treatment with intensive and prophylactic 
phototherapy starting immediately after birth, thereby reducing the risk of severe 
hyperbilirubinemia. In addition, the majority of infants included in our study were treated 
with IUT. By IUT, Rhesus incompatible erythrocytes of the fetus are replaced by Rhesus 
compatible cells of the donor. Dependent on the interval between the last IUT and delivery, 
these donor cells are still present after birth, resulting in less or more delayed hemolysis.25, 
26 However, several groups including ours have shown that even after IUT, neonates with 
Rhesus hemolytic disease still often require ET.27,28 In our study, IVIg was neither effective 
in the IUT group or in the group without IUT. However, the number of patients included 
in the subgroup without IUT (n = 27) may be too small to draw firm conclusions. Recently, 
a research group from Brazil finalized a similar RCT on IVIg for neonates with Rhesus 
hemolytic disease and, in accordance with our results, found no difference between both 
groups on the rate of ET. Importantly, in their study the vast majority of patients (n = 80) 
had no prior treatment with IUT (ClinicalTrials.gov NCT00288600).29 Therefore, both our 
RCT and the RCT from the Brazilian research group failed to show any effect of IVIg in 
Rhesus hemolytic disease infants, irrespective of whether or not the infants were treated 
with IUT. Care should be taken when interpreting our results, particularly the sub-group 
analyses, due to the relatively limited number of patients. In addition, caution should be 
used before applying the results of this study to all Rhesus isoimmunized infants. There may 
be a subset of Rhesus isoimmunized infants with (inappropriate) delayed start of intensive 
phototherapy, for whom IVIg might be effective. More studies are needed to study the 
effect of IVIg in this specific subset of infants.
Although IVIg is considered to be an extremely safe product, adverse events can not be 
totally eliminated. Rare but serious side effects such as transfusion transmitted diseases, 
anaphylaxis, hypersensitivity, thrombosis, pulmonary emboli and renal failure have been 
reported.21,22 Recently, Figueras-Aloy et al.30 reported a higher incidence of necrotizing 
enterocolitis (NEC) in near-term infants with Rhesus hemolytic disease treated with IVIg 
compared to a control group managed without IVIg. The authors correctly suggest that their 
results must be interpreted with care given the retrospective nature of the study. Whether 
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occurrence of NEC was related to the administration of IVIg or to the fact that infants 
receiving IVIg were more ill than the control group is not clear. Nevertheless, since potential 
(but rare) adverse effects associated with the use of IVIg can not be ruled out, the authors 
call for more caution when using IVIg in neonates with Rhesus hemolytic disease. IVIg is a 
blood product prepared by separating the gamma-globulin fraction from the plasma pooled 
from multiple donors. The manufacturing of IVIg, including fractionation and filtration 
of viruses is an extremely intensive and expensive process. Therefore, the use of IVIg for 
indications that are not confirmed by well-designed RCTs should be restricted.22
In conclusion, prophylactic treatment with IVIg (in a dosage of 0.75 g/kg) did not reduce the 
need for ET or the rates of other adverse neonatal outcomes. Our findings do not support 
the current recommendations of the AAP to use IVIg in neonates with Rhesus hemolytic 
disease. In view of the absence of beneficial effects, the use of IVIg for this indication should 
be discouraged.
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Exchange transfusion (ET) and phototherapy have traditionally been used to treat jaundice 
and avoid the associated neurological complications. Because of the risks and burdens of 
ET, intravenous immunoglobulin (IVIg) has been suggested as an alternative therapy for 
alloimmune hemolytic disease of the newborn (HDN) to reduce the need for ET.
Objectives
To assess whether, in newborns with alloimmune HDN, IVIg is effective in reducing the need 
for ET.
Search methods
Electronic searches were made of PubMed, Embase (OVID version), COCHRANE Library 
(including CENTRAL), Web of Science, CINAHL (EbscoHost-version), Academic Search 
Premier and the trial registers clinicaltrials.gov and controlled-trials.com. Reference lists 
of included and excluded trials and relevant reviews were searched for further relevant 
studies.
Selection criteria
All randomized and quasi-randomized controlled trials of the use of IVIg in the treatment of 
alloimmune HDN were considered. Trials must have used predefined criteria for both IVIg 
and ET therapy to be included.
Data collection and analysis
The standard methods of the Cochrane Collaboration and its Neonatal Review Group 
were used. Studies were assessed for inclusion and quality and data were extracted by 
two reviewers working independently. Any differences of opinion were discussed and a 
consensus reached. Investigators were contacted for additional or missing information. For 
categorical outcomes, relative risk (RR) and number needed to treat (NNT) were calculated. 
For continuous variables, mean difference (MD) was calculated.
Results
Fourteen studies fulfilled inclusion criteria and included a total of 942 infants. Term and 
preterm infants with Rh and/or ABO incompatibility were included. The use of ET decreased 
significantly in the immunoglobulin treated group (RR 0.40, 95% CI 0.27 to 0.59; NNT 5.4). 
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Mean number of ETs per infant was also significantly lower in the immunoglobulin treated 
group (MD -0.31, 95% CI -0.45 to -0.17). However, subgroup analysis of the only two high 
quality studies showed no difference in the need for or number of ETs. Two studies assessed 
long-term outcomes and found no cases of kernicterus, deafness or cerebral palsy.
Authors’ conclusions
Although overall results show a significant reduction in the need for ET in infants treated 
with IVIg, the applicability of the results is limited. The only two high quality studies show 
no benefit of IVIg in reducing the need for and number of ET. Further well designed studies 





Description of the condition  
The use of anti-D prophylaxis in Rh D negative women has led to a marked decline in Rh 
hemolytic disease of the newborn (HDN). However, anti-D immunoglobulin is in short 
supply world-wide. Sensitization can occur despite immunoprophylaxis, particularly if it 
is given too late or in insufficient dose. Fetal therapy has led to a reduction in severity of 
disease in Rh sensitized fetuses, but it does not comprehensively prevent need for neonatal 
treatment. A proportion of significant HDN is caused by antibodies to antigens other than 
Rh D and is therefore not preventable with anti-D immunoglobulin. Primary modes of 
postnatal therapy include phototherapy and exchange transfusion (ET) to reduce risk of 
mortality and kernicterus. Top-up transfusions are used to treat early and late anemia. In 
contemporary perinatal centers, 15-40% of neonates admitted for Rh or ABO HDN require 
at least one ET.1,2
The safety of ET has been reported for over 50 years. Published mortality rates vary from 
0.53-4.7% per infant.3-9 ET-related death is more common in sick or premature infants than 
in healthy term infants.1,4,6,7 Rates of morbidity and ET-related adverse events as high as 
74% have been reported. Risks related to ET include adverse cardio-respiratory events, 
catheter-related complications, those related to the use of blood products, metabolic 
derangements and other serious complications such as pulmonary hemorrhage, necrotizing 
enterocolitis, and bowel perforation.1,3,6,7,9-12 Because improved perinatal care has reduced 
the need for ET, the complication rate could increase as clinicians become less experienced 
with the procedure.1 However, Steiner et al. reported that over a 21 year period, despite a 
sharp decline in the number of ETs performed, no increase in morbidity and mortality was 
observed.1 
Description of the intervention  
Intravenous immunoglobulin (IVIg) is an alternative therapy that may be effective in treating 
alloimmune HDN. In 1987 the first report of successful treatment of late anemia due to Rh E 
incompatibility with IVIg was published.13 Subsequent case reports and case series reported 
success of IVIg treatment in neonates with both Rh or ABO incompatibility.14-16 However, 
Hammerman et al. found a reduced or no response to IVIg treatment in infants with ABO 
incompatibility who had early and severe hemolysis.17 In the last two decades several 
quasi-randomized or randomized controlled trials on the use of IVIg to reduce ET have been 
published. Timing of administration of IVIg varied from a few hours to several days after 
birth, single doses varied from 0.5 g/kg to 1 g/kg and total doses from 0.5 g/kg to 2.25 g/kg.
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The potential benefits of IVIg over ET include that the treatment is less complicated and 
less labor intensive. In addition, IVIg could allow safe treatment of some infants in less 
sophisticated neonatal units, or avoid delaying treatment whilst transferring infants for 
ET. Comprehensive assessment of IVIg in premature infants, particularly in the treatment 
of sepsis, has shown that it is safe and well tolerated.18 It is a well-established therapy for 
alloimmune thrombocytopenia due to maternal and fetal human platelet antigen (HPA) 
incompatibility. The risk of transmission of viral infection is extremely low.19 Hemolysis and 
acute renal failure have been reported as uncommon complications of IVIg treatment.20 One 
study showed an increased incidence of sepsis in premature infants receiving prophylactic 
IVIg.21 A recent case-control study showed a higher incidence of necrotizing enterocolitis 
in near-term infants with Rh HDN treated with IVIg.22 Other rare serious side effects of IVIg 
have been described in pediatric and adult cohorts, but not in newborns.23
 
How the intervention might work  
IVIg might reduce the rate of hemolysis in alloimmune HDN by non-specific blockade of 
Fc-receptors. Red blood cells are probably destroyed by an antibody-dependent cytotoxic 
mechanism mediated by Fc-receptor bearing cells of the neonatal reticuloendothelial 
system.24 Ergaz et al. demonstrated a decline in carboxyhemoglobin levels in four of 
five infants treated with IVIg for alloimmune HDN.25 Hammerman et al. demonstrated 
a significant reduction in carboxyhemoglobin levels in 19 of 26 Coombs positive infants 
treated with IVIg.26 Carboxyhemoglobin levels are a sensitive index of hemolysis and hence 
these studies suggest that immunoglobulin could decrease hemolysis.
Why it is important to do this review  
This is an update of a Cochrane review first published in 2002. Although results of the 
previous review showed a significant reduction in the need for ET in infants treated with 
IVIg, the applicability of the results was limited because none of three included studies was 
of high quality. Nevertheless, American Academy of Pediatrics (AAP) guidelines recommend 
the administration of 0.5-1 g/kg IVIg in alloimmune HDN if total serum bilirubin (TSB) is 
rising despite intensive phototherapy or if TSB level is within 34-51 µmol/L (2-3 mg/dL) of 
exchange level.27 As a result of these guidelines, despite the equivocal conclusions of the 
previous Cochrane review, the use of IVIg in alloimmune HDN has become widespread in 
many countries. However supplies of IVIg are limited and it does present some hazards. 





To assess the effect of IVIg in newborn infants with alloimmune HDN on the need for and 
number of ETs. The review also assesses complications of therapy, short-term outcomes 
such as bilirubin levels, duration of phototherapy and hospitalization, top-up transfusion 
requirements, and long-term outcomes such as hearing loss, kernicterus and cerebral palsy.
Methods  
Criteria for considering studies for this review  
Types of studies  
All randomized and quasi-randomized controlled trials of IVIg in the treatment of 
alloimmune HDN.
Types of participants  
Neonates with alloimmune HDN due to either Rh or ABO blood group antibodies with or 
without any other blood group antibodies.
Types of interventions  
IVIg given for treatment of alloimmune HDN, versus control (placebo or “standard care”). 
Early and late IVIg administration have been defined (for this review) as IVIg started within 
or after the first 12 hours of life, respectively. Studies should include predefined criteria for 
both IVIg and ET therapy.
Types of outcome measures  
Primary outcomes  
Efficacy:
•• Use of ET (proportion of infants receiving one or more ETs)
•• ETs performed per infant
Secondary outcomes  
Efficacy:
•• Use of top-up transfusion(s) in first week of life (% of infants)
•• Number of top-up transfusions performed in first week of life per infant
•• Use of top-up transfusion(s) after first week of life (% of infants)
•• Number of top-up transfusions performed after first week of life per infant
•• Maximum total serum bilirubin (TSB) (µmol/L (mg/dL))
Cochrane review on IVIg for alloimmune HDN
85
•• Duration of phototherapy (days)
•• Duration of hospitalization (days)
•• Incidence of sensorineural hearing loss (any severity)
•• Incidence of kernicterus
•• Incidence of cerebral palsy
Safety:
•• Neonatal mortality
•• Incidence of adverse reactions possibly related to the use of IVIg or ET
Search methods for identification of studies  
Electronic searches  
We performed a search in PubMed, Embase (OVID version), COCHRANE Library (including 
CENTRAL), Web of Science, CINAHL (EbscoHost-version), and Academic Search Premier. 
The subject query was applied in all databases taking into account the terminological 
differences between these databases. The query consisted of the combination of four 
subjects: immunoglobulins, alloimmune hemolytic jaundice, newborn infants, and 
randomized controlled trials. Various synonyms and related terms for all subjects were 
used. Two search strategies were used: the first strategy was limited to randomized trials 
and systematic reviews, the second strategy included only the subjects immunoglobulins 
and alloimmune hemolytic disease (and synonyms and related terms for those subjects). 
The search was performed on the 22nd of March 2012. The bibliographic databases yielded 
1251 references in total of which titles and abstracts were screened. In addition to database 
searches, searches were made of the trial registers clinicaltrials.gov and controlled-trials.
com. No language restrictions were applied.
Searching other resources  
We searched the reference lists of all included and excluded trials and relevant reviews for 
further relevant studies.
Data collection and analysis  
The standard method of the Cochrane Collaboration and its Neonatal Review Group was 
used.
Selection of studies  
Two reviewers independently screened all 1251 references for possible inclusion using 
predefined criteria for inclusion (see below). If a report appeared to meet inclusion criteria 
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for the review, or if it was not clear based on title and abstract, a full text version of the 
article was obtained. Any disagreements were resolved through discussion.
The inclusion criteria for this review were:
•• Randomized and quasi-randomized controlled trials
•• Study compared IVIg with any definition of “standard care” plus placebo, or with any 
definition of “standard care” without placebo
•• Study included patients with alloimmune HDN due to either ABO or Rh blood group 
antibodies with or without any other blood group antibodies
•• Study measured ETs (primary outcome) for each study arm and/or at least one of the 
secondary outcomes for each study arm
•• Study used predefined criteria for both IVIg and ET therapy
Data extraction and management 
Two review authors independently extracted data using a data collection form that was 
pilot tested before use. Any disagreements were resolved through discussion and if 
necessary with the help of a third reviewer blinded to trial author, institution and journal of 
publication. One review author contacted authors of studies that did not report all required 
data or information. Data were entered into Review Manager 5.1 by one review author and 
checked by at least one review author.
Assessment of risk of bias in included studies  
Two review authors independently assessed the risk of bias in included studies using 
the ‘Risk of bias’ tool as described in the Cochrane Handbook for Systematic Reviews 
of Interventions version 5.1.0 (Higgins 2011).28 The following items for risk of bias were 
assessed: random sequence generation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, incomplete outcome data, selective 
reporting, and other sources of bias. Each item was rated as ‘Low risk of bias’, ‘Unclear risk 
of bias’ or ‘High risk of bias’. Any differences of opinion were discussed with a third blinded 
reviewer and a consensus reached. For selective reporting the following criteria were used 
to rate a study as ‘Low risk of bias’:
•• For studies enrolling neonates with Rh or both Rh and ABO HDN: reporting (in paper or 
subsequent correspondence) at least one outcome related to each of ET, bilirubin and 
top-up transfusion, plus adverse effects and hospitalization.
•• For studies enrolling only neonates with ABO HDN: reporting (in paper or subsequent 
correspondence) at least one outcome related to each of ET and bilirubin, plus adverse 
effects and hospitalization. Top-up transfusion was not considered to be a preferred 
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outcome measure because anemia requiring treatment is an unusual consequence of 
ABO alloimmune hemolysis.
•• Study protocols or methods section of papers should not describe an intention to 
report outcomes that were not subsequently reported in the paper.
Measures of treatment effect  
For categorical outcomes, such as the incidence of ET, the relative risk (RR) was calculated. 
For continuous variables, such as the maximum bilirubin level, the mean difference (MD) 
was calculated. The number needed to treat (NNT) to avoid ET was also calculated.
Dealing with missing data  
Investigators were contacted for missing information about study design and/or results.
Assessment of heterogeneity  
Clinical heterogeneity was assessed by determining whether clinical characteristics of 
patients, interventions, outcome measures and timing of outcome measurements were 
similar for included studies. Statistical heterogeneity was assessed using Chi2 and I2 tests. An 
I2 test of ≥50% was considered as substantial or considerable heterogeneity according to the 
Cochrane Handbook.28
Assessment of reporting biases  
Funnel plots were used to assess publication bias for those outcomes with ≥10 trials. No 
substantial asymmetry was encountered in the funnel plots.
When selective reporting bias was suspected based on the criteria described under 
‘Assessment of risk of bias in included studies’, investigators were contacted to request the 
missing outcome data.
If the data remained unavailable and the absence was thought to introduce serious bias, 
the impact of including such studies was explored in the overall assessment of results by a 
sensitivity analysis.
Data synthesis  
Review Manager 5.1 was used to synthesize the available data. Whether a fixed-effect 
model or a random-effects model was used, depended on the level of clinical heterogeneity, 
the results of the Chi² test and I² statistic for heterogeneity28 and the number of included 
studies for an outcome. If substantial heterogeneity was detected and the number of 
included studies on that outcome was ≥10, a random-effects model was used and the 
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sources of heterogeneity examined. If no substantial statistical heterogeneity was detected 
or the number of included studies on an outcome was <10, a fixed-effect model was used.
Subgroup analysis and investigation of heterogeneity  




3. Gestational age at birth (<37 weeks and ≥37 weeks)
Intervention:
1. Early administration of IVIg: start of IVIg ≤12 hours after birth
2. Late administration of IVIg: start of IVIg >12 hours after birth
3. Single versus multiple doses
Quality of studies (see ‘Sensitivity analysis’)
Sensitivity analysis  
We conducted a sensitivity analysis based on the quality of included studies. We considered 
a study to be of high quality if it was rated as low risk of bias for random sequence 
generation, allocation concealment, blinding (performance and detection bias), incomplete 
outcome data, selective reporting and other risk of bias (if present).
Results  
Description of studies  
Detailed information of included and excluded studies is provided in Appendix 1 and 2.
Results of the search  
The search conducted up until 22 March 2012 identified a total of 1251 references. After 
title and abstract screening, the full text of 26 references was screened. After full text 
screening 14 studies were included in the meta-analysis (Rübo 1992; Dağoğlu 1995; Atici 
1996; Rübo 1996; Alpay 1999; Pishva 2000; Tanyer 2001; Garcia 2004; Miqdad 2004; Nasseri 
2006; Elalfy 2011; Hematyar 2011; Smits-Wintjens 2011; Santos 2011).2,29-41 Details of the 
studies are given in the table of included studies. Two studies have been excluded until 
further information is available from the authors.42,43 Three studies have been permanently 
excluded from this review. Details of these studies are given in appendix 2. Searching 
reference lists of included and excluded studies and relevant reviews has not resulted in 
additional studies. A flow diagram of the study selection process is presented in Figure 1.
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Figure 1. Flow diagram of the study selection process
Included studies  
Fourteen randomized controlled trials published between 1992 and 2011 were included in 
this review.
Participants
The 14 included studies comprised 942 participants. Six studies included only infants with 
Rh incompatibility.2,31-33,37,40 One study included only infants with ABO incompatibility.35 
Four studies enrolled mostly infants with ABO incompatibility but also some with Rh 
incompatibility and both ABO and Rh incompatibility (Alpay 1999: 93 ABO, 16 Rh, 7 both; 
Atici 1996: 49 ABO, 23 Rh; Hematyar 2011: 62 ABO, 11 Rh, 7 both; Nasseri 2006: 21 ABO, 
13 Rh).29,30,34,36 Pishva et al. predominantly included infants with Rh incompatibility (n = 
37) and only three infants with ABO incompatibility.38 Rübo et al. (Rübo 1996) stated that 
they included infants with Rh, Kell and Duffy incompatibility, although the breakdown 
into these groups is unclear from the paper.39 Tanyer et al. included 34 infants with ABO 
incompatibility, 18 with Rh incompatibility, 2 with “subgroup” incompatibility and 7 
with “more than one incompatibilities”.41 Only Nasseri et al. reported results for each 
type of incompatibility separately and Alpay et al. provided this information through 
correspondence.29,36 Five studies enrolled only term infants ≥37 weeks of gestation.29,30,32,36,41 
None of the studies only included premature infants <37 weeks of gestation. Three studies 
did not describe details of the gestational age at birth of enrolled infants.38-40 Santos et al. 
and Smits-Wintjens et al. provided outcomes for term and preterm infants separately.2,37
1251 references identified through 
database searching of which title and/or 
abstract were screened
No other references identified through other searches
26 articles screened full text for eligibility 12 articles excluded:
4: abstracts of included studies
    (Miqdad 2004; Santos 2011; Smits-Wintjens 2011) 
2: criteria for exchange transfusion not stated 
    (Huang 2006; Wang 2002)
2: not an RCT and abstract of that same non-RCT study 
1: abstract publication only 
    (Spinelli 2001) 
1: RCT comparing 2 doses of IVIg without a control 
    group without IVIg (Girish 2008)
1: duplicate article of included study
    (Rübo 1996)
1: article contains no outcomes in a form useable




Nine of 14 studies which met inclusion criteria examined the effect of a single dose of IVIg 
in combination with phototherapy.2,29-32,35,37,38,40 Two studies examined multiple doses33,36 
and two studies compared groups treated with a single dose or multiple doses with a 
control group.39,41 Tanyer et al. were inconsistent in describing which group received a single 
dose or multiple doses of IVIg and therefore this study was excluded from the subgroup 
analysis of single and multiple doses.41 In the study of Hematyar et al. 15 infants received 
a single dose of IVIg, also 15 infants received 2 doses and 9 infants received 3 doses of 
IVIg.34 Results were not provided separately for subgroups treated with a single dose and 
multiple doses of IVIg. Three studies used a placebo in addition to phototherapy for the 
control groups.2,33,37 The intensity and topography of phototherapy fits the definition of 
intensive phototherapy in only three studies.2,32,37 Tanyer et al. used an obsolete model with 
3 overhead lights from a single angle and Miqdad et al. did not use a phototherapy blanket 
beneath the baby.35,41 The remainder of included studies did not describe the intensity and 
topography of phototherapy in sufficient detail to allow a conclusion as to whether it is 
reasonable to describe it as intensive phototherapy. Seven studies started IVIg ≤12 hours 
after birth2,31-33,37,39,40 and five studies >12 hours.29,30,34,36,41 Miqdad et al. started IVIg within 12 
hours in 9 patients and >12 hours in 47 patients, but they did not report outcomes for early 
and late IVIg administration separately.35
Outcomes
All included studies reported ET as the primary outcome. In the abstract of Garcia et al. the 
number of ETs per infant was reported and data on the number of infants who received 
one or more ETs were provided by the authors.33 For nine studies mean (or median) 
number of ETs per infant were reported2,33,36,38 or could be calculated from reported 
data.30-32,40,41 Unpublished data (standard deviation and/or mean) on this outcome were 
provided by authors of five studies.2,29,33,35,37 The maximum bilirubin level was reported 
in five studies.2,31,37,39,40 Unpublished data on this outcome were provided by the authors 
of four studies.29,32-34 Although all studies commented on the duration of phototherapy 
in their results, the numerical data were reported or subsequently provided in ten 
studies.2,29,30,32-37,41 These studies, except for Hematyar et al., all used predefined criteria for 
commencing phototherapy but not all for ceasing it. Eight studies reported or subsequently 
provided numerical data on the duration of hospitalization.2,29,30,32,34-37 and Pishva et al. 
reported only a comment.38 Only three studies reported (after correspondence) predefined 
criteria for hospital discharge.34,35,37 Seven studies included top-up transfusion as an 
outcome.2,29,31,35,36,39,40 Additional data on top-up transfusions were provided by authors of 
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Garcia 2004; Elalfy 2011; Smits-Wintjens 2011 and Santos 2011.2,32,33,37 Smits-Wintjens et al. 
did not report top-up transfusions separately for the first week and after the first week of 
life, but subsequently provided this information.2 Elalfy et al. and Garcia et al. had a follow 
up period of only one week after discharge and until discharge, respectively.32,33 Predefined 
criteria for top-up transfusions were reported in only three studies2,29,36 and were later 
provided through correspondence by Santos et al.37 All studies reported on short-term 
adverse events and Garcia et al.33 provided additional information after correspondence. 
None of the included studies reported data on neurodevelopmental outcomes. Additional 
information on neurodevelopmental outcomes was provided by Miqdad et al. and Santos et 
al.35,37
Excluded studies  
In total, six studies were excluded after review by authors. One study had a retrospective 
design, one study only compared groups with a high or a low dose of IVIg44, and one study 
was only reported in abstract form.45 Two studies did not report pre-defined criteria for the 
primary outcome ET.42,43 One study did not report any outcome in a form usable for meta-
analysis.46 Details of excluded studies are given in Appendix 2.
Additional data
We have attempted to contact the authors of all studies (except for the seven studies which 
were identified for the previous review29,31,39-41,45,46) to request both further methodological 
information and results. We have to date successfully contacted the authors of ten papers 
(including contact for the previous review).2,29,32-35,37,39,40,42
Risk of bias in included studies  
For details of risk of bias of included studies, see Appendix 1 and Figure 2.
Allocation (selection bias)  
Only seven studies reported an adequate method of randomization and were rated as low 
risk of bias.2,31-35,37 Garcia et al., Miqdad et al., Elalfy et al., and Hematyar et al. provided 
information on randomization method only through correspondence.32-35 A quasi-RCT 
allocated participants by order of admission.41 This study was rated as high risk of bias for 
both random sequence generation and allocation concealment.
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Figure 2. Summary of risk of bias of included studies
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Blinding (performance bias and detection bias)  
Only three studies used a placebo in the control group and were rated as low risk of bias 
for performance bias and detection bias. 2,33,37  Miqdad et al. reported through subsequent 
correspondence that data were kept and entered to their database by personnel who were 
not involved in the management of the cases and this study was therefore rated as low risk 
of detection bias.35 Elalfy et al. replied to correspondence that the person who performed 
the randomization was different from the one who conducted the study and the one who 
analyzed the data, so their study was also rated as low risk of detection bias.32 None of the 
other studies described any method of blinding of intervention after allocation and were 
rated as high risk of bias on both items.
Incomplete outcome data (attrition bias)  
Reporting of outcome data was rated as low risk of bias in 11 studies.2,29-31,33,35-37,39-41 For 
nine of these studies there were no missing data. In the Rübo 1992 trial, the amount of and 
reasons for missing data were similar between groups and in the study by Garcia et al. the 
missing data related only to 3 patients who were excluded after randomization because 
their blood type was Rh negative.33,40 One study was rated as high risk of bias because of a 
substantial amount of missing data on bilirubin levels.32
Selective reporting (reporting bias)  
Reporting bias was suspected in nine studies because important outcomes were either not 
reported or were not reported in a form that was useable for meta-analysis, or that allowed 
judgement about local treatment practices (for example if the authors only stated that 
there was no significant difference between groups).30-34,38-41
Other potential sources of bias  
Two studies had non-random crossover after randomization,32,39 one study used an 
additional criterion for ET in the control group only35 and in two studies analysis was not 
performed on an intention to treat basis.34,39 These four studies were rated as high risk of 
bias. Dağoğlu et al. used post randomization consent and although follow-up was complete 
for all infants for whom consent was obtained, two infants randomized to each arm of 
the study were excluded because consent was withheld.31 Two infants were also excluded 
post-randomization in the Rübo 1992 study because of “protocol violations” but no details 
were given.40 The latter two studies were rated as unclear risk of bias because the review 
authors were unable to assess the impact of these withdrawals on overall outcomes. Six 
other studies were rated as unclear risk of bias or low risk of bias for a potential risk of 
bias.2,29,30,33,36,38 For details see “Risk of bias tables” in Appendix 1.
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Effects of interventions  
A complete overview of the results of all analyses is provided in Appendix 3. 
Primary outcomes
Exchange transfusion
The results of 14 included studies could be entered into the meta-analysis.2,29-41 Most 
studies found a statistically significant reduction in the use of ET for IVIg treated 
infants.29-32,34-36,40,41 Four studies concluded that the use of (one or more) ETs was not 
reduced despite using early IVIg in combination with phototherapy.2,33,37,39 The meta-analysis 
of all fourteen studies showed that IVIg reduces the need for an ET (RR 0.40, 95% CI 0.27 to 
0.59; NNT 5.4) (see Figure 3).
Figure 3. Forest plot of the use of exchange transfusion (one or more)
Subgroup analysis of infants with only Rh incompatibility supports a reduction in the use 
of ET with IVIg treatment (RR 0.42, 95% CI 0.29 to 0.61; NNT 5.7).2,29,31-33,36-38,40  Analysis of 
infants with only ABO incompatibility also showed a reduction in the use of ET (RR 0.33, 
95% CI 0.18 to 0.60; NNT 4.7).29,35,36,38 In only those infants born ≥37 weeks of gestation IVIg 
reduced the use of ETs (RR 0.37, 95% CI 0.24 to 0.57; NNT 5.7).2,29,30,32,36,37,41 In the subgroup 
of infants born <37 weeks of gestation IVIg did not reduce the use of ETs (RR 0.77, 95% CI 
0.31 to 1.91).2,37 Reductions in the use of ET were also found in the seven studies in which 
IVIg was used ≤12 hours after birth2,31-33,37,39,40 (RR 0.51, 95% CI 0.35 to 0.73; NNT 7.3) and 
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in the five studies which used IVIg >12 hours after birth29,30,34,36,41 (RR 0.27, 95% CI 0.17 to 
0.44; NNT 3.9). Subgroup analyses of both infants receiving a single dose of IVIg 2,29-32,35,37-40 
and those receiving multiples doses of IVIg33,36,39 support a reduction in the use of ET with 
IVIg treatment (RR 0.41, 95% CI 0.29, 0.57; NNT 6.3 and RR 0.48, 95% CI 0.27, 0.83, NNT 4.6, 
respectively).
However, despite these apparently promising results, analysis of the only two high quality 
studies did not show a reduction in the use of ET (RR 0.98, 95% CI 0.48 to 1.98; NNT 284) 
(see Figure 4).2,37
Figure 4. Forest plot of the use of exchange transfusion (one or more). High quality studies only.
Overall, immunoglobulin treatment also led to a reduction in the mean number of ETs per 
infant (MD -0.31, 95% CI -0.45 to -0.17). In contrast, analysis of the two high quality studies 
showed that IVIg did not reduce the number of ETs (MD -0.04, 95% CI -0.18 to 0.10).
Secondary outcomes
Top up transfusions during and after the first week
The results of five studies could be entered in the meta-analysis of the use of top-up 
transfusions in the first week2,29,32,33,37 and of 8 studies for the use of top-up transfusions 
after the first week of life.2,29,31,35-37,39,40 IVIg did not increase the need for top-up transfusions 
during the first week (RR 1.05, 95% CI 0.65 to 1.69) or in the period after the first week 
(RR 1.20, 95% CI 1.00 to 1.45). IVIg also did not increase the need for top-up transfusions 
in the first week and after the first week of life in the following subgroups: infants with Rh 
incompatibility only (RR 1.08, 95% CI 0.65 to 1.77 and RR 1.09, 95% CI 0.92 to 1.28); infants 
with ABO incompatibility only (RR 0.80, 95% CI 0.19 to 3.38 and RR 5.02, 95% CI 0.62 to 
40.67); infants born ≥37 weeks of gestation (RR 0.91, 95% CI 0.48 to 1.74 and RR 1.18, 95% 
CI 0.81 to 1.71); infants born <37 weeks of gestation (RR 1.39, 95% CI 0.70 to 2.73 and RR 
1.24, 95% CI 0.93 to 1.67); infants treated with IVIg ≤12 hours after birth (RR 1.18, 95% CI 
0.70 to 2.00 and RR 1.10, 95% CI 0.92 to 1.31); and in those infants treated with a single 
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dose of IVIg (RR 1.05, 95% CI 0.65 to 1.69 and RR 1.19, 95% CI 0.99 to 1.42). Although the 
need for top-up transfusions during the first week of life was not increased for the subgroup 
of infants treated with IVIg >12 hours after birth (RR 0.71, 95% CI 0.24 to 2.12), the need for 
top-up transfusions after the first week of life was increased with IVIg treatment (RR 8.00, 
95% CI 1.03 to 62.26). However, the CI is very large and the lower CI limit is nearly one. For 
infants treated with multiple IVIg doses the use of top-up transfusions after the first week of 
life was not increased (RR 2.09, 95% CI 0.54 to 8.13) and not estimable for the first week of 
life. For the subgroup of infants included in high quality studies only2,37, the need for top-up 
transfusions in the first week of life and thereafter was also not altered in infants treated 
with IVIg (RR 1.18, 95% CI 0.70 to 2.00 and RR 1.01, 95% CI 0.80 to 1.27).
Santos et al. and Smits-Wintjens et al. were the only studies included in the analysis of the 
number of top-up transfusions per infant.2,37 In the first week of life and thereafter, the 
number of top-up transfusions was not altered in IVIg treated infants (MD 0.05, 95% CI 
-0.07 to 0.17 and MD -0.00, 95% CI -0.12 to 0.12, respectively).
Maximum serum bilirubin
Results for this outcome were available for nine studies.2,29,31-34,37,39,40 The meta-analysis 
of all 9 studies showed that the mean maximum serum bilirubin decreased by 17.52 
µmol/L in those receiving IVIg (MD -17.52, 95% CI -25.20 to -9.84). Furthermore, subgroup 
analyses showed that IVIg decreased maximum bilirubin levels in infants with both Rh 
and ABO incompatibility, those of >37 weeks of gestation, those treated early or late and 
those treated with a single dose of IVIg. However, subgroup analyses of the only two high 
quality studies2,37, of infants born <37 weeks2,37 and of infants treated with multiple doses 
of IVIg33,39 showed that IVIg did not reduce maximum serum bilirubin (MD 0.92, 95% CI 
-23.94 to 25.79; MD -18.91, 95% CI -54.49 to 16.68; and MD 22.89, 95% CI -12.00 to 57.78, 
respectively).
Duration of phototherapy
Results of ten studies could be included in the meta-analysis of the duration of 
phototherapy.2,29,30,32-37,41 Although criteria for commencing phototherapy were given in all 
studies except for the study by Hematyar et al.34, only five studies described or provided 
predefined criteria for ceasing phototherapy.2,29,32,37,41 Analysis of all ten studies showed 
that duration of phototherapy decreased by 0.87 days with IVIg treatment (MD -0.87, 95% 
CI -1.24 to -0.50). All subgroup analyses showed a decrease in duration of phototherapy in 
IVIg treated infants varying from a mean decrease of 0.74 days in those infants treated with 
IVIg >12 hours after birth (MD -0.74, 95% CI -1.00 to -0.49) to 1.22 days (MD -1.22, 95% CI 
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-1.42 to - 1.01) in infants treated with IVIg ≤12 hours after birth. However, as for maximum 
bilirubin levels, analyses of the two high quality studies (MD -0.50 95% CI -1.24 to 0.24) 
and of infants born <37 weeks of gestation (MD -0.91, 95% CI -1.96 to 0.14) showed no 
reduction in duration of phototherapy.
Duration of hospitalization
Results of eight studies could be entered in the meta-analysis.2,29,30,32,34-37 None of these 
studies described predefined criteria for hospital discharge and only three studies provided 
them through correspondence.34,35,37 The analysis showed that IVIg treatment shortens 
duration of hospitalization by 1.50 days (MD -1.50, 95% CI -1.72 to -1.28). All subgroup 
analyses showed a shorter duration of hospitalization with IVIg treatment varying from a 
mean decrease of 0.87 days in the infants with ABO incompatibility (MD -0.87, 95% CI -1.40 
to -0.35) to 2.28 days less in infants born <37 weeks of gestation (MD -2.28, 95% CI -3.84 to 
-0.72).
Incidence of adverse reactions
All studies, except for Hematyar et al.34, reported or subsequently provided data on 
adverse reactions. Eleven studies reported that no adverse reactions of IVIg treatment 
were observed.2,29,31,32,35-41 In one study five patients developed fever up to 38.5 °C after 
ET which spontaneously disappeared after 4-6 hours.30 In the study by Garcia et al., two 
deaths/adverse events occurred in both groups.33 Causes of death in the IVIg group were 
pulmonary arrest and septic shock in babies with severe HDN and in the control group two 
infants died of hydrops and cardiac arrest also in the setting of severe HDN.33 In the study 
by Alpay et al. two control infants receiving ET developed hypoglycemia and hypocalcemia 
after ET.29 In the Rübo 1992 study, one control infant who required ET developed sepsis 
and one control infant who required ET developed inspissated bile syndrome.40 However, 
the authors stated that a causal relationship with ET could not be established in either 
infant. Also in the study by Dağoğlu et al., one control infant developed inspissated bile 
syndrome.31 Miqdad et al. described that “no immediate adverse effects related to IVIg 
were noted, including fever, allergic reactions, volume overload or hemolysis”, however 
they also stated that “ten of the babies who had ET, from both groups, had to be treated for 
blood culture-positive or clinical sepsis”.35 In the study by Smits-Wintjens et al. one infant 
from the IVIg group developed a Bacillus cereus sepsis with brain abscesses a few days after 
ET.2 Sterility tests on the used IVIg batches and cultures of all donor blood products used 
for IUTs and ET were found to be sterile. The sepsis may have been related to the umbilical 





Only the studies by Santos et al. and Miqdad et al. had a relatively long follow up period of 
one year and two years, respectively.35,37 In both studies no cases of kernicterus, deafness or 
cerebral palsy were observed.
Discussion  
Summary of main results  
Overall there is limited evidence that IVIg treatment in neonates with alloimmune HDN 
reduces the need for ET. Although this review update showed a significant reduction in the 
need for ET, most of the included studies were not of high quality. In contrast, subgroup 
analysis of the only two studies which were of high quality showed that IVIg treatment 
had no effect on the need for ET or the number of ETs per infant. IVIg treatment was 
also associated with a significant reduction in maximum bilirubin level and duration of 
phototherapy when all included studies were analyzed as well as for most of the subgroup 
analyses based on type of alloimmunization, gestational age at birth and timing and number 
of doses of IVIg. However, as for ET, analysis of the two high quality studies demonstrated 
no difference in maximum bilirubin level and duration of phototherapy. Duration of 
hospitalization was significantly reduced when analyzing all studies which reported this 
outcome and for almost all subgroup analyses, including the subgroup analysis of high 
quality studies only. Although there is some evidence that IVIg reduces hemolysis and 
shortens hospital stay, these results should be interpreted with caution because only 
three studies used predefined criteria for hospital discharge and criteria for stopping 
phototherapy were not reported in most studies. In addition, over the last two decades 
guidelines for phototherapy have recommended using it more promptly for infants at risk 
of hemolysis.48 In many hospitals, the quality of phototherapy has also improved over the 
years. Nevertheless, the quality/intensity of phototherapy can still vary today, especially in 
low-resource settings and if good quality control is not applied. The incidence of late top-
up transfusions is an important outcome, especially in areas where follow-up of infants is 
difficult or where supply of safe blood for transfusion is limited. However, as thresholds for 
top-up transfusions in neonates vary widely, this outcome is susceptible to bias, particularly 
in unblinded studies. Eight of fourteen studies were included in the analysis of the incidence 
of top-up transfusion after the first week of life. However, only five of the eight studies used 
predefined criteria for top-up transfusions. In addition, those predefined criteria varied 
between studies, thus conclusions that could be drawn for this outcome are limited. Data 
on adverse events of IVIg seem to indicate that it can be used safely, although it is unclear 
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whether IVIg contributed to the two deaths in the IVIg study arm in the study by Garcia et 
al.33
Overall completeness and applicability of evidence  
This review included all (quasi-)RCTs on the use of IVIg in alloimmune HDN. Nineteen 
trials were identified, of which fourteen trials, comprising a total of 942 infants, fulfilled 
inclusion criteria for the review. The only two included studies that were of high quality 
comprising a total of 172 infants, enrolled only infants with Rh HDN and the intervention 
consisted of a single dose of 0.5-0.75 g/kg IVIg administered within 4-6 hours after birth.2,37 
Santos et al. included infants of ≥32 gestational weeks and Smits-Wintjens et al. included 
infants of ≥35 gestational weeks.2,37 Criteria for phototherapy and ET were similar in both 
studies. From subgroup analysis of these two studies, it can be concluded that early 
administration of IVIg in a single dose of 0.5-0.75 g/kg does not reduce ETs or have other 
benefits in the treatment of Rh HDN. There is no clear evidence from this review that a 
higher dose will improve the efficacy. The only randomized controlled trial comparing 
the effect of two doses of IVIg in Rh HDN showed that 0.5 g/kg and 1 g/kg had a similar 
effect on the duration of phototherapy, duration of hospitalization and ET requirements.44 
However, this study was not powered to find a difference in the need for ET. Long-term 
neurodevelopmental outcome was only examined by Santos et al. and Miqdad et al. who 
found no cases of kernicterus, deafness or cerebral palsy in a follow up period of one year 
and two years, respectively.35,37
Subgroup analysis of infants with ABO HDN showed a reduction in ET, maximum serum 
bilirubin level and duration of phototherapy and hospitalization. However, none of the four 
studies was of high quality and results may be limited in applicability.29,35,36,38
American Academy of Pediatrics guidelines of 2004 recommend the administration of 0.5-1 
g/kg IVIg in alloimmune HDN if TSB is rising despite intensive phototherapy or if TSB level 
is within 34-51 µmol/l (2-3 mg/dL) of exchange level.27 Based on the results of this review 
and because IVIg administration is not completely without risks20-22 and supplies of IVIg are 
limited, we do not recommend routine use of IVIg. However, since there is some evidence 
that it reduces hemolysis and it appears safe in infants with alloimmune HDN, it might be 
reasonable to consider using it in special circumstances, such as during transfer of an infant 
to a location that can perform an ET, or where the risk of ET is considered to be much higher 
than usual, such as in very or extremely low birth weight infants.
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Quality of the evidence  
The quality of included studies ranged from fulfilling none of the ‘risk of bias’ criteria to 
fulfilling all criteria. Six of fourteen studies used adequate methods for random sequence 
generation and allocation concealment. Given the nature of the intervention, it was 
possible to blind patients by using an infusion fluid. However, only three of fourteen 
studies were placebo-controlled. The lack of blinding could have influenced the decision to 
perform an ET or top-up transfusion. None of the studies that were not placebo-controlled 
described any another method to blind outcome assessors except for Miqdad 2004 and 
Elalfy 2011.32,35 Attrition was rated as high risk of bias in only one study (on the basis of both 
extent and reasons for attrition) and two studies were rated as unclear risk of bias because 
the available information was too limited to make a judgement. Selective reporting was 
suspected in nine studies because they did not report on duration of hospitalization and/
or top-up transfusions, which could cause over- or underestimation of the overall benefits 
of IVIg. In addition, since ETs and top-up transfusions are related in Rh HDN, both outcome 
measures should be described.49 Finally, risk of other biases was suspected in four trials 
which used different ET criteria for the IVIg and control groups, did not perform analysis on 
an intention to treat basis, or had significant non-random crossover between study groups. 
In conclusion, only two of fourteen trials fulfilled all criteria to be rated as high quality 
studies.
Potential biases in the review process  
We tried to minimize bias by working with two reviewers who independently assessed 
eligibility for inclusion of trials, extracted data and assessed risk of bias. However, we 
were aware that these parts of the review process were based on personal judgement 
because reviewing research is influenced by prior beliefs. In addition, one included trial 
was performed by three of the four review authors. Nevertheless, we attempted to review 
all studies in a similar way. In addition, we were unable to contact authors of all potentially 
eligible studies and therefore we could not include all available data. While the translator of 
the Turkish included study was a medical doctor from Turkish parents, he may have missed 
some details regarding the risk of bias of that study.
Agreements and disagreements with other studies or reviews  
The overall findings of this review are consistent with previous systematic reviews. Gottstein 
et al. included 3 studies that were also included in our review (Rübo 1992; Dağoğlu 
1995; Alpay 1999) and one study that was excluded from our review (Voto 1995).50 They 
concluded that with IVIg treatment significantly fewer infants required ET. Duration of 
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hospitalization and phototherapy were also significantly reduced in their review.50 However, 
based on our judgement, none of their included studies was of high quality. Two Chinese 
systematic reviews also found a reduction in ET requirements, duration of phototherapy 
and hospitalization but concluded that well-designed trials with a larger sample size were 
required for further evaluation of the efficacy and safety of IVIg.51,52 Until the date we 
conducted our search, our review is the most recent, extensive and up-to-date review of all 
randomized and quasi-randomized trials on the effect of IVIg in alloimmune HDN.
Authors’ conclusions  
Implications for practice  
Routine use of IVIg for the treatment of alloimmune HDN should be discouraged. Results 
of the only two high quality studies show no reduction in the use of ET. In addition, IVIg 
is not without risks and supplies are limited. However, since there is some evidence that 
IVIg reduces hemolysis and appears safe in neonates with alloimmune HDN, it may have 
a limited role in special circumstances, such as where ET is impossible, or is considered 
particularly high risk. Nevertheless, undertaking preparations for ET, including ensuring birth 
at or transfer to a center that can perform ET, would seem to be strongly indicated in high 
risk infants, and should not be abandoned in the expectation that IVIg will be efficacious.
Implications for research  
Future research into the role of IVIg in the early treatment of alloimmune HDN may be 
warranted, particularly in infants for whom ET is considered to be high risk. Such a trial 
should examine the safety and efficacy of IVIg by recording both short-term outcomes such 
as the need for transfusion therapy and the incidence of adverse events and also long-term 
neurodevelopmental outcomes. Both ETs and (late) top-up transfusions should be recorded 
because reduction of ETs can increase the number of top-up transfusions.49 Consideration 
should also be given to including additional measures to assess the severity of hemolysis 
such as carboxyhemoglobin or end tidal carbon monoxide. Based on evidence from the 
two high quality trials, the conclusion of the review authors is that IVIg is of very limited 
usefulness in Rh HDN. However, neither of these high quality studies enrolled infants with 
severe established jaundice due to ABO incompatibility. In contrast to Rh incompatibility, 
ABO incompatibility mainly results in hyperbilirubinemia without significant anemia. This 
is primarily due to the relatively few group A and B antigenic sites on neonatal red blood 
cells.53 Furthermore, infants with ABO-mediated hemolysis often present for neonatal care 
when they already have severe jaundice. Due to these differences between Rh and ABO 
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incompatibility it is conceivable that IVIg has a greater role in ABO-mediated jaundice. If it 
is efficacious in ABO HDN, it could, for example, be used during transfer to a hospital that 
can provide intensive phototherapy and perform ET. However, due to the relative rarity of 
severe jaundice, unresponsive to phototherapy in ABO incompatibility, exploring the use 
of IVIg to treat established jaundice would require a multicenter randomized controlled 
trial. Such a trial should either use a placebo or an alternative method for blinding of 
treatment and outcome assessment. Future trials should be well planned and give priority 
to establishing guidelines for the “conventional” management of alloimmune HDN, 
focusing on the criteria for performing both top-up and ETs and on the role of intensive 
phototherapy.
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Appendix 1: Details of included studies
Alpay 199929
Methods RCT
Participants 116 newborn term infants. ABO and/or Rh incompatibility. TSB >204 µmol/L (12 
mg/dL), positive direct Coombs test and reticulocyte count ≥10%.
Interventions Treatment group: Single dose of IVIg 1 g/kg (ISIVEN) plus phototherapy, started at 
51.53 ± 3.5 h (mean ± SD) after birth. (n = 58)
Contol group: Phototherapy only, started 54.33 ± 4.0 h (mean ± SD) after birth. (n 
= 58)
Outcomes ETs, maximum TSB*, duration of phototherapy, duration of hospitalization, top-up 
transfusions*, and adverse events.
Criteria for ET: TSB >290 µmol/L (17 mg/dL) and increased by >17 µmol/L/hour (1 
mg/dL/hour).
Criteria for phototherapy: started and continued as long as TSB levels were above 
the levels for starting phototherapy.55 Details of phototherapy: 5 special blue 
lights (Philips F20 T12/BB) placed 30 cm above the patient; body position was 
changed periodically; no phototherapy blanket.
Criteria for top-up transfusions: after 15-21 days red blood cell transfusions were 
given because hemoglobin levels were ≤87 g/L .
* = (part of the) outcome available through correspondence











Unclear risk Only stated: “The attending neonatologists who made 
the decision regarding the choice of treatment were 
different from those conducting the study.”
Blinding of participants 
and personnel 
(performance bias)
High risk No placebo or other method of blinding described.
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Blinding of outcome 
assessment (detection 
bias)
High risk No placebo or other method of blinding described.
Incomplete outcome 
data (attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting 
(reporting bias)
Low risk Although adverse events of IVIg were not reported 
explicitly, assumed that there were no adverse events 
of IVIg because authors described that 2 patients had 
hypoglycemia and hypocalcemia after ET.
Other bias Unclear risk Average bilirubin levels at study entry were already 
above bilirubin thresholds to invoke outcome event ET.
Possible sources of bias include: 1) dilution effect of IVIg 
could have affected bilirubin after infusion, 2) rate of rise 
of bilirubin might have been measured over different 
intervals, 3) decision to prepare for ET might easily have 




Participants 116 newborn term infants. ABO and/or Rh incompatibility. TSB >204 µmol/L (12 
mg/dL), positive direct Coombs test and reticulocyte count ≥10%.
Interventions Treatment group: Single dose of IVIg 1 g/kg (ISIVEN) plus phototherapy, started at 
51.53 ± 3.5 h (mean ± SD) after birth. (n = 58)
Contol group: Phototherapy only, started 54.33 ± 4.0 h (mean ± SD) after birth. (n 
= 58)
Outcomes ETs, maximum TSB*, duration of phototherapy, duration of hospitalization and 
adverse events.
Criteria for ET: TSB level 86 µmol/L (5 mg/dL) above the limit in Oski 1982.56
Criteria for phototherapy: TSB level beneath the level for ET. Details phototherapy: 
blue light 420-470 nm.
* = not presented in a form usable for meta-analysis
Notes Not stated whether any ethics approval or if parental consent was given.















Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome 
assessment (detection bias)
High risk No placebo or other method of blinding described.
Incomplete outcome data 
(attrition bias)
Low risk 3 patients appear to be missing in Table 3 of 
outcome data (n = 36 for control group), but this 
is probably a typing mistake since percentages 
correspond with inclusion of all patients (n = 39) in 
control group.
Selective reporting (reporting 
bias)
High risk Top-up transfusions not reported.
Other bias Unclear 
risk
Absence of strict criteria for enrolment. In addition, 
a positive direct antiglobulin test was not a criterion 
for enrolment and only present in 63% and 59% 
of infants in IVIg and control group, respectively. 
Unclear if block randomization included 
stratification for Rh versus ABO HDN.
Dağoğlu 199531  
Methods RCT
Participants 45 term and preterm infants with Rh incompatibility randomized. Four infants 
withdrawn post-randomization because parental consent was not provided.
Rh positive infant, Rh negative mother and positive direct Coombs test.
Interventions Treatment group: Single dose of IVIg 0.5 g/kg (Sandoglobulin) as soon as possible 
after birth (usually within 2 hours) plus phototherapy. (n = 22)
Control group: Only phototherapy. (n = 19)
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Outcomes ETs, maximum TSB, duration of phototherapy*, top-up transfusions and adverse events.
Criteria for ET: TSB increase by >17 µmol/L/hour (1 mg/dL/hour) or TSB >342 
µmol/L (20 mg/dL) in term infants or if TSB >308 µmol/L (18 mg/dL) in infants 
weighing >2000g.
Criteria for phototherapy: started when bilirubin levels exceeded the relevant curves 
of Oski and Naiman (Oski 1982).56 Details phototherapy: blue lights 420-460 nm.
Criteria for top-up transfusion: not stated.
* = not presented in a form usable for meta-analysis




Random sequence generation 
(selection bias)
Low risk Stated “random numbers”.
Allocation concealment (selection 
bias)
Low risk Stated “sealed envelopes”.
Blinding of participants and 
personnel (performance bias)
High risk Stated “not blinded because an appropriate 
placebo for IVIg could not be found”.
Blinding of outcome assessment 
(detection bias)
High risk Not stated. Contact with authors 
unsuccessful. Assumed that blinding was not 
performed.
Incomplete outcome data (attrition 
bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting bias) High risk Duration of hospitalization not reported.
Other bias Unclear risk Consent after randomization and 2 
infants from each group withdrawn post-
randomization because consent not provided. 
Reasons for parental refusal are not stated.
Some differences in IVIg and control groups 
despite randomization: higher M:F ratio in 
IVIg group (72%) than control group (47%) 
although most other characteristics don’t 
differ. High rate of ET in control group (79%) 
for patients who all had IUT. ET criteria 
inconsistently described in Methods and 
Discussion.
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Elalfy 201132  
Methods RCT
Participants 90 term neonates (>38 weeks of gestation) born to Rh negative mothers who 
had not received anti-D after previous deliveries with: 1) isoimmune HDN 
“proven by”: Rh incompatibility between blood group of the mother and 
baby, a positive direct antiglobulin test and a high reticulocyte count and 2) 
significant hyperbilirubinemia requiring phototherapy in the first 12 hours of 
life and/or rising by 8.6 µmol/L/hour (0.5 mg/dL/hour) while TSB is still below 
the ET criteria on admission according to the AAP management guidelines for 
hyperbilirubinemia.27
Interventions Treatment group 1: Single dose of IVIg 0.5 g/kg administered at 12 hours after 
birth plus phototherapy. (n = 25) (Number randomized n = 23, however 3 moved 
to control group and 5 gained from high dose IVIg group.)
Treatment group 2: Single dose of IVIg 1 g/kg administered at 12 hours after birth 
plus phototherapy. (n = 15) (Number randomized n = 22, however 2 moved to 
control group and 5 to low dose IVIg group.)
Control group: phototherapy only. (n = 50) (Number randomized n = 45, however 
5 gained from IVIg groups)
Outcomes ETs, duration of phototherapy, top-up transfusions*, duration of hospitalization 
and adverse events.
Criteria for ET: “When bilirubin increased by 17 μmol/L/hour (1 mg/dL/hour), the 
neonate will require ET according to the guidelines of the AAP”.27
Criteria for phototherapy: “Initiation and discontinuation of phototherapy was 
according to the serum bilirubin levels as provided by the AAP guidelines”.27
Phototherapy details: 5 special blue lights, of which one fiberoptic blanket and 4 
overhead lights.
Criteria top-up transfusion: not stated.
* = information on this outcome through correspondence.










Low risk From correspondence: randomization by using sealed 
envelopes which were kept in a big box and shuffled. 




Low risk See above.
Blinding of participants 
and personnel 
(performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome 
assessment (detection 
bias)
Low risk No placebo or other method of blinding described. An 
e-mail reply to correspondence stated that the study was 
blinded and there was no detection bias, but does not 
state what methods were used. The authors explained 
that they meant by “the study was blinded” that the 
person who performed the randomization was different 




High risk Substantial amount of missing data for bilirubin levels 
after 48 hours (figure 2 in article).
Selective reporting 
(reporting bias)
High risk Top-up transfusions were not reported in the paper, 
but data on the number of top-up transfusions in 
the first week and thereafter were provided through 
correspondence. However, duration of follow-up was 
only until one week after discharge from the hospital, 
therefore top-up transfusions after the first week are still 
missing.
Other bias High risk Significant non-random crossover between study 
groups after randomization, quote: “...five parents 
in the intervention group did not consent using IVIg, 
so they were treated eventually by the conventional 
method. Of the 40 infants finally in the intervention 
group, five babies assigned to the higher IVIg dose...
their parents chose the lower dose...”. Authors explained 
through correspondence that when parents signed the 
informed consent form, they had the right to change 
the treatment without knowing in which arm their child 
was randomized. It happened to be that all parents who 
changed the treatment were initially randomized to the 
low dose arm.
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Garcia 200433  
Methods Double blind, placebo controlled RCT (pilot study)
Participants 18 neonates with jaundice due to Rh incompatibility and who required 
phototherapy.
Interventions Treatment group: IVIg 0.75 g/kg/day (15 ml/kg/day) for 3 days started 2 h (mean) 
after birth plus phototherapy. (n = 11)
Control group: An equal amount (15 ml/kg/day) of saline started 2 h (mean) after 
birth with the same frequency plus phototherapy. (n = 7)
Outcomes ETs, maximum TSB*, duration of phototherapy, top-up transfusions*, adverse 
events* and mortality*
Criteria for ET: based on a local protocol (“Instituto Nacional de Perinatologia. 
Incompatibilidad al Antigeno Rh. Normas y procedimientos de Neonatologica 
1998.”) which was based on the guidelines from the AAP.
Criteria for phototherapy: started when infants were enrolled and based on local 
protocol (see above). Details phototherapy: Blue lights were used, one light for 
each patient.
Criteria for top-up transfusion: not stated.
* = information on this outcome through correspondence.
Notes Unpublished data and information supplied. Ethics approval and parental consent 




Random sequence generation 
(selection bias)
Low risk From correspondence: By a random number 
table.
Allocation concealment (selection 
bias)
Low risk From correspondence: The random number 
table was managed by a secretary from the 
unit and each time a Rh negative woman was 
in the operating room for a caesarean section 
she informed the pharmacy which delivered 
the study medication labeled only with 
“Group 1” or “Group 2”.
Blinding of participants and 
personnel (performance bias)
Low risk A placebo was used and study medication 
only labeled with “Group 1” or “Group 2”.
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Blinding of outcome assessment 
(detection bias)
Low risk A placebo was used and study medication 
only labeled with “Group 1” or “Group 2”.
Incomplete outcome data (attrition 
bias)
Low risk Complete data for all pre-defined outcomes in 
abstract or after correspondence.
Selective reporting (reporting bias) High risk Duration of hospitalization not measured.
Other bias Unclear 
risk
Three infants were withdrawn post-
randomization because their blood type was 
Rh negative. Very small numbers of patients in 
each group. Because only one light was used 
per patient, phototherapy seems unlikely to 
have been intensive.
Hematyar 201134  
Methods RCT
Participants 80 newborns of >32 weeks of gestation and birth weight >2500 gram who 
developed jaundice on the first postnatal day due to ABO or Rh HDN with evidence 
of hemolysis (positive Coombs’ test, reticulocytes >10%, Hb or Ht decline) without 
other causes of jaundice. Exclusion criteria were: a serious condition such as 
hemodynamic instability and asphyxia, indication of ET at birth, fetal hydrops, 
congestive cardiac dysfunction and occurrence of serious IVIg complications.
Interventions Treatment group: 0.5 g/kg IVIg up to a maximum of 3 doses, if it was required, 
plus phototherapy. The first dose was administered after 12 hours after birth in all 
infants. (n = 39) 
Control group: phototherapy only. (n = 41)
Outcomes ETs*, maximum TSB*, duration of phototherapy*, and duration of hospitalization*.
Criteria for phototherapy: not provided (additional information has been 
requested).
Criteria for ET: according to the AAP guidelines.27
Criteria for hospital discharge: “When TSB levels did not significantly increased 24 
hours after terminating phototherapy.”
* = information on this outcome through correspondence.
Notes Follow up until discharge. The study was approved by an ethical committee and all 
parents gave informed consent.







Low risk From correspondence: “By a random number.”
Allocation concealment 
(selection bias)
Unclear risk Not enough information provided to make a 
judgement. Additional information has been 
requested.
Blinding of participants and 
personnel (performance bias)
High risk Not blinded.
Blinding of outcome 
assessment (detection bias)
High risk Not blinded.
Incomplete outcome data 
(attrition bias)
Unclear risk Not enough information to make a judgement. 
Additional information has been requested.
Selective reporting (reporting 
bias)
High risk Top-up transfusions, adverse events and number of 
ETs per infant not reported.
Other bias High risk Occurence of serious IVIg complications was 
an exclusion criterion and analyses were not 
performed on an intention to treat basis.
Miqdad 200435  
Methods RCT
Participants 112 neonates with “significant hyperbilirubinemia due to ABO HDN confirmed by 
a positive Coombs’ test”.
Interventions Treatment group: single dose of IVIg 0.5 g/kg plus phototherapy. (Nine patients 
received IVIg <12 h and 47 patients >12 h after birth). (n = 56)
Control group: phototherapy only. (n = 56)
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Outcomes ETs, duration of phototherapy, duration of hospitalization*, top-up transfusions, 
and adverse events.
Criteria for phototherapy: TSB rising by 8.5 μmol/L/hour (0.5 mg/dL/hour) or TSB 
>170 μmol/L (10 mg/dL) at <12 hours after birth, TSB >204 μmol/L (12 mg/dL) 
at <18 hours after birth or TSB >238 μmol/L (14 mg/dL) at 24 hours after birth. 
Phototherapy was discontinued when TSB was <205 μmol/L (12 mg/dL). Details 
of phototherapy: Blue fluorescent lights were used (Ameda, Switzerland and 
Airshields, USA). Each unit had 4 lights at wavelength 460 nm. During the study 
they used one unit to denote single phototherapy, two units to denote double 
phototherapy and three units for triple phototherapy. These were placed 35-40 
cm above the infant. They did not use phototherapy blankets.
Criteria for ET: if at any time TSB ≥340 μmol/L (20 mg/dL), in any of the two 
groups, or if it was rising by ≥8.5 μmol/L/hour (0.5 mg/dL/hour) in the neonates in 
the control group.
Criteria for top-up transfusions: Stated that no transfusions were performed 
because hemoglobin levels remained >100 g/L.
Criteria for hospital discharge: TSB levels not increasing 24 hours after terminating 
phototherapy, no feeding problems and nursing staff and parents satisfied with 
discharge.
* = measure of variance through correspondence
Notes Study was approved by their hospital research committee. However, it was not 
clear from correspondence whether parental consent was given for this study. 
Additional correspondence: At the time they conducted the trial in Saudi Arabia 
there was resistance of parents and patients to consent to research in general 
because of misconception that patients would not receive appropriate treatment 
if they were included in research projects. However, “now that there is a body 
governing medical practice things are changing and research now requires 
approval by the institute and consent of the patient or guardian.”





Random sequence generation 
(selection bias)
Low risk From correspondence: Randomization was done 
by simple sampling randomization. The first 
10 participants who were numbered 1,4,7 and 
10 were assigned to the IVIg group and those 
numbered 2,3,5,6,8 and 9 were assigned to the 
control group. The second group of 10 participants 
who were numbered 1,4,7 and 10 were assigned 
to the control group and those numbered 2,3,5,6,8 
and 9 to the IVIg group. This sequence continued 
alternating between the groups until they reached 
110 participants and the final 2 participants were 
assigned to the IVIg group so that each group 
consisted of 56 patients.
Allocation concealment 
(selection bias)
Low risk From correspondence: Random number table was 
kept by the head nurse and none of the treating 
physicians were involved in the randomization 
process.
Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome 
assessment (detection bias)
Low risk All data were kept and entered to their database 
by personnel who were not involved in the 
management of the cases and that data was given 
to the outcome assessors.
Incomplete outcome data 
(attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting 
bias)
Low risk All relevant outcomes reported.
Other bias High risk Control group has an additional criterion to 
perform ET which could have resulted in more ETs 
in the control group. Very high rate of ET for ABO 
HDN in both study groups, especially control group. 
Very high rate of clinical or culture positive sepsis in 
neonates who had ET. Not clear whether neonates 
in each group were enrolled at similar post-natal 
age. Unsubstantiated claim in conclusions that IVIg 
works even when given up to 72 hours of age. No 




Nasseri 200636  
Methods RCT (although in Methods stated that it was a prospective case control study).
Participants 34 neonates with: 1) gestational age of ≥37 weeks; 2) a positive direct Coombs’ 
test due to Rh or ABO incompatibility; 3) significant hyperbilirubinemia as defined 
by bilirubin rising by ≥0.5 mg/dL/hour (8.5 μmol/L/hour); 4) bilirubin below 
ET criterion on admission; and 5) “no other risk factors such as sepsis, G6PD 
deficiency”.
Interventions Treatment group: 3 doses of 0.5 g/kg IVIg 12 hours apart within 2-4 hours of 
admission (average age at admission about 20 hours) plus phototherapy. (n = 17)
Control group: Only phototherapy. (n = 17)
Outcomes ETs, duration of phototherapy, duration of hospitalization, top-up transfusions, 
and incidence of adverse events.
Criteria for phototherapy: “Phototherapy was started once the baby was admitted 
to the NICU”. Details phototherapy: “double surface blue light phototherapy”.
Criteria for ET: Bilirubin ≥342 μmol/L (20 mg/dL) or rising by 17 μmol/L/hour (1 
mg/dL/hour).




Random sequence generation 
(selection bias)
Unclear risk Not stated.
Allocation concealment (selection 
bias)
Unclear risk Not stated.
Blinding of participants and personnel 
(performance bias)
High risk No placebo or other method of blinding 
described.
Blinding of outcome assessment 
(detection bias)
High risk No placebo or other method of blinding 
described.
Incomplete outcome data (attrition 
bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting bias) Low risk All relevant outcomes reported.
Other bias Unclear risk Treatment group with multiple doses 
received a relatively large dose of IVIg (1.5 g/
kg in the first 26-28 hours of life). This might 
cause a dilutional effect on bilirubin levels 
and therefore influence the decision for ET.
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Pishva 200038  
Methods RCT
Participants 40 neonates with Rh or ABO incompatibility. Inclusion criteria: a) Rh positive 
neonates, b) History of Rh positive sibling(s), c) maternal blood group O, d) 
Positive direct Coombs’ test, both A and B in Rh negative mothers.
Interventions Treatment group: single dose of IVIg 0.5 g/kg (Sandoglobulin) in the first 24 hours 
of life plus phototherapy. (n = 20)
Control group: phototherapy only. (n = 20)
Outcomes ETs, maximum TSB*, duration of phototherapy*, duration of hospitalization*, and 
adverse events.
Criteria for phototherapy and ET: based on postnatal age (hours), birth weight and 
the level of bilirubin according to Faranoff et al.57
* = not presented in a form usable for meta-analysis




Random sequence generation 
(selection bias)
Unclear risk Not stated.
Allocation concealment (selection 
bias)
Unclear risk Not stated.
Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding 
described.
Blinding of outcome assessment 
(detection bias)
High risk No placebo or other method of blinding 
described.
Incomplete outcome data (attrition 
bias)
Unclear risk Not stated whether any attrition from 
study.
Selective reporting (reporting bias) High risk Top-up transfusions not reported.
Other bias Unclear risk Seems likely to have been only a 
mildly affected group of infants - using 
conservative criteria for phototherapy and 
ET, rates of these treatments were very low 
even in the control group.
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Rübo 199240  
Methods RCT
Participants 34 newborn infants. Rh incompatibility. Rh positive infant, Rh negative mother and 
positive direct Coombs’ test.
Interventions Treatment group: Single dose of IVIg 0.5 g/kg (Polyglobin N) as soon as Rh status 
confirmed, plus phototherapy. (n = 17)
Control group: Phototherapy only. (n = 17)
Outcomes ETs, maximum TSB, duration of phototherapy*, top-up transfusions and adverse 
events.
Criteria for ET: TSB 34 µmol/L (2 mg/dL) > modified curve of Polácek.58-59
Criteria for phototherapy: TSB 68 µmol/L (4 mg/dL) < modified curve of 
Polácek.58-59
Details phototherapy: performed with “quartz lamps or blue light”.
Criteria for top-up transfusion: not stated.
* = not presented in a form usable for meta-analysis
Notes Two infants were excluded post randomization because of unspecified “protocol 














Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome 
assessment (detection bias)
High risk No placebo or other method of blinding described.
Incomplete outcome data 
(attrition bias)
Low risk Not stated, but probably data complete for all 32 
infants who could be analyzed.
Selective reporting (reporting 
bias)
High risk Duration of hospitalization not reported.
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Other bias Unclear 
risk
Two post-randomization withdrawals (one from 
each group) because of protocol violations.
Insufficient data to determine that the 2 groups 
were similar at enrolment (e.g. with respect to 
post-natal age, gender, gestation, serum bilirubin).
Described that two infants in IVIg group who 
needed an ET were treated suboptimally. Different 
treatment in this unblinded study?
Rübo 199639 
Methods Multicenter RCT
Participants 74 neonates with HDN due to Rh, Kell or Duffy incompatibility proven by a 
positive direct Coombs’ test.
Interventions Treatment group 1: single dose of IVIg 0.5 g/kg (Polyglobin N) immediately started 
after Coombs’ test was known to be positive plus phototherapy. (n = 28)
Treatment group 2: as group 1 but with a second dose of IVIg administered after 
48 hours after the first dose. (n = 25)
Control group: phototherapy only. (n = 21)
Outcomes ETs, maximum TSB, duration of phototherapy, top-up transfusions and adverse 
events.
Criteria for phototherapy: phototherapy was given when bilirubin levels were 68 
μmol/L (4 mg/dL) or less below predefined levels of ET.
Criteria for ET: if bilirubin levels were ≥34 μmol/L (2 mg/dL) above the modified 
curves from Polácek (reference 7 and 8 of article).




Random sequence generation 
(selection bias)
Unclear risk Not stated.
Allocation concealment  
(selection bias)
Unclear risk Not stated.
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Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome  
assessment (detection bias)
High risk No placebo or other method of blinding described.
Incomplete outcome data 
(attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting 
bias)
High risk Duration of hospitalization not reported and for 
duration of phototherapy only mentioned that 
it was not significantly different between the 3 
groups without providing the data.
Other bias High risk Protocol violations led to 2 post-randomization 
withdrawals (unclear from what group(s)) and 4 
control group infants being treated with IVIg and 
subsequently included in analysis (not intention to 
treat analysis). 
Stated that the treatment was conducted in ac-
cordance to guidelines of the individual hospitals. 
Risk of bias possible if participating hospitals did 
not provide the same number of patients to each 
study group. At admission, the control group had 
a significantly higher bilirubin level than the two 
IVIg groups.
Santos 201137,60  
Methods Double blind, placebo controlled RCT
Participants 92 neonates: 1) born to Rh D negative woman with anti-Rh D antibodies; 2) of 
gestational age ≥32 weeks; 3) with Rh D positive blood type; and 4) with positive 
direct Coombs’ test.
Interventions Treatment group: single dose of IVIg 0.5 g/kg (Immunglobulin®) in the first 6 hours 
of life plus phototherapy. (n = 46)
Control group: Saline in corresponding volume as IVIg (10 ml/kg) plus 
phototherapy. (n = 46)
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Outcomes ETs, maximum TSB*, top-up transfusions*, duration of phototherapy, duration of 
hospitalization, sensorineural hearing loss*, kernicterus*, mortality*, and adverse 
events.
Criteria for phototherapy: Started in the first hours of life and discontinued when 
bilirubin level fell below 10 mg/dL after 2 days of life. Phototherapy details: high 
intensity phototherapy (irradiance >30 IW/cm²/nm) with special blue fluorescent 
light (Bili-berҫo, model 006/FB, FANEM, São Paulo, Brazil), halogen lamp 
(Bilispot, model 006/BP, FANEM); irradiance level checked prior to initiation of 
phototherapy using a FANEM radiometer, model 2620.
Criteria for ET: bilirubin level ≥340 μmol/L (20 mg/dL) or rising by ≥8.5 μmol/L/
hour (0.5 mg/dL/hour).
Criteria for top-up transfusions: hemotocrit <25% with positive direct or indirect 
Coombs’ test; hematocrit <21% with negative Coombs’ test and reticulocytes <1%; 
hematocrit <30% with clinical signs of severe anemia (lethargy, dyspnea, feeding 
problems, need for oxygen, failure to thrive).
Criteria for hospital discharge: gestational age >34 weeks, absence of clinical signs 
of anemia, bilirubin level <10 mg/dL and decreasing, ability to suck without tiring.
* = information available through correspondence and from paper published after 
our search on 22 March 2012.60




Random sequence generation 
(selection bias)
Low risk Computer generated randomization in blocks of 4 
with a 1:1 allocation was performed by a statisti-
cian.
Allocation concealment  
(selection bias)
Low risk Statistician was responsible for concealment and 
opaque envelopes were used.
Blinding of participants and 
personnel (performance bias)
Low risk The medication was prepared by the pharmacist 
and applied such that the parents, nurses and 
pediatricians were blinded to its identity (IVIg 
versus placebo).
Blinding of outcome  
assessment (detection bias)
Low risk Intervention blinded as described above and 




Incomplete outcome data  
(attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting 
bias)
Low risk Data on top-up transfusions were provided after 
correspondence but reason for not including data 
(journal advised to remove that information) in 
the report was reasonable and therefore classified 
as low risk of bias.
Smits-Wintjens 20112  
Methods Double blind, placebo controlled RCT
Participants 80 neonates of ≥35 weeks of gestation. Rh HDN with positive direct Coombs’ 
test caused by anti-D or -c antibodies of Rh D negative or Rh c negative mother. 
Maternal antibody-dependent cellular cytotoxicity test >50% (comparable with 
titer 1:64)
Interventions Treatment group: Single dose of IVIg 0.75 g/kg (Nanogam, Sanquin, The Nether-
lands) within first 4 hours after birth, plus intensive phototherapy. (n = 41) (Also 
stratified for treatment with intrauterine transfusion.)
Control group: Placebo 5% glucose infusion plus phototherapy. (n = 39)
Outcomes ETs, maximum TSB, duration of phototherapy, duration of hospitalization, top-up 
transfusions* and adverse events.
Criteria for ET: according to AAP 2004 guidelines27 TSB > threshold or rate of rise of 
TSB >8.5 µmol/L/hour (0.5 mg/dL/hour) despite intensive phototherapy, or clinical 
symptoms of acute bilirubin encephalopathy.
Criteria for phototherapy: started when infants were admitted and continued 
according to AAP 2004 guidelines.27 Phototherapy details: intensive phototherapy 
using white light with an intensity of 10-20 µW/cm/nm given by Air Shield and 
Ohmeda lamps, in combination with a phototherapy blanket providing blue light 
30 µW/cm/nm. During phototherapy extra fluids (10 ml/kg) were administered.
Criteria for top-up transfusion: Hemoglobilin level <8 g/dL or <9.6 g/dL in the pres-
ence of clinical symptoms of anemia (such as lethargy, feeding problems, need for 
oxygen, or failure to thrive).
* = not presented in a form usable for meta-analysis
Notes Unpublished data and information supplied.





Random sequence  
generation (selection bias)




Low risk Pharmacy controlled block randomization.
Blinding of participants and 
personnel (performance bias)
Low risk Identical coded drug boxes and vials. One infant’s 
treatment unblinded due to serious adverse 
event. Unblinding unlikely to have affected study 
outcomes.
Blinding of outcome 
assessment (detection bias)
Low risk Sequence code broken after three months follow-up 
period of last included patient.
Incomplete outcome data 
(attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting 
bias)
Low risk Some outcomes are not completely reported as 
described in the published protocol. In protocol 
described that changes in bilirubin in the first 24 
and 48 hours (%) will be measured. The paper only 
describes bilirubin levels at birth and maximum 
bilirubin during admission. In protocol described 
that top-up transfusions would be measured in 
the first week of life and after the first week until 
three months of life. The paper describes top-
up transfusions for the whole period until three 
months after birth. However, data on changes in 
bilirubin levels are available and data on the top-up 
transfusion were provided for the first week and 
thereafter separately, therefore rated as low risk of 
bias.
Other bias Low risk One set of twins randomized to same treatment 
(done to avoid discrepant treatment for infants of 




Tanyer 200141  
Methods Quasi-randomized trial
Participants 61 neonates with a positive direct Coombs’ test; ABO or Rh or subgroup 
incompatibility, without “contributing risk factors (such as sepsis, drug use by 
mothers) that could raise bilirubin levels”, not prematurely born and with bilirubin 
levels below ET criterion on admission.
Interventions Treatment group 1: Single dose of IVIg 0.5 g/kg within 2-4 hours of admission 
(mean age of admission 2.3 days) plus phototherapy. (n = 20)
Treatment group 2: IVIg 0.5 g/kg/day for 3 days within 2-4 hours of admission 
(mean age of admission 2 days) plus phototherapy. (n = 20)
Control group: Phototherapy only (mean age of admission 2.8 days). (n = 21)
Outcomes ETs, duration of phototherapy, and adverse events.
Criteria for phototherapy: phototherapy was started once patient was admitted 
to the clinic and stopped when bilirubin level “decreased to the safe limit”. Details 
phototherapy: performed using a white quartz halogen lamp (Air Shields Microlite 
Phototherapy system) with a distance between the infant and light source of 41 
cm.
Criteria for ET: performed when bilirubin levels exceeded the accepted limits 




Random sequence generation 
(selection bias)
High risk By order of admission. Given the distribution of 
bilirubin levels at admission, some infants may 
have been at ET thresholds on admission. This 
could have influenced treatment allocation.
Allocation concealment  
(selection bias)
High risk Not concealed.
Blinding of participants and 
personnel (performance bias)
High risk No placebo or other method of blinding described.
Blinding of outcome  
assessment (detection bias)
High risk No placebo or other method of blinding described.
Incomplete outcome data 
(attrition bias)
Low risk Complete data for all pre-defined outcomes.
Selective reporting (reporting 
bias)
High risk Duration of hospitalization and top-up transfusions 
not reported.
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This randomized controlled trial compared two doses of IVIg and had no placebo 




This abstract only selectively reports outcome for enrolled infants who had 
moderate-severe hemolysis. Criteria for severity were not stated although strati-
fication into mild, moderate and severe was pre-defined. Correspondence with 
authors seems unlikely to yield further information given interval since report, 




This randomized controlled trial compared a single dose of IVIg with control. How-
ever, none of the outcomes were reported in a form usable for the meta-analysis. 
Top-up transfusions and ET were not separately reported, bilirubin levels were 
presented as graphs rather than tables, and although the means of duration of 
phototherapy and hospitalization were presented in a table, the measure of vari-
ance was not clear. Correspondence with authors seems unlikely to yield further 
information given interval since report and previous unsuccessful attempt.
Studies awaiting assessment
Huang 200642
Methods Quasi-randomized trial. Randomization “by date of birth”.
Participants 74 neonates who “tested positive for ABO HDN” and had “high bilirubin levels”.
Interventions Treatment group: IVIg 0.4-0.6 g/kg/day for 1-2 days plus albumin 1-2 g/kg/day for 
2-3 days plus phototherapy. (n = 36)
Control group: Phototherapy plus albumin 1-2 g/kg/day for 2-3 days. (n = 38)
Outcomes ETs and duration of phototherapy.
Notes Authors provided additional information, however it was still not clear what 
criteria for ET were used and consequently this study could not be included yet. 





Participants 121 neonates with: 1) blood type A or B of mothers with type O, 2) mothers with 
a Anti-A or Anti-B IgG >1:128, 3) a positive DAT or free-antibody test or antibody-
release test, 4) methemoglobin reduction rate >75%, and 5) “clinical characteris-
tics: hemolysis, jaundice, anemia and the like”.
Interventions Treatment group: IVIg 0.4 g/kg/day for 3 days (although in conclusion section 
2-3 days) plus phototherapy and albumin 1 g/kg/day for 1-3 days and correcting 
acidosis, supplement of fluid and calories. (Mean (± SD) time of admission 41 ± 20 
h). (n = 61)
Control group: phototherapy and albumin 1 g/kg/day for 1-3 days and correcting 
acidosis, supplement of fluid and calories. (n = 51)
Outcomes ETs, duration of phototherapy (not in form useable for meta-analysis), kernicterus, 
and adverse events.
Notes Not stated whether any ethics approval or parental consent was given.
Criteria for ET: not stated. Criteria for initiating phototherapy: not stated, (stop-
ping criteria: transcutaneous bilirubin level <110mmol/L). Further information has 
been requested.
Appendix 3: Results of analyses
1. IVIg plus phototherapy versus phototherapy
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Use of exchange  
transfusion (one or more)
14 942 RR (M-H, Random, 
95% CI)
0.40 [0.27, 0.59]
1.2 Exchange transfusions 
per infant
12 788 MD (IV, Random, 
95% CI)
-0.31 [-0.45, -0.17]
1.3 Use of top-up  
transfusion in 1st week
5 396 RR (M-H, Fixed, 
95% CI)
1.05 [0.65, 1.69]
1.4 Top-up transfusions in 
1st week per infant
4 280 MD (IV, Fixed, 
95% CI)
0.05 [-0.07, 0.17]
1.5 Use of top-up  
transfusion after 1st week
8 581 RR (M-H, Fixed, 
95% CI)
1.20 [1.00, 1.45]
1.6 Top-up transfusions 
after 1st week per infant
4 316 MD (IV, Fixed, 
95% CI)
-0.00 [-0.12, 0.12]
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1.7 Maximum serum 
bilirubin (µmol/L)
9 623 MD (IV, Fixed, 
95% CI)
-17.52 [-25.20, -9.84]
1.8 Duration of  
phototherapy (days)
10 755 MD (IV, Random, 
95% CI)
-0.87 [-1.24, -0.50]
1.9 Duration of  
hospitalization (days)
8 676 MD (IV, Fixed, 
95% CI)
-1.50 [-1.72, -1.28]
1.10 Incidence of adverse 
reaction
13 837 RR (M-H, Fixed, 
95% CI)
0.83 [0.43, 1.58]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
2. IVIg plus phototherapy versus phototherapy. Rh incompatibility only
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
2.1 Use of exchange  
transfusion (one or more)
9 426 RR (M-H, Fixed, 
95% CI)
0.42 [0.29, 0.61]
2.2 Exchange transfusions 
per infant
9 426 MD (IV, Fixed, 
95% CI)
-0.25 [-0.34, -0.16]
2.3 Use of top-up  
transfusion in 1st week
5 303 RR (M-H, Fixed, 
95% CI)
1.08 [0.65, 1.77]
2.4 Top-up transfusions in 
1st week per infant
4 280 MD (IV, Fixed, 
95% CI)
0.05 [-0.07, 0.17]
2.5 Use of top-up  
transfusion after 1st week
6 281 RR (M-H, Fixed, 
95% CI)
1.09 [0.92, 1.28]
2.6 Top-up transfusions 
after 1st week per infant
3 204 MD (IV, Fixed, 
95% CI)
-0.00 [-0.12, 0.12]
2.7 Maximum serum 
bilirubin (µmol/L)




2.8 Duration of  
phototherapy (days)
6 316 MD (IV, Fixed, 
95% CI)
-1.21 [-1.40, -1.01]
2.9 Duration of  
hospitalization (days)
5 298 MD (IV, Fixed, 
95% CI)
-1.47 [-1.75, -1.19]
2.10 Incidence of adverse 
reaction
8 403 RR (M-H, Fixed, 
95% CI)
0.79 [0.22, 2.87]




3. IVIg plus phototherapy versus phototherapy. ABO incompatibility only
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
3.1 Use of exchange  
transfusion (one or more)
4 229 RR (M-H, Fixed, 
95% CI)
0.33 [0.18, 0.60]
3.2 Exchange transfusions per 
infant




3.3 Use of top-up transfusion 
in 1st week
1 93 RR (M-H, Fixed, 
95% CI)
0.80 [0.19, 3.38]
3.4 Use of top-up transfusion 
after 1st week
3 226 RR (M-H, Fixed, 
95% CI)
5.02 [0.62, 40.67]
3.5 Maximum serum bilirubin 
(µmol/L)




3.6 Duration of phototherapy 
(days)




3.7 Duration of hospitalization 
(days)




3.8 Incidence of adverse 
reaction
3 136 RR (M-H, Fixed, 
95% CI)
1.00 [0.45, 2.21]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
4. IVIg plus phototherapy versus phototherapy. Gestational age ≥37 weeks
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
4.1 Use of exchange 
transfusion (one or more)
7 463 RR (M-H, Fixed, 
95% CI)
0.37 [0.24, 0.57]
4.2 Exchange transfusions 
per infant
7 463 MD (IV, Fixed, 
95% CI)
-0.18 [-0.25, -0.10]
4.3 Use of top-up  
transfusion in 1st week
4 296 RR (M-H, Fixed, 
95% CI)
0.91 [0.48, 1.74]
4.4 Top-up transfusions in 
1st week per infant
3 180 MD (IV, Fixed, 
95% CI)
-0.01 [-0.35, 0.33]
4.5 Use of top-up  
transfusion after 1st week
4 240 RR (M-H, Fixed, 
95% CI)
1.18 [0.81, 1.71]
4.6 Top-up transfusions 
after 1st week per infant
2 90 MD (IV, Fixed, 
95% CI)
-0.03 [-0.20, 0.13]
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4.7 Maximum serum 
bilirubin (µmol/L)
4 296 MD (IV, Fixed, 
95% CI)
-26.81 [-35.97, -17.65]
4.8 Duration of  
phototherapy (days)
7 463 MD (IV, Fixed, 
95% CI)
-1.01 [-1.17, -0.84]
4.9 Duration of  
hospitalization (days)
6 402 MD (IV, Fixed, 
95% CI)
-1.20 [-1.45, -0.96]
4.10 Incidence of adverse 
reaction
7 463 RR (M-H, Fixed, 
95% CI)
0.59 [0.09, 3.70]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
5. IVIg plus phototherapy versus phototherapy. Gestational age <37 weeks
Outcome or Subgroup Studies Participants Statistical 
Method
Effect Estimate
5.1 Use of exchange  
transfusion (one or more)
2 82 RR (M-H, Fixed, 
95% CI)
0.77 [0.31, 1.91]
5.2 Exchange transfusions 
per infant
2 82 MD (IV, Fixed, 
95% CI)
-0.10 [-0.32, 0.12]
5.3 Use of top-up transfusion 
in 1st week
2 82 RR (M-H, Fixed, 
95% CI)
1.39 [0.70, 2.73]
5.4 Top-up transfusions in 1st 
week per infant
2 82 MD (IV, Fixed, 
95% CI)
0.08 [-0.12, 0.27]
5.5 Use of top-up transfusion 
after 1st week
2 82 RR (M-H, Fixed, 
95% CI)
1.24 [0.93, 1.67]
5.6 Top-up transfusions after 
1st week per infant
2 82 MD (IV, Fixed, 
95% CI)
0.04 [-0.13, 0.20]
5.7 Maximum serum  
bilirubin (µmol/L)




5.8 Duration of phototherapy 
(days)
2 82 MD (IV, Fixed, 
95% CI)
-0.91 [-1.96, 0.14]
5.9 Duration of  
hospitalization (days)
2 82 MD (IV, Fixed, 
95% CI)
-2.28 [-3.84, -0.72]




6. IVIg plus phototherapy versus phototherapy. IVIg administration ≤12 hours after birth
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
6.1 Use of exchange  
transfusion (one or more)
7 427 RR (M-H, Fixed, 
95% CI)
0.51 [0.35, 0.73]
6.2 Exchange transfusions 
per infant
6 353 MD (IV, Fixed, 
95% CI)
-0.19 [-0.28, -0.10]
6.3 Use of top-up  
transfusion in 1st week
4 280 RR (M-H, Fixed, 
95% CI)
1.18 [0.70, 2.00]
6.4 Top-up transfusions in 
1st week per infant
4 280 MD (IV, Fixed, 
95% CI)
0.05 [-0.07, 0.17]
6.5 Use of top-up  
transfusion after 1st week
5 319 RR (M-H, Fixed, 
95% CI)
1.10 [0.92, 1.31]
6.6 Top-up transfusions 
after 1st week per infant
3 204 MD (IV, Fixed, 
95% CI)
-0.00 [-0.12, 0.12]
6.7 Maximum serum  
bilirubin (µmol/L)




6.8 Duration of  
phototherapy (days)
4 280 MD (IV, Fixed, 
95% CI)
-1.22 [-1.42, -1.01]
6.9 Duration of  
hospitalization (days)
3 262 MD (IV, Fixed, 
95% CI)
-1.46 [-1.76, -1.17]
6.10 Incidence of adverse 
reaction
7 427 RR (M-H, Fixed, 
95% CI)
0.79 [0.22, 2.87]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
7. IVIg plus phototherapy versus phototherapy. IVIg administration >12 hours after birth
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
7.1 Use of exchange  
transfusion (one or more)
5 363 RR (M-H, Fixed, 
95% CI)
0.27 [0.17, 0.44]
7.2 Exchange transfusions 
per infant
4 283 MD (IV, Fixed, 
95% CI)
-0.29 [-0.41, -0.17]
7.3 Use of top-up  
transfusion in 1st week
1 116 RR (M-H, Fixed, 
95% CI)
0.71 [0.24, 2.12]
7.4 Use of top-up  
transfusion after 1st week
2 150 RR (M-H, Fixed, 
95% CI)
8.00 [1.03, 62.26]
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7.5 Maximum serum 
bilirubin (µmol/L)




7.6 Duration of  
phototherapy (days)
5 363 MD (IV, Fixed, 
95% CI)
-0.74 [-1.00, -0.49]
7.7 Duration of  
hospitalization (days)
4 302 MD (IV, Fixed, 
95% CI)
-1.60 [-1.93, -1.26]
7.8 Incidence of adverse 
reaction
4 283 RR (M-H, Fixed, 
95% CI)
0.20 [0.01, 4.08]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
8. IVIg plus phototherapy versus phototherapy. Single dose of IVIg
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
8.1 Use of exchange  
transfusion (one or more)
10 724 RR (M-H, Fixed, 
95% CI)
0.41 [0.29, 0.57]
8.2 Exchange transfusions 
per infant
9 675 MD (IV, Fixed, 
95% CI)
-0.21 [-0.27, -0.14]
8.3 Use of top-up  
transfusion in 1st week
4 378 RR (M-H, Fixed, 
95% CI)
1.05 [0.65, 1.69]
8.4 Top-up transfusions in 
1st week per infant
3 262 MD (IV, Fixed, 
95% CI)
0.05 [-0.07, 0.17]
8.5 Use of top-up  
transfusion after 1st week
7 522 RR (M-H, Fixed, 
95% CI)
1.19 [0.99, 1.42]
8.6 Top-up transfusions 
after 1st week per infant
4 316 MD (IV, Fixed, 
95% CI)
-0.00 [-0.12, 0.12]
8.7 Maximum serum  
bilirubin (µmol/L)




8.8 Duration of  
phototherapy (days)
6 562 MD (IV, Fixed, 
95% CI)
-0.95 [-1.12, -0.79]
8.9 Duration of  
hospitalization (days)
6 562 MD (IV, Fixed, 
95% CI)
-1.21 [-1.46, -0.96]
8.10 Incidence of adverse 
reaction
10 724 RR (M-H, Fixed, 
95% CI)
0.86 [0.43, 1.73]




9. IVIg plus phototherapy versus phototherapy. Multiple doses of IVIg
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
9.1 Use of exchange 
transfusion (one or more)
3 98 RR (M-H, Fixed, 
95% CI)
0.48 [0.27, 0.83]
9.2 Exchange transfusions 
per infant
2 52 MD (IV, Fixed, 
95% CI)
-0.83 [-1.28, -0.38]
9.3 Use of top-up 
transfusion in 1st week
1 18 RR (M-H, Fixed, 
95% CI)
Not estimable
9.4 Top-up transfusions in 
1st week per infant
1 18 MD (IV, Fixed, 
95% CI)
Not estimable
9.5 Use of top-up 
transfusion after 1st week
2 80 RR (M-H, Fixed, 
95% CI)
2.09 [0.54, 8.13]
9.6 Maximum serum 
bilirubin (µmol/L)




9.7 Duration of 
phototherapy (days)
2 52 MD (IV, Fixed, 
95% CI)
-1.00 [-1.90, -0.10]
9.8 Duration of 
hospitalization (days)
1 34 MD (IV, Fixed, 
95% CI)
-1.41 [-2.51, -0.31]
9.9 Incidence of adverse 
reaction
3 98 RR (M-H, Fixed, 
95% CI)
0.64 [0.11, 3.54]
RR = Risk Ratio, M-H = Mantel-Haenszel, CI = Confidence Interval, MD = Mean Difference, IV = Inverse 
Variance
10. IVIg plus phototherapy versus phototherapy. High quality studies only.
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
10.1 Use of exchange  
transfusion (one or more)
2 172 RR (M-H, Fixed, 
95% CI)
0.98 [0.48, 1.98]
10.2 Exchange transfusions 
per infant
2 172 MD (IV, Fixed, 
95% CI)
-0.04 [-0.18, 0.10]
10.3 Use of top-up  
transfusion in 1st week
2 172 RR (M-H, Fixed, 
95% CI)
1.18 [0.70, 2.00]
10.4 Top-up transfusions in 
1st week per infant
2 172 MD (IV, Fixed, 
95% CI)
0.05 [-0.07, 0.17]
10.5 Use of top-up  
transfusion after 1st week
2 172 RR (M-H, Fixed, 
95% CI)
1.01 [0.80, 1.27]
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10.6 Top-up transfusions 
after 1st week per infant
2 172 MD (IV, Fixed, 
95% CI)
-0.00 [-0.12, 0.12]
10.7 Maximum serum  
bilirubin (µmol/L)




10.8 Duration of  
phototherapy (days)
2 172 MD (IV, Fixed, 
95% CI)
-0.50 [-1.24, 0.24]
10.9 Duration of  
hospitalization (days)
2 172 MD (IV, Fixed, 
95% CI)
-1.38 [-2.55, -0.20]
10.10 Incidence of adverse 
reaction
2 172 RR (M-H, Fixed, 
95% CI)
2.86 [0.12, 68.10]
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 Exchange transfusions and top-up transfusions 
in neonates with Kell hemolytic disease 















To evaluate neonatal outcome in Kell hemolytic disease compared to Rh D hemolytic 
disease.
Study design
Retrospective study of all (near)-term neonates with Kell (n = 34) and Rh D hemolytic 
disease (n = 157) admitted to our center between January 2000 and December 2008. We 
recorded the need for exchange transfusion and top-up transfusions up to three months of 
age.
Results
Neonates in the Kell group required less days of phototherapy than neonates in the Rh D 
group (2.4 versus 4.1 days, respectively (p = <0.01)). The percentage of neonates requiring 
an exchange transfusion was lower in the Kell group than in the Rh D group (6% (2/34) and 
62% (98/157), respectively (p = <0.01)). The percentage of neonates in the Kell group and 
Rh D group requiring a top-up transfusion was 62% (21/34) and 72% (113/157), respectively 
(p = 0.20). The median number of top-up transfusions per neonate in the Kell group and Rh 
D group was 1 (interquartile range (IQR) 0-2) and 2 (IQR 0-2), respectively (p = 0.07).
Conclusion
Neonates with Kell hemolytic disease require less phototherapy and less exchange 
transfusions compared to neonates with Rh D hemolytic disease, but an equal number of 
top-up transfusions.
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Introduction
Kell alloimmunization is second only to Rh D in causing antibody-mediated fetal anemia. 
Since the introduction of Rh D immunoprophylaxis, Kell antibodies account for 10% of 
antibody-mediated fetal anemia.1  After introduction of routine antibody-screening of 
all pregnant women in the Netherlands in 1998, perinatal survival of fetuses with Kell 
hemolytic disease of the neonate (HDN) treated with intrauterine transfusion (IUT) 
increased from 61% to 100%.2 
In contrast to Rh D HDN, fetal anemia in Kell HDN is often more severe due to concomitant 
suppression of erythropoiesis rather than hemolysis of erythrocytes.3-5 Consequently, the 
immediate neonatal management in Kell HDN is different from Rh D HDN. A previous small 
study showed that neonates with Kell HDN have lower serum bilirubin levels and require 
less phototherapy and exchange transfusions (ETs) than neonates with Rh D hemolytic 
disease.6
In analogy with Rh D hemolytic disease, neonates with Kell HDN may require top-up 
transfusions for up to several months after birth.7 Whether the incidence and severity 
of neonatal anemia in Kell hemolytic disease differs from neonates with Rh D hemolytic 
disease, is not known. Only a limited number of studies (mostly case reports) have been 
published on the severity of anemia in the postnatal period.6,8-10
The aim of this study was to evaluate neonatal and hematological outcome in a large series 
of neonates with Kell hemolytic disease compared to neonates with Rh D hemolytic disease. 
Patients and Methods
All (near)-term neonates (gestational age ≥35 weeks) with hemolytic disease due to 
maternal Kell and Rh D alloimmunization, born between January 2000 and December 
2008 at the Leiden University Medical Center (LUMC) were included in this retrospective 
observational study. Part of the neonates included in the Rh D group have previously 
been described in a different study.11 Our center is the national referral center for the 
management and intrauterine treatment of red cell alloimmunization in the Netherlands. 
We excluded all neonates with other types of HDN and neonates participating in an ongoing 
randomized trial for the use of immunoglobulin in Rh D hemolytic disease, which started 
in August 2006 at our institution (LIVIN-study: http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=832).
The guideline for the application of phototherapy at our neonatal division has previously 
been described.11,12 The guidelines for ET used at our neonatal division were changed 
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in December 2005. Before December 2005, criteria for ET included: (1) bilirubin level at 
birth >3.5 mg/dL (so-called early criterion) and/or (2) total serum bilirubin level above 
ET thresholds (rise of bilirubin value >0.5 mg/dL/hr despite intensive phototherapy). 
In neonates not treated with IUT, a hemoglobin level at birth of <12.9 g/dL was also 
considered as an early criterion for ET.12 In December 2005 a new guideline of the American 
Academy of Pediatrics (AAP) with higher bilirubin thresholds for phototherapy and ET 
was implemented by our department.13 The criteria for ET after December 2005 were: 
(1) total serum bilirubin above (higher) ET thresholds13 and/or (2) rise of bilirubin >0.5 
mg/dL/hr despite intensive phototherapy, and/or (3) clinical symptoms of acute bilirubin 
encephalopathy regardless of bilirubin level. ET was performed with double-volume 
transfusion (160 mL/kg) using irradiated and leukocyte-depleted compatible erythrocytes. 
We recorded the following obstetric and neonatal data: fetal hemoglobin concentration 
at first IUT and number of IUTs, gestational age at birth, birth weight, hemoglobin level 
and reticulocyte count at birth, bilirubin level at birth, maximum bilirubin level during 
admission, duration of phototherapy (days), number of ETs required, number of top-up 
red blood cell transfusions received during the first 3 months of life and hemoglobin levels 
prior to the top-up transfusion. Data on the number of top-up transfusions and hemoglobin 
levels prior to the top-up transfusion in infants who received follow-up outside the LUMC 
were collected through correspondence with the local pediatrician or blood transfusion 
department. 
After discharge from our center, top-up transfusions were performed in referring hospitals 
when hemoglobin levels were <8.0 g/dL, or <9.6 g/dL if clinical symptoms of neonatal 
anemia were present (such as lethargy, feeding problems, need for oxygen or failure to 
thrive). Folic acid (50 mcg/day) was administered orally during the first three months of life 
to all neonates with hemolytic disease.
Primary outcome was the number of ETs and the number of top-up transfusions. Outcome 
was compared between neonates with Kell hemolytic disease (Kell group) and neonates 
with Rh D hemolytic disease (Rh D group).
Data are reported as means and standard deviations (SD) or as medians and interquartile 
range (IQR), as appropriate. Statistical analysis was performed using Student-t-test and 
Mann-Whitney test for continuous variables. Chi square and Fisher’s exact test were used 
for categorical variables, as appropriate. Linear regression analysis was performed using 
the Pearson Correlation coefficient. A p-value <0.05 was considered statistically significant. 
Statistical analysis was executed with SPSS 16.0 (SPSS Inc, Chicago, IL, USA).
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Results
During the study period 309 neonates with hemolytic disease were admitted to our 
neonatal nursery. Two hundred and seventy-seven (90%) of these neonates were born at 
a gestational age ≥35 weeks. Fifty-five neonates were excluded because of participation 
in a randomized trial for the use of intravenous immunoglobulin. Thirty-one neonates 
were excluded due to HDN caused by Rh c (n = 17), Rh C (n = 3), Rh E (n = 3), Cw (n = 
2), Jka (n = 1), presence of both Rh D and Kell antibodies (n = 2), and unknown type of 
irregular antibody (n = 3). A total of 191 patients were included in this study, 34 (18%) in 
the Kell group and 157 (82%) in the Rh D group. Baseline characteristics in both groups are 
summarized in Table 1. Intrauterine transfusions (IUTs) were performed in 82% of neonates 
in the Kell group and 66% of neonates in the Rh D group (p = 0.07). The median number of 
IUTs in the Kell group and Rh D group was 3 (IQR 2-4, range 0-5) and 2 (IQR 0-4, range 0-6) 
respectively (p = 0.01). In the Kell group the median antibody titer at first IUT was 1:128 
(range 1:2-8000).






Neonates treated with IUT, n (%) 28 (82) 104 (66) 0.07
Number of IUTs per neonatea 3 (2-4) 2 (0-3.5) 0.01
Gestational age at first IUT, weeksa 27 (23-29) 29 (24-33) 0.07
Hemoglobin level at first IUT, g/dLa 5.3 (3.5-7.3) 6.4 (5.0-7.4) 0.16
Gestational age at birth, weeksa 36 (36-37) 37 (36-37) 0.52
Birth weight, gramsb 3190 ± 348 2947 ± 418 <0.01
Male, n (%) 25 (74) 92 (59) 0.11
a Value given as median (IQR), b Value given as mean ± SD 
Phototherapy and ET
Detailed information on neonatal outcome in both groups, in particular treatment with 
phototherapy and ET is presented in Table 2. Mean bilirubin level at birth and maximum 
bilirubin level during admission were significantly lower in the Kell group than in the Rh D 
group, 3.1 versus 6.0 mg/dL (p = <0.01) and 8.0 versus 14.3 mg/dL (p = <0.01), respectively. 
Neonates in the Kell group required significantly less days of phototherapy than neonates 
in the Rh D group (2.4 and 4.1 mean days, respectively, (p = <0.01)). At least one ET was 
required in 6% (2/34) of the patients in the Kell group compared to 62% (98/157) of the 
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patients in the Rh D group (p = <0.01). The median number of ETs was 0 in the Kell group 
(IQR 0-0, range 0-1) and 1 in the Rh D group (IQR 0-1, range 0-5) (p = <0.01). None of the 
infants in the Kell group without IUT required an ET.






Hemoglobin level at birth, g/dLa 7.9 ± 1.8 7.2 ± 1.6 0.01
Bilirubin level at birth, mg/dLa 3.1 ± 1.7 6.0 ± 2.3 <0.01
Reticulocyte count at birth, ‰b,c 12 (8-49) 21 (3-66) 0.90
Maximum bilirubin, mg/dLb 8.0 (3.9-10.7) 14.3 (10.8-16.9) <0.01
Neonates treated with phototherapy, n (%) 31 (91) 154 (98) 0.07
Phototherapy, daysa,d 2.4 ± 1.3 4.1 ± 1.7 <0.01
Neonates treated with ET, n (%) 2 (6) 98 (62) <0.01
Number of ETs per neonateb 0 (0-0) 1 (0-1) <0.01
a Value given as mean ± SD, b Value given as median (IQR), c Assessed in 15/34 and 81/157 neonates in 
the Kell and Rh D-group, respectively, d Assessed in 134/157 neonates with Rh D
Top-up transfusions
Complete information on the number of top-up red cell transfusions was obtained for 98% 
(188/191) of neonates. The percentage of neonates requiring a top-up transfusion was 
similar in the Kell group and Rh D group (62% (21/34) and 72% (113/157), respectively 
(p = 0.20). The median number of top-up transfusions per neonate in the Kell group and 
Rh D group was 1 (IQR 0-2, range 0-4) and 2 (IQR 0-2, range 0-6), respectively (p = 0.07). 
Mean hemoglobin level at first top-up transfusion and median number of days until first 
top-up transfusion were similar in both groups. Detailed information on the use of top-up 
transfusions in the Kell group and Rh D group is presented in Table 3.
In the sub-group analysis of neonates treated with IUT (n = 132), we found that neonates 
with Rh D HDN required significantly more top-up transfusions than neonates with Kell HDN 
(median of 2 range 0-6 and median of 1 range 0-4), respectively (p = 0.02). We performed 
a linear regression analysis between the number of IUTs and the reticulocyte count at birth 
in both groups. A higher number of IUTs was correlated with a lower reticulocyte count at 
birth in the Rh D group (Pearson Correlation coefficient -0.49; p = <0.001). This negative 
correlation was not found in the Kell group (Pearson Correlation coefficient -0.05; p = 0.85). 
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Neonates requiring top-up transfusions, n (%) 21 (62) 113 (72) 0.20
Number of top-up transfusions per neonatea 1 (0-2) 2 (0-2) 0.07
Neonates requiring:         1 top-up transfusion, n (%)
                                        2 top-up transfusions, n (%)
                                         3 top-up transfusions, n (%)
                                        4 top-up transfusions, n (%)
                                        5 top-up transfusions, n (%)























Hemoglobin level at first top-up transfusion, g/dLb 8.2 ± 1.4 8.4 ± 1.5 0.73
Number of top-up transfusions (per neonate) in the 
subgroup treated with IUTa
1 (0-2) 1.9 (1-3) 0.02
a Value given as median (IQR), b Value given as mean ± SD
Discussion
This study shows that fetuses with severe Kell hemolytic disease are more often treated 
with IUT compared to fetuses with Rh D hemolytic disease. Subsequently, infants with HDN 
due to Kell-antibodies need less phototherapy and ETs in the neonatal period than neonates 
with Rh D hemolytic disease. However, the need for top-up transfusions was similar in both 
groups.
Various researchers have suggested that anemia in Kell hemolytic disease is caused 
primarily by erythroid suppression rather than hemolysis, as in Rh disease.3,4 An alternative 
theory is that anti-Kell-antibodies are responsible for the destruction of early erythroid 
progenitor cells, which lack hemoglobin.5,14 A lower amniotic fluid bilirubin and only mild 
neonatal hyperbilirubinemia in Kell hemolytic disease compared to Rh D are consistent 
with this theory. In addition, an in vitro study by Vaughan et al. demonstrated that human 
monoclonal anti-Kell antibodies and the serum of women with anti-Kell antibodies 
specifically inhibit the growth of Kell-positive erythroid progenitor cells.5 Vaughan et al. 
found no correlation between the anti-Kell antibody titer and the degree of inhibition.5 Poor 
correlation between antibody titer and disease severity in Kell supports the theory that Kell 
alloimmunization has a different pathogenesis than Rh alloimmunization. In a recent study 
of 43 pregnancies with Kell alloimmunization, we found that the vast majority of severely 
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affected cases had antibody titers of 1:32 or more. Nevertheless, to be on the safe side, 
we recommended that all pregnancies with Kell titers of 1:2 or higher (and a proven Kell 
positive fetus) should be closely monitored.2  
In accordance with previous studies from the group of Weiner4 and our group15 we found 
that antenatal course of fetuses with Kell alloimmunization is different from Rh D hemolytic 
disease. Fetuses with Kell alloimmunization have lower hemoglobin levels at first IUT and 
require more IUTs. Moreover, the first IUT was performed at an earlier gestational age 
than in Rh D fetuses.15 These findings underscore that fetal anemia is more severe in Kell 
sensitized fetuses than in Rh D sensitized fetuses. Weiner et al. also found a significant 
lower reticulocyte count, reflecting the destruction of Kell expressing erythroid progenitor 
cells in Kell hemolytic disease.4
In terms of neonatal management and outcome, this study shows that neonates with Kell 
hemolytic disease have milder hyperbilirubinemia, requiring less phototherapy and ETs 
than infants with Rh D hemolytic disease. In our study we found no relation between lack 
of IUT and number of ETs or top-up transfusions. Our findings are consistent with previous 
reports6,8,16-18 and reflect the observation that hemolysis of mature (hemoglobinized) 
erythrocytes in Kell hemolytic disease is less than in Rh D hemolytic disease.3,4
Given the significantly higher number of IUTs in the Kell group, one could expect an 
increased incidence of postnatal anemia (and top-up transfusions). As shown in previous 
studies, repeated IUTs result in a decreased reticulocyte count, indicating a suppression of 
fetal erythropoiesis.12,19 In contrast, we found a trend towards less top-up transfusions in 
neonates with Kell hemolytic disease compared to neonates with Rh D hemolytic disease, 
however this difference was not significant (p = 0.07). This finding could support the fact 
that fetal and neonatal anemia due to Kell alloimmunization has a different pathogenesis 
than Rh alloimmunization. Larger studies are required to confirm these findings. In contrast 
to anti-D, most anti-Kell antibodies have a strong lytic potential which also affects red cell 
precursor cells.3,4,19  Vaughan and colleagues found no correlation between the antibody 
titer and the degree of inhibition of Kell-positive erythroid progenitor cells.5 The titers 
of anti-Kell antibodies associated with fetal anemia are generally substantially lower 
compared to ten to 100 fold higher titers in case of Rh D hemolytic disease. Consequently 
anti-D antibodies may circulate in the newborn for a longer period after birth, whereas Kell 
antibodies disappear sooner, which may explain the more moderate late anemia in Kell 
hemolytic disease, despite concomitant suppression of the erythropoiesis.5
This is the first study comparing the degree of postnatal anemia in a relatively large number 
of infants with Kell- and Rh D hemolytic disease. Santiago et al. described three neonates 
with Kell HDN of whom only one required a top-up transfusion.17
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Collinet et al. reported a case of severe fetal anemia due to Kell alloimmunization, which 
was postnatally treated with two top-up transfusions and recombinant erythropoietin and 
iron supplementation.7 
The results of this study should be interpreted with care due to the small number of 
neonates with Kell hemolytic disease in this study which is inherent to the low incidence of 
this disease. Larger, multicenter studies are required to confirm our findings. 
In conclusion, although neonates with Kell hemolytic disease require less phototherapy and 
exchange transfusions, the equal need for top-up transfusions justifies similar follow-up 
management as in Rh D hemolytic disease. Finally, because of the destruction of red cell 
precursor cells as well, treatment with erythropoietin may be more effective in neonates 




1. Lee S, Russo D, Redman CM: The Kell blood group system: Kell and XK membrane proteins. Semin 
Hematol 2000; 37(2):113-121.
2. Kamphuis MM, Lindenburg I, Van Kamp IL, Meerman RH, Kanhai HH, Oepkes D: Implementation 
of routine screening for Kell antibodies: does it improve perinatal survival? Transfusion 2008; 
48(5):953-957.
3. Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM: Erythropoietic suppression in 
fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994; 171(1):247-252.
4. Weiner CP, Widness JA: Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. 
Am J Obstet Gynecol 1996; 174(2):547-551.
5. Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA: Inhibition of erythroid 
progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 
338(12):798-803.
6. Babinszki A, Lapinski RH, Berkowitz RL: Prognostic factors and management in pregnancies 
complicated with severe kell alloimmunization: experiences of the last 13 years. Am J Perinatol 
1998; 15(12):695-701.
7. Collinet P, Subtil D, Puech F, Vaast P: Successful treatment of extremely severe fetal anemia due 
to Kell alloimmunization. Obstet Gynecol 2002; 100(5 Pt 2):1102-1105.
8. Wenk RE, Goldstein P, Felix JK: Kell alloimmunization, hemolytic disease of the newborn, and 
perinatal management. Obstet Gynecol 1985; 66(4):473-476.
9. Dhodapkar KM, Blei F: Treatment of hemolytic disease of the newborn caused by anti-Kell 
antibody with recombinant erythropoietin. J Pediatr Hematol Oncol 2001; 23(1):69-70.
10. Manoura A, Korakaki E, Hatzidaki E, Saitakis E, Maraka S, Papamastoraki I, Matalliotakis E, 
Foundouli K, Giannakopoulou C: Use of recombinant erythropoietin for the management of 
severe hemolytic disease of the newborn of a K0 phenotype mother. Pediatr Hematol Oncol 
2007; 24(1):69-73.
11. Rath ME, Smits-Wintjens VE, Lindenburg I, Brand A, Oepkes D, Walther FJ, Lopriore E: Top-up 
transfusions in neonates with Rh hemolytic disease in relation to exchange transfusions. Vox Sang 
2010; 99(1):65-70.
12. De Boer IP, Zeestraten EC, Lopriore E, Van Kamp IL, Kanhai HH, Walther FJ: Pediatric outcome in 
Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 
2008; 198(1):54.
13. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation: 
Pediatrics 2004; 114(1):297-316.
14. Daniels G, Hadley A, Green CA: Causes of fetal anemia in hemolytic disease due to anti-K. 
Transfusion 2003; 43(1):115-116.
15. Van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH: Treatment of fetal 
anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-
1999. Acta Obstet Gynecol Scand 2004; 83(8):731-737.
16. Bowman JM, Pollock JM, Manning FA, Harman CR, Menticoglou S: Maternal Kell blood group 
alloimmunization. Obstet Gynecol 1992; 79(2):239-244.
17. Santiago JC, Ramos-Corp, Oyonarte S, Montoya F: Current clinical management of anti-Kell 
alloimmunization in pregnancy. Eur J Obstet Gynecol Reprod Biol 2008; 136(2):151-154.
Neonatal outcome in Kell versus Rh D HDN
149
18. McKenna DS, Nagaraja HN, O’Shaughnessy R: Management of pregnancies complicated by anti-
Kell isoimmunization. Obstet Gynecol 1999; 93(5 Pt 1):667-673.
19. Goodrum LA, Saade GR, Belfort MA, Carpenter RJ, Jr., Moise KJ, Jr.: The effect of intrauterine 
transfusion on fetal bilirubin in red cell alloimmunization. Obstet Gynecol 1997; 89(1):57-60.

Chapter 8
 Postnatal outcome in neonates with severe 

















Neonates with Rhesus c (Rh c) hemolytic disease of the fetus and newborn (HDFN) are often 
managed in the same way as neonates with Rhesus D (Rh D) HDFN, although evidence to 
support this policy is limited. The objective of this study was to evaluate neonatal outcome 
in severe Rh c HDFN compared to Rh D HDFN.
Methods
Retrospective study of (near-)term neonates with severe Rh c (n = 22) and Rh D HDFN (n 
= 103) (without additional antibodies) admitted to the Leiden University Medical Center 
between January 2000 and October 2011. The need for intrauterine transfusions (IUT), 
phototherapy, exchange transfusions (ET) and top-up transfusions up to three months of 
age were recorded and compared between both groups.
Results
Although there was a trend for a slightly more severe antenatal course of Rh D HDFN 
reflected by an earlier need for and higher number of IUTs (median (IQR) 2 (1.5-4) versus 2 
(1-2) in Rh c HDFN, p = 0.070), no significant differences were found for the postnatal course 
between Rh c and Rh D group in days of phototherapy (mean days 4.8 and 4.6, respectively 
(p = 0.569)), need for ET (50% versus 44%, respectively (p = 0.589)) and top-up transfusions 
(62% versus 78%, respectively (p = 0.128)).
Conclusion
Postnatal outcome in neonates with severe Rh c HDFN is similar compared to neonates with 
severe Rh D hemolytic disease in terms of days of phototherapy, need for ET and need for 
top-up transfusions. These results justify a similar postnatal management of neonates with 
Rh D and Rh c HDFN.
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Introduction
Anti-c is, after anti-D and anti-Kell, the most important red cell antibody causing severe 
hemolytic disease of the fetus and newborn (HDFN) necessitating intrauterine red cell 
transfusions (IUTs).1 
The postnatal outcome in neonates with Rhesus c (Rh c) HDFN is not well known. 
Neonatologists manage neonates with Rh c HDFN in the same way as they manage 
neonates with Rhesus D (Rh D) HDFN. However, this policy is based on only a few case 
reports and case series with limited information. No studies have been published comparing 
outcome in Rh c and Rh D HDFN with respect to need for IUTs, the incidence and severity of 
neonatal anemia, hyperbilirubinemia, phototherapy, number of exchange transfusions (ETs) 
and top-up transfusions. 
The objective of this study was to evaluate postnatal outcome and management in a large 
series of neonates with severe Rh c HDFN compared to neonates with Rh D HDFN. In 
addition, we investigated whether anti-c as compared to anti-D caused prolonged anemia 
needing late top-up transfusions in relation to antibody titers at birth. 
Patients and Methods
Neonates with hemolytic disease due to maternal Rh c and Rh D alloimmunization, born 
between January 2000 and October 2011 at the Leiden University Medical Center (LUMC) 
were eligible for this retrospective observational study. Since neonatal hemolytic disease 
can be more severe in the presence of multiple antibodies directed against fetal antigens,1 
neonates with other clinically relevant antibodies directed against fetal antigens in addition 
to anti-c or anti-D were excluded as well as neonates born <35 weeks’ gestation (Figure 1). 
Neonates with additional maternal antibodies, for which the child is lacking the antigen, 
were not excluded in the Rh c group. Table 1 provides a complete overview of all antibody 
combinations in Rh c and Rh D alloimmunization to outline the real clinical problem. 
Antibody titers were determined in the fetal period (maternal titers) and at birth by serial 
dilution in standard serological techniques using indirect antiglobulin test.2,3 Functional 
potential of anti-D and anti-c antibodies were evaluated by the Antibody Dependent 
Cellular Cytotoxicity (ADCC) assay. This functional bioassay estimates the lytic potential of 
the antibodies in vitro aiming to predict severity of HDFN. The percentage of hemolysis 
in ADCC has been validated for Rh D.4,5 In case of ADCC ≥30% and/or titer ≥1:16 patients 
are generally referred for ultrasound and Doppler assessment of the peak velocity in the 
middle cerebral artery (MCA) to determine the need for IUT.6 The LUMC is the national 
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referral center for the management and intrauterine treatment of red cell alloimmunization 
in the Netherlands. A subgroup of the neonates has previously been described in different 
studies.7-11
Figure 1. Diagram of inclusion of neonates for Rh c versus Rh D study
Ab = antibody
Irrelevant Ab = Ab for which the child is lacking the antigen
IUT was scheduled when the peak velocity in the MCA was ≥1.50 multiples of the median. 
In all cases, blood was transfused, although occasionally, the degree of fetal anemia was 
only mild. Our IUT treatment protocol for Rh D and Rh c alloimmunization is identical. In 
December 2005 new guidelines for phototherapy and ET based on the guidelines of the 
American Academy of Pediatrics were implemented in our clinic. Intensive phototherapy 
(= 30µW/cm2/nm) using 4 lamps including a phototherapy blanket was started as soon as 
the infant was admitted and discontinued when bilirubin level was below phototherapy 
thresholds.9 Criteria for ET before December 2005 included: (1) bilirubin level at birth >3.5 
mg/dL (so-called early criterion) and/or (2) total serum bilirubin level above ET thresholds 
(and rise of bilirubin value >0.5 mg/dL/h despite intensive phototherapy).9 In neonates 
not treated with IUT, a hemoglobin level at birth of <12.9 g/dL was also considered as an 
early criterion for ET. The criteria for ET after December 2005 were: (1) total serum bilirubin 
above (higher) ET thresholds and/or (2) rise of bilirubin >0.5 mg/dL/h despite intensive 
phototherapy, and/or (3) clinical symptoms of acute bilirubin encephalopathy regardless 
of bilirubin level.9 ET was performed with double-volume transfusion (160 mL/kg) using 
irradiated and leukocyte-depleted erythrocytes compatible with mother and child. Top-up 
transfusions were performed in our clinic and after discharge in referring hospitals when 
hemoglobin levels were <8.0 g/dL, or <9.6 g/dL if clinical symptoms of anemia were present 
393 with red cell alloimmune HDFN
333 with anti-c or anti-D
296 with anti-D 37 with anti-c
114 with only anti-D 23 with anti-c or anti-c + irrelevant Ab
103 in Rh D group 22 in Rh c group
11 born < 35 weeks 
of gestation
14 with additional Ab
1 born < 35 weeks of 
gestation
60 with other  
Ab than anti-c or -D
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(lethargy, feeding problems, need for oxygen or failure to thrive). Our phototherapy, ET and 
top-up transfusion guidelines for neonates with Rh D and Rh c HDFN are identical. Folic acid 
(50 mcg/day) was administered orally during the first three months of life to all neonates 
with hemolytic disease.
Table 1. Specificity of all antibody combinations in cases with anti-D and anti-c
Cases with anti-c (n = 37) Cases with anti-D (n = 296)
Antibody specificity Frequency Antibody specificity Frequency
c 17 D 128
c, E 5 D, C 108
c, Kell 2 D, C, E 12
c, E, Jka 1 D, E 10
c, Kell, Jka, M 1 D, C, Jka 6
c, Fya 1 D, Jka 5
c, Jka 1 D, C, Fya 4
c, Lewisa 1 D, Kell 2
c, Cw 1 D, C, M 2
E, c 5 D, C, Kpa 2
Kell, c 1 D, E, C 2
Fya, c 1 D, Fya 1
Antibodies were placed in order based on high-
est antibody titer.
A possible fourth antibody was not recorded.
D, C, G 1
D, C, Jkb 1
D, C, Kell 1
D, C, Fyb 1
D, E, Fya 1
D, E, Jka 1
D, Kell, C 1
D, Kell, E 1
D, Fya, C 1
D, Jka, C 1
D, Jka, S 1
C, D 1
E, D 1
Fya, C, D 1
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We recorded the following obstetric and neonatal data: fetal hemoglobin concentration 
at first IUT and number of IUTs, maximum maternal antibody titer, gestational age at 
birth, birth weight, born before/after December 2005 (implementation new ET guideline), 
hemoglobin level and reticulocyte count at birth, titer of irregular antibody test at birth, 
bilirubin level at birth, maximum bilirubin level during admission, duration of phototherapy, 
number of ETs required, number of top-up red blood cell transfusions received during the 
first three months of life and hemoglobin levels prior to the top-up transfusions. Data on 
the number of top-up transfusions and hemoglobin levels prior to the top-up transfusions in 
infants who received follow-up outside the LUMC were collected through correspondence 
with the local pediatrician or blood transfusion department. 
Primary outcome was the number of ETs and top-up transfusions. Outcome was compared 
between neonates with Rh c HDFN (Rh c group) and neonates with Rh D HDFN (Rh D 
group).
Data are reported as means with standard deviation (SD) or as medians with interquartile 
range (IQR), as appropriate. Statistical analysis was performed using Student-t-test and 
Mann-Whitney test for continuous variables. Chi square and Fisher’s exact test were used 
for categorical variables, as appropriate. To assess the relationship between antibody titers 
and transfusion requirements Spearman correlations were calculated. A p-value <0.05 was 
considered statistically significant. Statistical analysis was executed with SPSS 17.0 (SPSS Inc, 
Chicago, IL, USA).
Results
During the study period 393 neonates with hemolytic disease due to red cell 
alloimmunization were admitted to our neonatal nursery. Figure 1 shows the derivation 
of the included population and the reasons for exclusion. A total of 125 patients were 
included in this study, 22 (18%) in the Rh c group and 103 (82%) in the Rh D group. Baseline 
characteristics in both groups are summarized in Table 2. Intrauterine transfusions (IUTs) 
were performed in 41% of neonates in the Rh c group and 59% of neonates in the Rh D 
group (p = 0.116). The median number of IUTs in the Rh c group and Rh D group was 2 (IQR 
1-2, range 1-3) and 2 (IQR 1.5-4, range 1-6), respectively (p = 0.070). The maximum ADCC 
result was significantly lower in the Rhesus c group (median 45%, range <10% - >80%) 
compared to the Rhesus D group (median >80%, range <10% - >80%) (p = <0.001).
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Table 2. Baseline characteristics of Rh c group and Rh D group 
Rh c group 
(n = 22)
Rh D group  
(n = 103)
p-value
Neonates treated with IUT, n (%) 9 (41) 61 (59) 0.116
Number of IUTs in IUT treated neo-
natesa 
2 (1-2) 2 (1.5-4) 0.070
Gestational age at first IUT, weeksa 33 (30-34) 29 (25-33) 0.127
Hemoglobin level at first IUT, g/dLb,c 8.5 ± 1.8 6.5 ± 2.3 0.015
Maximum ADCC test result, %a,d 45 (11.25-80) >80 (65 - >80) <0.001
Maximum maternal antibody titer,a,e 1:1000 (1:1000-1:3500) 1:4000 (1:1000-1:8000) 0.001
Titer of irregular antibody test at birth 
in cord blooda,f
1:200 (1:128-1:500) 1:500 (1:64-1:2000) 0.087
Gestational age at birth, weeksa 37 (36-38) 37 (36-37) 0.087
Birth weight, kgb 3.21 ± 0.45 3.00 ± 0.42 0.107
Male, n (%) 14 (64) 65 (63) 0.963
Hydrops at birth, n (%) 0 (0) 2 (2) 1.000
Born before ET guideline change in 
December 2005, n (%)
13 (59) 50 (49) 0.391
a Value given as median (IQR), b Value given as mean ± SD, c Assessed in 59/61 Rh D neonates treated 
with IUT, d Assessed in 16/22 in Rhesus c group and 97/103 in Rhesus D group, e Assessed in 20/22 in 
Rhesus c group and 97/103 in Rhesus D group, f Assessed in 15/22 in Rhesus c group and 55/103 in 
Rhesus D group
Blood results at birth, phototherapy and ET
Detailed information on neonatal outcome in both groups, in particular treatment 
with phototherapy and ET is presented in Table 3. Although reticulocyte count at birth 
was only measured in 55% (12/22) and 63% (65/103) of neonates of the Rh c and Rh D 
group, respectively, the median absolute reticulocyte count of neonates with Rh c HDFN 
was higher than of neonates with Rh D HDFN: 25.4 (IQR 8.9-49.2) and 15.1 (IQR 1.6-
29.2), respectively, p = 0.100). There were no significant differences in bilirubin levels, 
phototherapy treatment and ETs between both groups.
Top-up transfusions
Complete information on the number of top-up red cell transfusions was obtained for 
98% (123/125) of neonates. We found no significant differences between the percentage 
of neonates requiring at least one top-up transfusion, the median number of top-up 
transfusions per neonate and the median number of days after birth until the last top-up 
transfusion between the two groups. Detailed information on the use of top-up transfusions 
in the Rh c group and Rh D group is presented in Table 4.
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Table 3. Neonatal outcome and management in Rh c group and Rh D group
Rh c group 
 (n = 22)
Rh D group  
(n = 103)
p-value
Hemoglobin level at birth, g/dLa 12.4 ± 2.7 12.3 ± 2.9 0.599
Bilirubin level at birth, mg/dLa 6.9 ± 4.7 6.2 ± 3.0 0.990
Reticulocyte percentage at birth, %b,c 9 (4.2-15.2) 5.8 (0.8-8.9) 0.035
Absolute reticulocyte count at birth, 109/Lb,c 25.4 (8.9-49.2) 15.1 (1.6-29.2) 0.100
Maximum bilirubin, mg/dLa,d 15.9 ± 4.3 14.7 ± 4.7 0.136
Neonates treated with phototherapy, n (%) 21 (95) 101 (98) 0.443
Phototherapy, daysa,e 4.8 ± 2.4 4.6 ± 1.8 0.569
Neonates treated with ET, n (%) 11 (50) 55 (44) 0.589
Number of ETs per neonateb 2 (1-2) 1 (1-2) 0.076
a Value given as mean ± SD, b Value given as median (IQR), c Assessed in 12/22 in Rhesus c group and 
65/103 in Rhesus D group, d Assessed in 21/22 in Rhesus c group, e Assessed in 93/103 in Rhesus D 
group
Table 4. Top-up transfusions in neonates in Rh c group and Rh D group 
Rh c  group 
 (n = 22)
Rh D group  
(n = 103)
p-value
Neonates requiring top-up transfusions, n (%) 13/21 (62) 80/103 (78) 0.128
Number of top-up transfusions per neonatea,b 2 (1-2) 2 (1-3) 0.418
Neonates requiring:             1 top-up transfusion, n (%)
                                          2 top-up transfusions, n (%)
                                          3 top-up transfusions, n (%)
                                                 4 top-up transfusions, n (%)
                                          5 top-up transfusions, n (%)













Days after birth until first top-up transfusiona,c 19 (1-28.5) 10 (1.5-30.5) 0.972
Days after birth until last top-up transfusiona,d 31.5 (11-55) 42 (27-58) 0.337
Hemoglobin level at first top-up transfusion, g/dLe,f 8.26 ± 1.53 8.21 ± 1.47 0.900
Number of top-up transfusions per neonate in subgroup 
treated with IUTa,g
1 (1-2) 2 (2-4) 0.040







a Value given as median (IQR), b Assessed in 12/13 in Rh c group and 79/80 in Rh D group, c Assessed in 
77/80 in Rh D group, d Assessed in 12/13 in Rh c group and 75/80 in Rh D group , e Value given as mean 
± SD, f Assessed in 75/80 in Rh D group, g Only assessed in neonates treated with top-up transfusions 
Neonatal outcome in Rh c versus Rh D HDN
159
In the sub-group analysis of neonates treated with IUT (n = 70), we found a significantly 
higher number of top-up transfusions in the Rh D group compared to the Rh c group 
(median (IQR) 2 (2-4) versus 1 (1-2), respectively, p = 0.040). 
Antibody titer at birth and maximum maternal antibody titer in relation to postnatal 
transfusions
Antibody titer at birth (measured in cord blood) was assessed in 15/22 neonates in the 
Rhesus c group and 55/103 neonates in the Rhesus D group. 
In the Rhesus c group, we found a positive correlation between antibody titer at birth and 
need for ET (correlation coefficient 0.614; p = 0.015). In case an ET was indicated in the Rh 
c group, antibody titer at birth was never <1:200. Antibody titer at birth is not correlated to 
the number of ETs, the need for top-up transfusions and the number of top-up transfusions 
in the Rh c group. 
In the Rhesus D group, we found a positive correlation between antibody titer and need for 
top-up transfusions and number of top-up transfusions (correlation coefficients 0.406, p = 
0.002 and 0.579, p = <0.001, respectively). Antibody titer is not correlated to the need for 
ET or the number of ETs in the Rh D group. 
Maximum antibody titer was assessed in the mothers of 97/103 and 20/22 neonates of the 
Rh D and Rh c group respectively. Maximum maternal antibody titer is correlated to need 
for and number of top-up transfusions in the Rh D group (correlations coefficients 0.277, p 
= 0.006 and 0.537, p = <0.001, respectively), but not in the Rh c group. Maximum maternal 
antibody titer was not correlated to the need for ET or the number of ETs in the Rh D and 
Rh c group.
Discussion
This study shows that the need for phototherapy, ETs and top-up transfusions is similar 
between neonates with severe Rh c and Rh D HDFN. In particular number and timing of top-
up transfusions were similar between both groups. 
This is the first large study describing the postnatal outcome and management in neonates 
with severe Rh c HDFN compared to neonates with Rh D HDFN. Several cohort studies have 
been published on anti-c immunization in pregnancy, but postnatal management in Rh c 
alloimmunization was extrapolated from the data available for the management of Rh D 
HDFN.
We found a trend towards a lower number of IUTs in neonates with Rh c HDFN compared 
to Rh D HDFN suggesting that fetuses with Rh c HDFN may have less severe hemolysis. 
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The significantly lower ADCC test and maximum maternal antibody titer results in the Rh c 
group are consistent with this trend. One previous small study reported a median number 
of 3 IUTs in 57 affected pregnancies with Rh D alloimmunization and the number of IUTs 
in 2 pregnancies with Rh c alloimmunization (2 and 3 IUTs), but the study was to small to 
show any differences.12 In a study from Hackney et al., 17% (8/46) of fetuses with Rh c 
HDFN required treatment with IUT. The mean number of IUTs in their study was 5 (range 
2-9).13  Kozlowski et al. reported that only 1 of 14 infants with Rh c HDFN who required 
ET received three IUTs.14 A prospective study was performed in the Netherlands between 
2003 and 2005, including 118 pregnant women with anti-c as dominant antibody. Only 
one fetus required an IUT, 6 received no IUT but one or more ETs (in some cases followed 
by top-up transfusion) and 5 received only top-up transfusion(s).15 The high percentage of 
neonates with Rh c HDFN treated with IUT in our study reflects the more severely diseased 
group of neonates because our center is the national referral center for HDFN. Although 
our IUT-protocol is similar for Rh D as for Rh c HDFN, the hemoglobin level before first IUT 
was significantly higher in fetuses with Rh c HDFN compared to fetuses with Rh D HDFN. 
In addition, the timing of first IUT in neonates with Rh c is later (median of 2.6 weeks) 
compared to neonates with Rh D. This influences the hemoglobin level before first IUT since 
fetal hemoglobin level increases with higher gestational age.16
At birth, neonates with Rh c HDFN showed a significantly higher reticulocyte percentage 
and a trend towards a lower absolute reticulocyte count compared to neonates with Rh D 
HDFN in this study. This might be due to the lesser amount of IUTs in the Rh c group since 
IUT suppresses erythropoiesis.17 In addition, in case of a high titer, anti-D antibodies can 
hemolyse reticulocytes and cause prolonged anemia.18,19 
Treatment with phototherapy and ET was not significantly different between both groups. 
Our percentages of neonates with Rh c HDFN requiring phototherapy (96%) and ET (50%) 
are not consistent with previous studies. Most studies report lower rates of phototherapy 
(range: 7 to 77%) and ET (range: 5 to 17%).13-15,20-22 In the most recent study of Karagol et al. 
77% (17/22) of neonates with anti-c HDFN required phototherapy and 9% (2/22) required 
ET.23 As mentioned before, these figures cannot be compared between studies because 
of different patient populations and our cohort represents a population of more severely 
diseased neonates.
Postnatal anemia requiring top-up transfusion and time until the last top-up transfusion 
were also not significantly different between neonates with Rh c and Rh D HFDN. 
Nevertheless, we did find a trend towards a lower number of top-up transfusions in the 
sub-group of neonates with Rh c HDFN treated with IUT compared to Rh D HDFN.  
The positive correlation between antibody titer (measured in cord blood) and top-up 
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transfusions in our Rh D group is in accordance with other studies showing that (maternal) 
anti-D titer is a good indicator of the severity of hemolytic disease.24 For Rh c HDFN Hackney 
et al. showed that all neonates who required IUT or with a hemoglobin level of <10 g/dL 
at birth had an antibody titer of ≥1:32.13 The predictive value of antibody titer on postnatal 
transfusion requirements in Rh c HDFN has not been evaluated yet. However, further 
studies are needed to confirm the positive correlation between antibody titer and the need 
for ET in Rh c HDFN in our study. 
The results of this study should be interpreted with care due to the relatively small number 
of neonates with severe Rh c HDFN which is inherent to the low incidence of this disease. In 
addition, some results were also limited by missing data of outcome variables.
In conclusion, severe Rh c HDFN behaves postnatally similar as Rh D HDFN in terms of need 
of phototherapy, ETs and top-up transfusions and justifies similar follow-up management. 
As suggested for Rh D HDFN, also for Rh c, the titer at birth might be helpful to predict the 
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To evaluate the incidence and severity of and risk factors for thrombocytopenia at birth in 
neonates with red cell alloimmunization.
Study design
All neonates with hemolytic disease of the fetus/newborn (HDFN) due to red cell 
alloimmunization admitted to our center between January 2000 and September 2010 
were included in this retrospective study. We measured platelet counts at birth and 
determined the incidence of thrombocytopenia (platelet count <150 × 109/L) and severe 
thrombocytopenia (platelet count <50 × 109/L). Risk factors for thrombocytopenia at birth 
were evaluated. 
Results
Thrombocytopenia was present in 26% (94/362) of included neonates with HDFN at birth. 
Severe thrombocytopenia was found in 6% (20/362) of neonates. Three risk factors were 
found to be independently associated with thrombocytopenia at birth: treatment with 
intrauterine red cell transfusion (IUT) (OR 3.32, 95% CI 1.67-6.60, p = 0.001), small for 
gestational age (SGA) below the 10th percentile (OR 3.32, 95% CI 1.25-8.80, p = 0.016), and 
lower gestational age at birth (OR 1.22 per week, 95% CI 1.02-1.44, p = 0.025).
Conclusions
Thrombocytopenia at birth occurs in 26% of neonates with HDFN due to red cell 
alloimmunization and is independently associated with IUT treatment, SGA and lower 
gestational age at birth.
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Introduction
Limited studies have shown that fetuses with red cell alloimmunization are at increased 
risk of thrombocytopenia (platelet count <150 × 109/L).1-3 In Rhesus D hemolytic disease 
treated with intrauterine red cell transfusion (IUT), thrombocytopenia was detected in 
26% of fetuses at cordocentesis and was associated with fetal hydrops.2 In Kell hemolytic 
disease, the incidence of fetal thrombocytopenia appears to be lower (10%) and less severe 
compared to fetuses with Rhesus D alloimmunization.2,3 
Incidence and severity of thrombocytopenia in neonates with red cell alloimmunization 
at birth is unclear. In one small study (n = 20) thrombocytopenia was detected in 55% of 
neonates with Rhesus hemolytic disease during the neonatal period.4 However, platelet 
count was not routinely measured at birth and possibly neonatal thrombocytopenia 
developed after birth due to treatment with exchange transfusion for hyperbilirubinemia.5
The exact cause of fetal and neonatal thrombocytopenia in red cell alloimmunization is 
not well known. Decreased production, increased destruction or a combination of both 
may play a role.1,4,6 Common risk factors for fetal and neonatal thrombocytopenia such as 
preeclampsia, maternal diabetes and intrauterine growth retardation may also play a role in 
pregnancies affected by red cell alloimmunization.7,8 
The aim of this study was to evaluate the incidence and severity of and risk factors for 
thrombocytopenia at birth in a large series of neonates with hemolytic disease of the fetus/
newborn (HDFN) due to red cell alloimmunization. 
Patients and Methods
All neonates with HDFN due to maternal red cell alloimmunization admitted between 
January 2000 and September 2010 at the Leiden University Medical Center (LUMC) were 
included in this retrospective observational study. Our center is the single national referral 
center for the management and intrauterine treatment of red cell alloimmunization 
in the Netherlands. Part of the fetuses/neonates has been described in two previous 
studies on fetal thrombocytopenia,2,3 two retrospective studies on transfusions in red cell 
alloimmunization9,10 and in a randomized trial on the use of intravenous immunoglobulin.11
Our management guidelines in neonates with HDFN dictate that a full blood count 
(including hemoglobin level, reticulocyte count and platelet count) must be routinely 
performed in all neonates at birth. In addition, in the subgroup of fetuses treated with IUT, 
a full blood count is routinely performed at cordocentesis before each IUT to determine the 
desired amount of packed donor red cells.  
Chapter 9
170
Primary outcome was the incidence of and risk factors for thrombocytopenia at birth in 
neonates with HDFN. 
Thrombocytopenia was defined as a platelet count <150 × 109/L and was classified as mild 
(101 to 149 × 109/L), moderate (51 to 100 × 109/L), severe (21 to 50 × 109/L) and very severe 
(≤20 × 109/L). A fully automated cell counter (Sysmex XE-2100), utilizing optical fluorescent 
platelet count in situations where an impedance count is unreliable, was used to determine 
fetal and neonatal platelet counts. A concentrated platelet transfusion (single donor 
plasma-reduced platelet apheresis concentrates) in a dose of 20 × 109/kg was given at birth 
if: (1) platelet count was <20 × 109/L (before November 2009 <30 × 109/L) in clinically stable 
neonates; (2) platelet count was <50 × 109/L in neonates with a manifest bleeding, those 
undergoing a procedure with risk of bleeding and in clinically unstable neonates with birth 
weight <1500 gram.
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of IUTs, presence of fetal hydrops, fetal platelet count before each IUT, number 
of fetal platelet transfusions and neonatal platelet transfusions at birth, gestational age 
at birth, birth weight, small for gestational age (SGA) (defined as a birth weight <10th 
percentile),12 perinatal asphyxia (defined as Apgar score <7 at 5 minutes after birth), the 
presence of early onset neonatal sepsis (defined as clinical symptoms of infection and 
positive blood culture in the first 72 hours of life) and test results for TORCH infection 
and fetal/neonatal alloimmune thrombocytopenia (FNAIT). We recorded the presence of 
clinical signs of bleeding at birth and intracranial hemorrhage on the first cranial ultrasound 
performed within 24 hours after birth. A cranial ultrasound is performed on all IUT 
treated neonates. We documented the following maternal data: PIH (pregnancy induced 
hypertension)/preeclampsia, HELLP syndrome (syndrome of Hemolysis, Elevated Liver 
enzymes, Low Platelet counts) diabetes and TORCH infection.
Statistical analysis was performed using Student-t-test and Mann-Whitney test for 
continuous variables. Chi square and Fisher’s exact tests were used for categorical variables, 
as appropriate. The following possible risk factors for thrombocytopenia at birth were 
included in a multivariate logistic regression model to measure independent effects: Rhesus 
D type of red cell alloimmunization, PIH/preeclampsia, HELLP syndrome, maternal diabetes, 
gestational age at birth, SGA, treatment with IUT, perinatal asphyxia and fetal hydrops. 
The results of the logistic model were expressed as odds ratios (OR). A p-value <0.05 was 
considered statistically significant. Statistical analysis was executed with SPSS 17.0 (SPSS Inc, 
Chicago, IL, USA).
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Results
During the study period 364 neonates with HDFN of 330 mothers were admitted to our 
neonatal nursery. A flow chart of included neonates and information on severity and causes 
of thrombocytopenia at birth is presented in figure 1. A full blood count was measured in all 
but 2 neonates (99%, 362/364). In IUT treated neonates, a full blood count was measured in 
all but 2 fetuses (99%, 242/244) at cordocentesis. Baseline characteristics are summarized 
in table 1.
Figure 1. Flowchart showing numbers of neonates enrolled and severity and causes of 
thrombocytopenia at birth
Incidence, cause and severity of thrombocytopenia in HDFN
Incidence and severity of thrombocytopenia at birth
Thrombocytopenia was detected in 26% (94/362) of neonates at birth and was classified 
as mild (49%, 46/94), moderate (30%, 28/94), severe (19%, 18/94) and very severe (2%, 
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neonate (born at 30 weeks’ gestation) with intraventricular hemorrhage grade 2 on day 
one. His platelet count at birth was 53 × 109/L. 
Four percent (14/362) of neonates received a platelet transfusion at birth due to 
thrombocytopenia.
Table 1. Baseline characteristics of all included neonates with HDFN due to red cell alloimmunization 
Neonates with HDFN  
(n = 362)
Neonates treated with IUT, n (%) 244 (67)
Number of IUTs in IUT treated neonatesa 3 (1-6)
Fetal thrombocytopenia before IUT, n (%) 42 (17)
Fetal thrombocytopenia*, n (%) 97 (40)
Gestational age at birth (weeks)a 36 (27-42)
Birth weight (grams)b 2904 ± 548
SGA (birth weight <p10), n (%) 22 (6)
Male, n (%) 228 (63)
Rhesus D alloimmunization, n (%) 268 (74)
Kell alloimmunization, n (%) 51 (14)
Rhesus c alloimmunization, n (%) 28 (8)
Rhesus E alloimmunization, n (%) 9 (3)
Fy(a) alloimmunization, n (%) 2 (1)
Cw alloimmunization, n (%) 2 (1)
Jk(a) alloimmunization, n (%) 1 (0)
Rhesus C alloimmunization, n (%) 1 (0)
a Value given as median (range); * Based on all fetal platelet counts before each IUT;  b Value given as 
mean ± SD
Fetal thrombocytopenia and IUT in neonates with thrombocytopenia at birth
Eighty of the 94 thrombocytopenic neonates at birth received at least one IUT 
(figure 1). Thirty-one percent (24/78) and 95% (76/80) of IUT treated neonates with 
thrombocytopenia at birth had fetal thrombocytopenia based on the first fetal platelet 
count (before the first IUT) and all fetal platelet counts, respectively.
Only one (non-hydropic) fetus received an intrauterine platelet transfusion at a platelet 
count of 27 × 109/L in addition to a single IUT at 33 weeks’ gestation. He was born after 35 
4/7 weeks’ gestation with a birth weight of 2580 gram (p25-p50) and Apgar scores of 4, 
7 and 7 after 1, 5 and 10 minutes, respectively. Platelet count at birth was 22 × 109/L and 
he received one platelet transfusion on day one. Screening tests in this patient showed no 
evidence of FNAIT or TORCH congenital infection.
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Diagnostic tests in neonates with thrombocytopenia at birth
Fifteen neonates with thrombocytopenia at birth were screened for fetal/neonatal 
alloimmune thrombocytopenia (FNAIT) and one neonate had FNAIT coinciding with her 
Rhesus D HDFN. Maternal and/or neonatal serologic screening tests for congenital TORCH 
infection were performed in 63% (59/94) of neonates with thrombocytopenia. All TORCH 
screening tests were negative. No cases of early onset neonatal sepsis were detected. 
Risk factors for thrombocytopenia at birth
Detailed information on risk factors for thrombocytopenia at birth and blood results of 
neonates with and without thrombocytopenia at birth are summarized in table 2. 
Univariate analysis:
Type of alloimmunization 
The incidence of thrombocytopenia at birth in neonates with Rhesus D, Kell, Rhesus c and 
other types of red cell alloimmunization was 26% (69/268), 24% (12/51), 36% (10/28) and 
20% (3/15), respectively. Type of red blood cell alloimmunization was not associated with 
thrombocytopenia at birth (table 2). The incidence of severe thrombocytopenia (platelet 
count ≤50 × 109/L) at birth was also not statistically different in neonates with Rhesus D, 
Kell, or Rhesus c compared to neonates without Rhesus D, Kell or Rhesus c respectively (p = 
0.672, p = 0.434 and p = 0.696, respectively). 
Perinatal risk factors 
Several risk factors were associated with thrombocytopenia at birth including: treatment 
with IUT (OR 3.62, 95% CI 1.95-6.73, p = <0.001), fetal hydrops (OR 2.97, 95% CI 1.58-5.58, p 
= <0.001), PIH/preeclampsia (OR 7.36, 95% CI 1.40-38.6, p = 0.015), lower gestational age at 
birth (OR 1.33 for each week less, 95% CI 1.16-1.54, p = <0.001) and SGA (OR 3.10, 95% CI 
1.30-7.40, p = 0.012). 
Only one mother had HELLP syndrome and one mother had diabetes (both neonates had 
normal platelet counts at birth).  
Multivariate analysis
On multivariate analysis, the following risk factors were independently associated with 
thrombocytopenia at birth: treatment with IUT, lower gestational age at birth and SGA 
(table 2). Fetal hydrops was not significant at the 5% level, but the relatively low p-value (p = 
0.083) is suggestive of a possible independent association with thrombocytopenia at birth.
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of limited number of cases. As birth weight and gestational age at birth are closely related, 
birth weight was also excluded from multivariate analysis.
Discussion
This study demonstrates that thrombocytopenia at birth is common among neonates with 
HDFN due to red cell alloimmunization, occurring in 26% of neonates compared to 1-5% in 
the general population and 22-35% in the neonatal intensive care unit (NICU) population.13 
Severe thrombocytopenia was present in 6% of all neonates with HDFN compared to 5-10% 
in the NICU population.
This is the first study describing the incidence of neonatal thrombocytopenia at birth in 
HDFN due to red cell alloimmunization. Koenig et al. described neonatal thrombocytopenia 
in 11 of 20 (55%) neonates with Rhesus HDFN during admission.4 In this study, platelet 
count was not routinely measured at birth and in several cases only after exchange 
transfusion. Exchange transfusion is a known risk factor for thrombocytopenia, 
independently of red cell alloimmunization.5,14
We found a positive association between IUT treatment and thrombocytopenia at 
birth. The cause of this association is not clear and several mechanisms may play a role. 
Increased erythropoiesis could theoretically lead to suppression of thrombopoiesis by the 
hematopoietic stem cells.1,4 However, since IUT is known to suppress erythropoiesis,15 this 
theory only supports fetal thrombocytopenia at the first IUT. Increased incidence of fetal 
thrombocytopenia from 17% to 40% in fetuses treated with several IUTs may be explained 
by a decreased production, increased consumption, increased destruction, or dilution. In 
addition, IUT with packed red cells can cause dilution of platelets.16 However, it is unlikely 
that this effect is still present at the time of a consecutive IUT after two to three weeks. 
We found that type of red cell alloimmunization was not a risk factor for thrombocytopenia 
at birth. In a previous study fetal thrombocytopenia (at first IUT) appeared to be less 
common in Kell HDFN than in Rhesus D HDFN.3 The discrepancy between the results may be 
due to several factors including methodological differences between the two studies. The 
higher rate of thrombocytopenia in Kell HDFN found in this study may be due to the higher 
number of IUTs in the Kell population.10 
Prematurity and intrauterine growth restriction have previously been described as risk 
factors for early-onset (<72 hours) neonatal thrombocytopenia.7,8 In accordance, we 
demonstrated that lower gestational age at birth and SGA are independent risk factors for 
thrombocytopenia at birth in neonates with HDFN. In addition, we found that lower birth 




Perinatal asphyxia (Apgar score <7), maternal PIH/preeclampsia and syndrome of HELLP 
have formerly been described as risk factors for thrombocytopenia at birth.7,17,18 In our 
study population perinatal asphyxia was not associated with thrombocytopenia at birth and 
the number of cases with PIH/preeclampsia was limited.
Interestingly, one case of thrombocytopenia in this cohort was found to be due to FNAIT. 
Four other case reports of thrombocytopenia due to FNAIT have been described in fetuses/
neonates with Rhesus hemolytic disease.19-22 
Fortunately only one neonate had clinical signs of bleeding at birth (intraventricular 
hemorrhage grade 2).  Although this neonate was thrombocytopenic at birth, in this 
case other factors such as prematurity and hydrops could have contributed to this 
bleeding complication. Moreover, the causal relation between thrombocytopenia and 
intraventricular hemorrhage is controversial.23  
The results of this study should be interpreted with care because of the retrospective 
study design. We have not systematically investigated all other possible causes of neonatal 
thrombocytopenia such as maternal immune thrombocytopenic purpura (ITP), FNAIT and 
perinatal/neonatal infection. Hence the incidence of 26% of thrombocytopenia at birth 
due to red cell alloimmunization can be an overestimate. Finally, the number of spurious 
thrombocytopenia because of clotted samples and platelet clumping is unclear. 
In conclusion, this study shows that 26% of neonates with HDFN due to red cell 
alloimmunization have thrombocytopenia at birth. Risk for thrombocytopenia is 
independently associated with IUT treatment, SGA and lower gestational age at birth.
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Cholestasis in neonates with red cell 
alloimmune hemolytic disease: incidence, risk 













Etiology of cholestatic liver disease in neonates with hemolytic disease of the newborn 
(HDN) has been associated with iron overload due to intrauterine red cell transfusions 
(IUTs). Data on the incidence and severity of cholestasis in neonates with HDN is scarce, and 
little is known about pathogenesis, risk factors, neonatal management and outcome.
Objective
To evaluate incidence, risk factors, management and outcome of cholestasis in neonates 
with red cell alloimmune hemolytic disease.
Methods
All (near-) term neonates with HDN due to red cell alloimmunization admitted to our 
center between January 2000 and July 2010 were included in this observational study. Liver 
function tests (including conjugated bilirubin) were routinely performed in the neonatal 
period. We recorded the presence of cholestasis, investigated several potential risk factors 
and evaluated the management and outcome in affected neonates. 
Results
A total of 313 infants with red cell alloimmune hemolytic disease treated with or without 
IUTs were included. The incidence of cholestasis was 13% (41/313). Two risk factors were 
independently associated with cholestasis: treatment with at least one IUT (OR 5.81, 95% CI 
1.70-19.80, p = 0.005) and Rhesus D type of alloimmunization (OR 4.66, 95% CI 1.05-20.57, 
p = 0.042). Additional diagnostic tests to investigate possible causes of cholestasis were all 
negative. In five infants (12%) supportive medical and nutritional therapy was started and 
one neonate required iron chelation therapy.
Conclusion
Cholestasis occurs in 13% of neonates with HDN due to red cell alloimmunization and is 
independently associated with IUT treatment and Rhesus D type of alloimmunization.
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Introduction
Hemolytic disease of the newborn (HDN) due to red cell alloimmunization may lead to 
excessive unconjugated hyperbilirubinemia, anemia and iron overload.1 A few studies 
have reported an association between HDN and the development of conjugated 
hyperbilirubinemia, i.e. cholestasis.2-5 Some of these studies (mostly case reports) describe 
that cholestasis in neonates with HDN is uncommon and usually mild and transient.3-5 Other 
reports however detail severe and protracted courses of cholestasis.2,4,6,7 The etiology of 
cholestatic liver disease in neonates with HDN has been associated with iron overload due 
to intrauterine transfusions (IUTs).6,8-10 Data on the incidence and severity of cholestasis in 
neonates with red cell alloimmune hemolytic disease is scarce, and little is known about 
pathogenesis, risk factors, neonatal management and outcome. 
The aim of this study was to evaluate incidence, potential risk factors, management 
and outcome of cholestasis in a large series of neonates with HDN due to red cell 
alloimmunization. 
Patients and Methods
All consecutive cases of (near-) term neonates (≥35 weeks of gestation) with HDN due to 
maternal red cell alloimmunization admitted to our center between January 2000 and July 
2010 were included in this retrospective study. Neonatal outcome in part of this group 
was described in previous studies.11-14 The Leiden University Medical Center (LUMC) is 
the national referral center for the management and intrauterine treatment of red cell 
alloimmunization in the Netherlands. We excluded all preterm neonates (<35 weeks of 
gestation) and neonates in whom conjugated bilirubin tests were not performed. The 
guidelines for the management of neonates with HDN admitted to our nursery (including 
intensive phototherapy and exchange transfusion (ET)) have previously been described.12,13 
In addition to frequent total bilirubin levels, extensive diagnostic evaluations are routinely 
performed at birth and during the first week of life in infants with red cell alloimmune HDN 
admitted to our neonatal nursery. These evaluations include hematologic tests (complete 
blood counts), liver function tests (liver enzymes and total and conjugated bilirubin) and 
blood group, Coombs and irregular antibody tests. 
Primary outcome of this study was the incidence of cholestatic icterus in neonates with 
HDN due to red cell alloimmunization. Secondary outcomes were management and 
outcome of cholestasis. 
Chapter 10
184
Cholestasis or conjugated hyperbilirubinemia was defined as a conjugated serum bilirubin 
level above 1.0 mg/dL if total serum bilirubin level is less than 5 mg/dL, or a value of 
conjugated bilirubin that represents more than 20% of total bilirubin if the total bilirubin 
level is greater than 5 mg/dL.15 Severe cholestasis was defined as a conjugated bilirubin 
level >50% of the total serum bilirubin concentration. 
In neonates with cholestasis we recorded the following data: symptoms of cholestasis 
(such as discolored stools and dark urine), duration of conjugated hyperbilirubinemia, (type 
of) therapy (including Ursodeoxycholic acid (15 mg/kg/d), Vitamin A (2500-5000 IU/d, in 
prematures 1000-1500 IU/kg/d), vitamin D (800 IU/d, in prematures 400 IU/d), vitamin E (5-
10 mg/kg/d, in prematures 10-20 mg/kg/d), vitamin K (1 mg/d, birth weight <1500 grams: 
0.5 mg/d) and formula with medium chain triglycerides) and investigations performed to 
establish a specific cause for the cholestatic icterus. Possible causes for neonatal cholestasis 
are (1) infections (sepsis, urinary tract infection, toxoplasmosis, rubella, cytomegalovirus, 
human herpes virus 6, syphilis, parvovirus B19, echovirus, adenovirus, coxsackie virus, 
hepatitis B and C); (2) bile duct anomalies, including biliary atresia and choledochal cyst; 
(3) inborn errors of metabolism, including alpha-1-antitrypsin deficiency, galactosemia, 
cystic fibrosis, tyrosinemia and progressive familial intrahepatic cholestasis, and (4) 
endocrinopathies (hypothyroidism and hypopituitarism).
We recorded the following obstetric and neonatal data: type of red cell alloimmunization, 
number of IUTs, gestational age at birth, birth weight, total bilirubin level and conjugated 
bilirubin level at birth, maximum total bilirubin level and maximum conjugated bilirubin 
level during admission, time until cholestasis disappeared (within 1 week, between 1 
week and 1 month or after 1 month), maximum ferritin level during admission, duration 
of phototherapy, number of ETs required and number of top up red blood cell transfusions 
received during the first 3 months of life. 
Data are reported as means and standard deviations (SD) or as medians and ranges. 
Statistical analysis was performed using Student-t test and Mann-Whitney test for 
continuous variables. Chi-square and Fisher’s-exact test were used for categorical 
variables. To assess the relationship between ferritin level and treatment with IUT a 
Spearman correlation was calculated. A p-value <0.05 was considered to indicate statistical 
significance. All predicting risk factors for cholestasis identified with univariate analysis were 
included in a multivariate logistic regression model to measure independent effects. The 
results of the logistic models were expressed as odds ratios (OR). Statistical analysis was 
performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
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Results
During the study period 357 neonates with HDN due to red cell alloimmunization were 
admitted to our neonatal nursery. We excluded 35/357 (10%) neonates due to prematurity 
(<35 weeks of gestation) and 9/357 (3%) neonates because conjugated bilirubin levels were 
not available. A total of 313 patients were included in this study. Forty-one neonates (13%) 
met the criteria for cholestasis (cholestasis group). Baseline characteristics are summarized 
in Table 1. 
Table 1. Baseline characteristics
Neonates with HDN  
(n = 313)
Neonates treated with IUT, n (%) 206 (66)
Number of IUTs in IUT treated neonatesa 3 (1-6)
Gestational age at birth, weeksa 37 (35-42)
Birth weight, kgb 3.0 ± 0.4
Male, n (%) 197 (63)
Type of red cell alloimmunization
       Rhesus D, n (%) 240 (76.7)
       Rhesus C, n (%) 2 (0.6)
       Rhesus c, n (%) 24 (7.7)
       Rhesus E, n (%) 7 (2.2)
       Kell, n (%) 38 (12.1)
       Cw, n (%) 1 (0.3)
       Jk(a), n (%) 1 (0.3)
a Value given as median (range), b Value given as mean ± SD
Risk factors for cholestasis
Detailed information on risk factors for cholestasis is summarized in Table 2.16,17
Eighty-eight percent of neonates with cholestasis had both Rhesus D type of 
alloimmunization and were treated with IUT.
Univariate analysis
Several risk factors were found to be associated with cholestasis, including: lower birth 
weight (OR 3.70 for each kg less, 95% CI 1.61-8.33, p = 0.001 and OR 1.92 for each 500 
grams less, 95% CI 1.27-2.89, p = 0.002), Rhesus D type of alloimmunization (OR 6.89, 95% 
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total serum bilirubin level at birth (OR 1.19, 95% CI 1.07-1.33, p = 0.004), maximum ferritin 
level (OR 1.04 per 100 μg/L more, 95% CI 0.99-1.08, p = <0.001) and number of top up 
transfusions (OR 1.43, 95% CI 1.15-1.77, p = 0.004).
Multivariate analysis
On multivariate analysis, the following risk factors were independently associated with 
cholestasis: Rhesus D type of alloimmunization (OR 4.66, 95% CI 1.05-20.57, p = 0.042) and 
treatment with IUT (OR 5.81, 95% CI 1.70-19.80, p = 0.005). 
Because a higher total bilirubin level at birth is part of the definition of cholestasis and 
thus closely related to a higher conjugated bilirubin level, total bilirubin level at birth was 
excluded from multivariate analysis. As ferritin levels were determined only in 89/313 (28%) 
neonates and ferritin level and treatment with IUT were positively correlated (r = 0.565, p = 
<0.001), ferritin was not included in the multivariate analysis. 
Clinical characteristics and outcome of cholestasis
In the cholestasis group 11/41 infants (27%) had severe cholestasis with a conjugated 
bilirubin level >50% of the total serum bilirubin concentration. Four neonates (10%) 
had symptoms of cholestasis such as discolored stools or dark urine. In 15% (6/41) the 
cholestasis disappeared spontaneously within 1 week, in 15% (6/41) between 1 week 
and 1 month and in 15% (6/41) within 1 to 3 months. In the remaining 56% (23/41) of 
infants the time of disappearance of cholestasis is not clear due to incomplete follow up. 
However, only 9% (2/23) of neonates with incomplete follow up had severe cholestasis. In 
five infants (12%) supportive medical and nutritional therapy was started (Ursodeoxycholic 
acid, Vitamin A, D, E, K and/or formula with medium chain triglycerides). In one infant 
Ursodeoxycholic acid was given for a period of 18 days, in the remaining 4 infants duration 
of therapy is not known since they were transferred to other hospitals while they were still 
on medication.
One patient with Rhesus D alloimmunization, who received 6 IUTs, developed severe 
cholestasis (maximum bilirubin level 41.3 mg/dL and maximum conjugated bilirubin level 
35.1 mg/dL) and severe hyperferritinemia (maximum serum ferritin level 73000 μg/L). 
Iron chelation therapy with desferrioxamine was started and continued for one month to 
reduce the serum ferritin concentration and liver iron contents. After having excluded other 
causes of cholestasis, the most probable explanation for the cholestasis in this case was 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































Additional investigations in cholestasis group
In the cholestasis group, laboratory investigations to evaluate possible liver injury were 
performed in 36/41 infants (88%). Elevated levels for alkaline phosphatase were detected 
in 6 (15%), for aspartate aminotransferase (AST) in 17 (41%), for alanine aminotransferase 
(ALT) in 13 (32%) and for gamma-glutamyl transpeptidase (γGT) in 8 infants (20%).16
In 18/41 (44%) neonates in the cholestasis group additional tests were performed to 
investigate possible causes of cholestasis. Sixteen infants (39%) were screened for infection. 
In all of them bacterial cultures of blood and urine were negative and there were no proven 
infections with toxoplasmosis, rubella, cytomegalovirus, human herpes virus 6, syphilis, 
parvovirus B19, echovirus, adenovirus, coxsackie virus and hepatitis B and C. Additional 
tests to exclude endocrinologic or metabolic disorders were performed in 9/41 (22%) 
and 7/41 (17%) of infants, respectively. In none of these infants an endocrinopathy and/
or an inborn error of metabolism was diagnosed. In 12/41 (29%) neonates an abdominal 
ultrasound was performed to exclude impairments in bile flow. All infants had normal 
ultrasound findings. 
Discussion
This study shows that cholestasis is a common problem in HDN, occurring in 13% of 
neonates. Cholestasis is found particularly in neonates with Rhesus D alloimmunization 
treated with IUTs. Although cholestasis was mild and transient in most cases, a few 
neonates had severe cholestatic liver disease with protracted course and required intensive 
treatment and in one case chelation therapy was needed. 
In the past, several studies have been published on the co-occurrence of cholestasis in 
neonates with HDN due to red cell alloimmunization. In 1963, Dunn described a large case 
series of 133 infants with Rhesus HDN and found that 8% of these patients developed 
‘obstructive jaundice’ defined as conjugated bilirubin level >3 mg/dL.3,4 However, in addition 
to the more stringent definition, their study is not fully comparable with contemporary 
care strategies for Rhesus HDN. In 1963 perinatal mortality and morbidity were far higher 
than nowadays, due to the absence of RhD prophylaxis, Doppler ultrasound to detect fetal 
anemia and in particular treatment with IUTs. Later, Bowman et al., Perez et al. and Allgood 
et al. also published on cholestasis in neonatal HDN, but none of these studies reported an 
exact incidence of cholestasis.2,5,18
We found that treatment with IUT is an independent risk factor for cholestasis. This could 
be due to iron overload which have been reported in neonates with HDN who underwent 
IUT.6,8-10 In 1990 Berger and colleagues demonstrated elevated ferritin levels in 12 infants 
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with Rhesus HDN and suggested that iron overload could be an explanation for cholestatic 
icterus in Rhesus HDN.9 In 1991, Nasrat et al. measured higher fetal plasma ferritin 
concentrations in 23 Rhesus alloimmunized fetuses compared to controls and serial IUTs 
were associated with additional increases in serum ferritin.10 On the contrary, in 2004 
Aygun et al. found higher cord blood ferritin levels in neonates affected with Rhesus HDN 
compared to birth weight and gestational age matched controls, but IUTs did not affect 
the ferritin status of the babies with Rhesus HDN.8 This finding is in contrast with our 
observations. We found a positive correlation between treatment with one or more IUTs 
and high ferritin levels during admission, both risk factors for cholestasis in this study. Our 
data support the hypothesis of iron overload as a mechanism of cholestasis in HDN.
In addition to iron overload, the following etiologic mechanisms of cholestasis in HDN were 
previously described: overload of pigment causing stasis and blocking of bile canaliculi; liver 
necrosis caused by hypoxia due to anemia; and pressure by extramedullary hematopoiesis 
in the liver caused by anemia leading to damage of intrahepatic canaliculi.19 Hence, the 
finding that IUT treatment is a risk factor for cholestasis could be due to the disease severity 
(more severe anemia necessitating IUT), to transfusion induced iron overload or to a 
combination of both. Theoretically, other causes such as infection or metabolic diseases 
or total parenteral nutrition may play a role. However, extensive investigations to rule out 
other causes of cholestasis in infants with cholestasis included in this study yielded no 
additional information. 
This study shows that Rhesus D type of alloimmunization is an independent risk factor for 
cholestasis. This finding has not been described before. However, the vast majority (88%) of 
neonates within the cholestasis group had both Rhesus D type of alloimmunization and was 
treated with IUT, preventing reliable distinction between the actual role of both risk factors.
In our series cholestasis resolved spontaneously within 1 week to 3 months after birth 
in almost half of the patients, which is comparable with other studies.2,18 In 56% of 
the included infants, conjugated bilirubin levels and liver enzyme levels (AST, ALT, γGT, 
and alkaline phosphatase) were not monitored until they reached normal values. We 
recommend to measure conjugated bilirubin levels and liver enzyme levels during the first 
three months of life or until they reach normal values. 
We suggest that a full work-up to exclude other causes of cholestasis in a child with red cell 
alloimmnune HDN treated with at least one IUT, is not necessary, provided that no other 
factors are involved and monitoring of ferritin, liver enzymes and conjugated bilirubin levels 
is guaranteed during the first 3 months of life.
The results of this study should be interpreted with care due to the relatively small number 
of neonates in the cholestasis group and the retrospective study design. In addition, 
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our conclusions are limited due to incomplete measurements. For example, only 17% of 
neonates with cholestasis were tested for metabolic conditions and some of them may have 
had alpha-1-antitrypsin deficiency. Larger, multicenter studies are required to confirm our 
findings.
In conclusion, we found a 13% incidence of cholestasis in HDN due to red cell 
alloimmunization and identified several risk factors for cholestasis, in particular treatment 
with IUT and Rhesus D type of alloimmunization. Larger follow-up studies are required to 
determine the exact course and etiology of cholestasis in infants with red cell alloimmune 
hemolytic disease.
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Ferritin levels are often highly elevated at birth in neonates with alloimmune hemolytic 
disease of the fetus and newborn (HDFN). Data on ferritin levels in these infants in the first 
three months of life are lacking. Objective of this study was to examine the course of iron 
status and incidence of iron deficiency and overload in neonates with alloimmune HDFN up 
to three months of age. Secondary objective was to analyze bilirubin levels, liver enzymes 
and red blood cell indices in the same time period and the association with intrauterine 
transfusion (IUT). 
Materials and Methods
Observational study of neonates with alloimmune HDFN admitted to our center between 
November 2010 and March 2012. Data on iron status, bilirubin levels, liver enzymes and red 
blood cell indices up to three months of age were collected prospectively and compared 
between neonates treated with and without IUT. 
Results
Thirty-five infants with alloimmune HDFN were included. Iron overload occurred in 70% of 
neonates at birth and in 50% and 18% at the age of one and three months, respectively. No 
cases of iron deficiency at birth and only one case of iron deficiency at three months of age 
were found. No infants received iron therapy. Infants who received IUT had a significantly 
lower hemoglobin level and reticulocyte count and higher ferritin level at birth.
Conclusion
The vast majority of neonates with alloimmune HDFN have iron overload at birth. 
Incidence of iron overload gradually decreases within the first three months without iron 
supplementation.
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Introduction
Iron supplementation therapy is occasionally given to support erythropoiesis in neonates 
with hemolytic disease of the fetus and newborn (HDFN) due to red cell alloimmunization.1 
However, iron stores in neonates with alloimmune HDFN are often not depleted at birth. 
On the contrary, ferritin levels in fetal and cord blood are often highly elevated.2-4 Increased 
fetal and neonatal iron stores are most probably caused by the increased rate of fetal 
hemolysis.4,5 Moreover, intrauterine red blood cell transfusions (IUTs) and/or postnatal 
red blood cell transfusions (top-up transfusions) can further increase iron overload.6,7 Iron 
overload can cause damage to the liver, heart and endocrine organs, alter immune response 
and increase susceptibility to infection.8 Nevertheless, iron is also crucial for early brain 
development and function. Iron deficiency as well as iron overload have been associated 
with neurodevelopmental impairment.8 
Iron overload is most accurately diagnosed by measuring tissue iron using liver (and cardiac) 
biopsies.9 However, these procedures are invasive, expensive and difficult to perform in 
neonates. Magnetic resonance imaging (MRI) and magnetic susceptometry are noninvasive 
methods to measure tissue iron stores, but are also expensive and complex.10 Serum 
ferritin, which reflects total body iron capacity, is the most convenient and cost-effective 
technique to diagnose iron overload. An important limitation of serum ferritin levels as the 
sole marker for iron overload is that they can be influenced by inflammation, infection, liver 
damage, hemolysis, ineffective erythropoiesis and ascorbate deficiency independently of 
changes in body iron.9,10
Although it is known that ferritin levels at birth are frequently elevated, the course of iron 
status after birth in infants with HDFN is not clear. Primary aim of this study was to examine 
the course of iron status in infants with alloimmune HDFN. Secondary aim was to measure 
the course of bilirubin levels, liver enzymes, red blood cell indices, the incidence of iron 
overload and cholestatic disease and the association with IUT.
Materials and Methods
All term and preterm neonates with HDFN due to maternal red cell alloimmunization 
admitted to our center between November 2010 and March 2012 were eligible for this 
prospective observational study. The Leiden University Medical Center (LUMC) is the 
national referral center for the management and intrauterine treatment of HDFN. Informed 
consent was obtained to collect data from outpatient clinics. We recorded the following 
obstetric and neonatal data: type of red cell alloimmunization, number of IUTs, gestational 
Chapter 11
196
age at birth, birth weight, small for gestational age (SGA, defined as below the 10th 
percentile according to Kloosterman et al.11), presence of hydrops at birth, hemoglobin (Hb) 
level, reticulocyte count, iron status (serum iron, ferritin, transferrin and total iron binding 
capacity (TIBC)), liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (γGT) and lactate dehydrogenase (LDH)) and total 
serum bilirubin (TSB) and conjugated bilirubin levels at birth. We also recorded duration 
of phototherapy, number of exchange transfusions (ETs), number of top-up transfusions 
and days after birth until the last top-up transfusion was given. In addition, we recorded 
whether infants had sepsis during admission. We prospectively collected data on iron 
status, bilirubin levels, liver enzymes (measured monthly) and Hb level and reticulocytes 
(measured weekly) up to three months of age. We collected these data and the number 
of top-up transfusions received during the first 3 months of life and Hb levels prior to 
the top-up transfusions through correspondence with the clinical chemistry and/or 
transfusion laboratories of the outpatient clinics. A uniform transfusion trigger according 
to our transfusion guidelines was followed. After initial discharge from the LUMC, top-up 
transfusions were performed when Hb levels fall below 8.0 g/dL or at higher levels (<9.8 
g/dL) if clinical symptoms of anemia (lethargy, feeding difficulties or failure to thrive) 
were present. Iron supplementation was not used; however folic acid (50 μg/day) was 
administered orally in all infants during the first three months of life.
At birth, iron overload is defined as a serum ferritin level above the 95th percentile and iron 
deficiency as a serum ferritin level below the 5th percentile according to a recent study of 
Siddappa et al.8 In their study, the 95th percentile for term infants (≥37 weeks of gestation) 
was 309 μg/L and for preterm infants (<37 weeks of gestation) 267 μg/L. The 5th percentile 
was 40 μg/L for term infants and 35 μg/L for preterm infants.8 From the first day of life 
until the age of three months, iron overload and iron deficiency were defined as a ferritin 
concentration above the 97.5th percentile (775 μg/L) and below the 2.5th percentile (40 
μg/L) respectively, according to a study by Soldin et al.12
To enhance specificity of high ferritin levels in diagnosing iron overload, transferrin 
saturation (TSAT) is also calculated (serum iron divided by TIBC and multiplied by 100) 
in infants with iron overload based on the abovementioned definitions. Iron overload is 
suggested by a TSAT level of >60% based on the 95th percentile measured in premature 
newborns of 35-36 weeks of gestation by Lackmann et al.13 
Cholestasis is defined as a conjugated serum bilirubin concentration above 1.0 mg/dL if 
the total serum bilirubin level is less than 5 mg/dL, or a value of conjugated bilirubin that 
represents more than 20% of the total bilirubin if the total bilirubin is greater than 5 mg/
dL.14
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Data are reported as means and standard deviations (SD) or as medians and interquartile 
ranges (IQR). Statistical analysis was performed using Student-t test and Mann-Whitney test 
for continuous variables and Chi-square and Fisher’s-exact test for categorical variables. A 
p-value <0.05 was considered to indicate statistical significance. The associations between 
iron status parameters and top-up transfusions were examined by Spearman correlation 
coefficients. Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA).
Results
During the study period, 35 neonates with HDFN due to red cell alloimmunization were 
admitted to our nursery. Characteristics of included patients are summarized in Table 1. 
Antibody specificities of included patients were D (n=19), Kell (n=5), E (n=4), c (n=1), D,C 
(n=1), C,D (n=1), C,E (n=1), D,Wra (n=1), Kell,c (n=1) and D,C,E (n=1). Six percent (2/35) of 
infants were SGA, of whom one was treated with IUT. Eighty percent (28/35) of infants 
received one or more top-up transfusions and 71% (20/28) received their first top-up 
transfusion within one month after birth. 
Table 1. Characteristics of study patients 
 n = 35
Neonates treated with IUT, n (%) 22 (63)
       Number of IUTs a 2 (1-3.25, 1-5)
Gestational age at first IUT, weeks a 29.8 (23.8-31.2, 18.29-34.29)
Gestational age at birth, weeks a 36 (35-37,33-38) 
SGA, n (%) 2 (6)
Birth weight, kg b 2.88 ± 0.53
Male, n (%) 20 (57)
Neonates treated with phototherapy, n (%) 35 (100%)
Days of phototherapy per infants b 4.49 ± 1.93
Neonates treated with ET, n (%) 9 (25.7)
       Number of ETs a 1 (1-1.5,1-2 )
Neonates treated with top-up transfusions, n (%) 28 (80)
       Number of top-up transfusions a 2 (1-3,1-6 )
Days after birth until first top-up transfusion a 17 (3-31, 0-42)
Days after birth until last top-up transfusion a 34.5 (25.5-60.5, 0-79)
a Value given as median (IQR, range)
b Value given as mean ± SD
Chapter 11
198
Table 2 provides an overview of the course of iron status, bilirubin levels (total and 
conjugated) and liver enzymes measured at birth, at one month, at two months and three 
months after birth. Evaluation of all parameters at each time point was often incomplete. 
Median ferritin level was 442 μg/L at birth (T=0), 763 μg/L at one month (T=1), 630 μg/L 
at two months (T=2) and 417 μg/L at three months of age (T=3). Minimum and maximum 
ferritin levels were 103 μg/L and 1211 μg/L at T=0, 154 μg/L and 2700 μg/L at T=1, 70 μg/L 
and 1504 μg/L at T=2 and 33 μg/L and 1100 μg/L at T=3.










Ferritin level, μg/La 442 (242-710) 763 (413-936) 630 (311-935) 417 (184-704)
Iron level, μmol/Lb 34.0 ± 7.5 20.4 ± 7.0 14.2 ± 7.7 12.7 ± 6.1 
TIBC, μmol/Lc 33 (29.3-37) 36 (30-40) 48 (40-53) n=2: 44 and 49
Transferrin, g/Ld 1.61 (1.45-1.86) 1.50 (1.30-1.60) 1.70 (1.42-1.94) 2 (1.70-2.24)
TSB level, μmol/Le 77 (62-117) 28 (13-52) 12 (7-16) 8 (5.3-10)
Conjugated bilirubin 
level, μmol/Lf
10 (8-12) 8 (4.3-16) 6 (1-12) 2 (0.5-12.5)
AST, U/Lg 34 (26-48) 33 (22-43) 39 (21-51) 39 (26-56.5)
ALT, U/Lh 12 (8.5-15) 24 (17-28.5) 33 (25-66) 39.5 (24-56)
γGT, U/Li 126 (73.5-212) 80 (51-116) 51.5 (38.5-83.3) 29 (21.5-40.0)
LDH, U/Lj 434 (343.5-635.5) 253 (233.5-309.5) 257.5 (206.5-291) 236 (196-290)
Hb level, g/dLk 12.9 (11.0-15.8) 8.5 (7.9-9.5) 8.9 (8.2-10.0) 9.8 (9.3-10.8)
Reticulocyte count, ‰l 57 (16-101) 4.5 (2-22.8) 27 (13.3-41.1) 22.8 (20.2-35.7)
Values are given as mean ± SD or median (IQR). Hb = hemoglobin. 
a Measured in 33, 20, 12 and 11 infants at T = 0, 1, 2, and 3, respectively. b Measured in 31, 18, 12 and 
10 infants at T = 0, 1, 2, and 3, respectively. c Measured in 32, 7, 5 and 2 infants at T = 0, 1, 2, and 3, 
respectively d Measured in 32, 19, 11 and 9 infants at T = 0, 1, 2, and 3, respectively. e Measured in 35, 
23, 11 and 9 infants at T = 0, 1, 2, and 3, respectively. f Measured in 31, 19, 5 and 5 infants at T = 0, 1, 2, 
and 3, respectively. g Measured in 33, 19, 12 and 9 infants at T = 0, 1, 2, and 3, respectively. h Measured 
in 33, 21, 11 and 10 infants at T = 0, 1, 2, and 3, respectively. i Measured in 34, 23, 10 and 10 infants at 
T = 0, 1, 2, and 3, respectively. j Measured in 29, 17, 12 and 9 infants at T = 0, 1, 2, and 3, respectively.  
k Measured in 35, 29, 22 and 15 infants at T = 0, 1, 2, and 3, respectively. l Measured in 35, 22, 18 and 
14 infants at T = 0, 1, 2, and 3, respectively. 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 shows the comparison of parameters measured at birth and at one month after 
birth between infants treated with or without IUT. Ferritin level at birth was significantly 
higher in infants treated with IUT than in infants not treated with IUT (mean ± SD: 598 ± 
249 and 270 ± 111, respectively, p=<0.001). Hb level and reticulocyte count at birth were 
significantly lower in infants treated with IUT (median (IQR): 7.45 (6.5-8.4) and 9 (7.8-10.5), 
p=0.026 and 24 (2-142) and 73 (59.5-124), p=0.004, respectively). At one month of age, no 
significant differences were found between the groups treated with or without IUT. 
Seventy percent of neonates (23/33) had iron overload at birth and 83% (19/23) of these 
infants had been treated with IUT. Twenty percent of neonates (2/10) without iron overload 
at birth had been treated with IUT. Iron overload was present in 10/20 (50%) infants at one 
month, in 5/12 (42%) infants at two months and 2/11 (18%) infants at three months of age. 
In all neonates with iron overload at birth TSAT was >60% (mean of 86%), except one 
neonate with a TSAT of 44%. The TSAT was measured in only two of ten neonates with 
iron overload at one month of age (54% and 73%), in only one of five neonates with iron 
overload at the age of two months (24%) and in none of the neonates with iron overload at 
the age of three months.
None of the infants had iron deficiency at birth. However, one term infant gradually 
developed iron deficiency after birth (ferritin level at birth: 145 μg/L, at T=1: 154 μg/L, at 
T=2: 70 μg/L, at T=3: 33 μg/L). This male infant with Rh D alloimmune HDFN had received 
one IUT and no top-up transfusions. Serum iron level at 3 months was 9 μmol/L and serum 
transferrin level 2.40 g/L. 
Five of 35 neonates (14%) had cholestasis during admission and those five neonates all had 
iron overload at birth with ferritin levels varying from 322 μg/L to 1211 μg/L. Four of five 
cholestatic neonates had Rh D HDFN, one had Kell HDFN, and four of these five had been 
treated with IUT.
Only one infant (treated with ET) had signs of neonatal sepsis during admission with a 
positive blood culture for Staphylococcus Aureus. After exclusion of this infant, ferritin level 
at birth remained significantly higher in infants treated with IUT than those not treated with 
IUT (598 ± 249 and 269 ± 116 respectively, p= <0.001).
There were no significant correlations between the number of top-up transfusions and 
ferritin level, serum iron, TIBC and transferrin measured at one month after birth (data not 
shown).
In infants who did not receive top-up transfusions, ferritin levels at one month, two months 
and three months after birth varied between 154-715 (n=4), 70-435 (n=3) and 33-122 (n=2), 
respectively.  
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Discussion
This study shows the course of iron status after birth until the age of three months in infants 
with alloimmune HDFN. Based on our definitions, we found that 70% had iron overload 
and none had iron deficiency at birth. After birth, the incidence of iron overload gradually 
decreased from 50% at the age of one month to 18% at the age of three months. 
The high ferritin levels at birth in our study group are consistent with a previous small 
study by Berger et al. They found a mean ferritin level of 372 μg/L at birth in 14 neonates 
with Rh D hemolytic disease of whom 9 (64%) were treated with IUT. In addition, the mean 
serum iron level at birth and the number of infants treated with IUT in our study are also 
comparable with their study.3 IUTs are associated with increased fetal ferritin levels, but 
ferritin levels were also increased in fetuses with Rh alloimmune hemolytic disease before 
the first IUT in a study by Nasrat et al.4 The significantly higher ferritin levels at birth in IUT 
treated neonates in our study are consistent with the findings of Nasrat et al. In a study 
by Aygun et al. cord blood ferritin levels in infants with Rh D HDFN were also significantly 
higher than levels in a control group. However, they found no difference in ferritin levels 
between neonates with Rh D HDFN treated with or without IUT.2 
There is a number of case reports published on the risk of severe iron overload, diagnosed 
by liver biopsies, following IUTs for Rh HDFN.6,7,15,16 These infants were all born at 33 or 34 
weeks of gestation and received 2-5 IUTs and several postnatal transfusions. Their serum 
ferritin levels ranged from 2479 to 28800 μg/L.6,7,15,16
In addition to transfusions for alloimmune HDFN, the hemolysis itself can also contribute 
to iron overload in alloimmune HDFN. Abbas et al. measured maternal and fetal serum 
ferritin concentrations at 18-38 weeks of gestation in 40 red alloimmunized pregnancies 
and compared them to those of normal pregnancies. They found that serum ferritin 
concentrations are increased in the fetus and decreased in the mother. Their explanation 
for these findings was enhanced transplacental iron transfer despite fetal iron overload due 
to the extravascular hemolysis similar to increased iron absorption from the gastrointestinal 
tract in certain types of postnatal hemolytic anemia.5 
Follow up ferritin levels are described in several studies in term and preterm neonates 
without alloimmune HDFN.17-19 However, no studies report ferritin levels for neonates with 
alloimmune HDFN after birth. In a study by Mukhopadhyay et al. the median ferritin level 
in 50 term (≥37 weeks of gestation) appropriate for gestational age neonates at birth was 
141 μg/L and mean level at one month of age was 226 μg/L.19 In our study group, ferritin 
levels at one month after birth were higher than in their study group of neonates without 
alloimmune HDFN. However, in their study none of the infants received a red blood cell 
Chapter 11
202
transfusion in contrast to our study in which 80% of infants were transfused postnatally of 
whom 71% were transfused within one month after birth.19 Another difference between 
both studies was the gestational age of participants. In our study also premature infants 
were included. Because most of fetal iron is transported from mother to fetus in the third 
trimester of pregnancy, prematurely born infants have lower iron stores at birth.8 Schiza 
et al. showed that serum ferritin levels decreased from the age of 2 weeks to 6 months 
and were stable thereafter in late premature infants (34-36 weeks of gestation). At the 
chronological age of three months they found a mean ferritin level of 70 (± 68) μg/L. Soldin 
et al. summarized serum ferritin levels in 800 in- and outpatient participants. Reference 
intervals for ferritin levels in males and females of 0-90 days of age were 40-775 and 79-501 
μg/L, respectively.12 
In recent literature, a ferritin level <12 μg/L is used for the definition of iron deficiency 
during the first year of life.17,20 Based on that definition, no cases of iron deficiency were 
present until three months of age in our study group. Based on the lower reference 
range (40 μg/L) in the study of Soldin et al., only one neonate met the definition of iron 
deficiency. This male term infant with Rh D HDFN received one IUT but no postnatal top-up 
transfusions. Whether this neonate may have benefited from iron supplementation is not 
clear.
The incidence of cholestasis in this study is similar as reported in a previous study form our 
group.21 In the previous report IUT and Rh D type of alloimmune HDFN were identified as 
risk factors for cholestasis. In the present study, the majority of cholestatic neonates was 
also treated with IUT and had Rh D type of alloimmunization. In addition, all five cholestatic 
neonates had iron overload at birth. Although the numbers are small, these results are 
consistent with the previously published hypothesis that iron overload can cause cholestasis 
in neonates with alloimmune HDFN.21 
This is the first study describing follow up data on iron status in neonates with alloimmune 
hemolytic disease exclusively. However, conclusions are limited by the relative small 
numbers of participants. In addition, iron overload is difficult to diagnose in neonates 
and ferritin levels could have been influenced by infection, liver damage, ineffective 
erythropoiesis, and ascorbate deficiency.9,10 Follow up studies should also take into account 
factors that can influence neonatal iron status such as maternal diabetes, pregnancy 
induced hypertension, maternal smoking, severe maternal iron deficiency, intrauterine 
growth restriction and type of feeding of the infants (formula or breastfeeding).8 
In conclusion, iron deficiency in the first three months of life is very rare among infants 
with alloimmune HDFN and does not occur in infants who received top-up transfusions 
postnatally. On the contrary, iron overload occurs in 70% of neonates with alloimmune 
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HDFN at birth, 50% at the age of one month and 18% at the age of three months. Therefore, 
we advise to measure iron status and we discourage the use of iron supplementation in the 
first three months of life in neonates with alloimmune HDFN. Hemolysis and intrauterine 
and postnatal transfusions probably both contribute to the high incidence of iron overload 
in alloimmune HDFN. Further studies are required to confirm our findings and to study the 
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Summary and general discussion
This thesis investigated the management and outcome of neonates with hemolytic disease 
of the fetus and newborn (HDFN) due to red cell alloimmunization. The focus of this thesis 
was mainly on the hematological complications and transfusion practices rather than on the 
management and treatment options of hyperbilirubinemia. 
Hematological complications of HDFN include (early and late) anemia, thrombocytopenia, 
leukocytopenia, coagulation disorders and iron overload. An overview of the literature on 
these hematological complications and its treatment options in neonates with HDFN due to 
red cell alloimmunization was given in Chapter 2. 
Anemia necessitating top-up transfusions in red cell alloimmune hemolytic disease can be 
present in the first three months of life. Early onset anemia (within 7 days after birth) is 
mainly caused by antibody induced hemolysis of red blood cells (RBCs) and characterized 
by a high bilirubin level and an increased reticulocyte count. Late onset anemia can be 
subdivided in “late hyporegenerative anemia” characterized by inappropriate erythropoiesis 
and “late anemia of hemolytic disease” with an active bone marrow and normal or high 
reticulocyte counts.1 However, this subdivision is theoretical and in practice these forms can 
coincide. 
Severity and duration of anemia can be difficult to predict in individual cases and as a result 
frequent monitoring of hemoglobin level and reticulocyte count is required. Factors that 
are associated with a more severe course of anemia include on one hand a high hemolytic 
potential of the antibodies (which is determined by the strength (titer) and IgG-subclass) 
and on the other hand the antigen density of the target antigen on fetal/neonatal red cells 
or erythrocyte precursor cells. Also treatment with intrauterine transfusion (IUT) by the 
mechanism of suppression of fetal erythropoiesis contributes to neonatal anemia.2,3 In 
contrast, exchange transfusion (ET) was associated with less occurrence of late anemia in a 
study of 36 infants with Rh D HDFN, probably due to the elimination of antibodies from the 
circulation which reduces hemolysis and anemia.1
Exchange transfusions
In Chapter 3 we studied the influence of ET practices in a large group of near-term 
neonates with Rh hemolytic disease. In 2005 a more restrictive ET guideline, based on the 
American Academy of Pediatrics (AAP) guidelines, was implemented at our center. After 
implementation of that guideline, ET rate decreased considerably from 66% to 26%. The 
rate of top-up transfusion however was increased from 68% to 81% after guideline change. 
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In addition, we found a significant negative correlation between the number of ETs and 
the number of top-up transfusions in those infants treated with IUT. These results suggest 
that removal of antibodies and replacing Rh positive cells by Rh negative cells through ET is 
particularly effective in reducing anemia in the more severely affected neonates with high 
antibody titers. 
In 1925 the first successful ET was performed by Hart for the treatment of severe jaundice 
in a newborn infant.4 However, it was until the 1940s that exchange transfusions became 
common practice in the treatment of neonates with HDFN.5-7 ET has more beneficial 
effects in addition to removing excess bilirubin. ET also removes part of the antibodies but 
most importantly, similarly as with IUT, the infants’ blood is replaced by red cells that are 
immunologically compatible with mother and infant, hence not destructed by the action 
of remaining antibodies. Although ET carries less risk than IUT, ET remains an invasive 
procedure with a significant risk of side effects. Although reported mortality rates are 
less than 2%, morbidity rates can be as high as 74% depending on how adverse events 
are defined and the population in which they are measured.8-15 Adverse events include 
cardio-respiratory events (apneas, cardiac arrest, hypo- and hypertension, cardiac rhythm 
disorders, pulmonary hemorrhage) catheter-related complications (sepsis, malposition, 
thrombus), those related to the use of blood products (infection, graft versus host 
reactions), metabolic derangements (acidosis, disturbances of serum calcium, glucose, 
potassium and sodium) and other serious complications such as necrotizing enterocolitis, 
and bowel perforation.8-15 We performed a retrospective study to evaluate the type and 
rate of ET-associated complications in a large series of neonates with HDFN due to red 
cell alloimmunization exclusively (Chapter 4). Comparison between ET-treated neonates 
and non-ET-treated neonates showed that ET treatment was independently associated 
with an increased risk on: clinical and blood-culture positive sepsis (8% versus 1%, OR 8.3, 
95% CI 1.7-40.3, p = 0.009), leukocytopenia (88% versus 23%, OR 36.0, 95% CI 17.5-73.8, 
p = <0.001), severe thrombocytopenia (platelet count <50 × 109/L) (63% versus 8%, OR 
31.4, 95% CI 14.0-70.4, p = <0.001), hypocalcemia (22% versus 1%, OR 27.4, 95% CI 5.9-
126.8) and hypernatremia (8% versus 0%, p = <0.001). Severe symptoms of hypernatremia 
(seizures) did not occur and neonatal death did also not occur in the group treated with 
ET. In our center platelet transfusions are given when platelet counts fall below 100 × 109/L 
before planned ET and <50 × 109/L after ET. In the ET-treated group only one infant with 
severe thrombocytopenia showed an intracerebral bleeding (ICB) on cranial ultrasound. In 
the non-ET-treated group three neonates had signs of ICB on cranial ultrasound and/or MRI 
of whom one had severe thrombocytopenia for which he received 4 platelet transfusions. 





Since ET can be associated with significant procedure-related morbidity, alternatives 
to prevent ET or to optimize the effect of ET have been investigated. These alternatives 
include (maternal) phenobarbital, albumin, metalloporphyrins, clofibrate and IVIg.16 
Except for the latter, routine use of these alternatives are not recommended because 
evidence on the effectiveness is too limited or treatment has been associated with serious 
adverse effects.16-19 Although the exact mechanism of IVIg remains unclear, IVIg might 
reduce the rate of hemolysis in alloimmune HDFN by blockade of Fc-receptors involved in 
phagocytosis of antibody coated RBCs. In particular in Rh D antagonism, RBCs are destroyed 
by an antibody-dependent cellular cytotoxic (ADCC) mechanism mediated by Fc-receptor 
bearing cells of the neonatal reticulo-endothelial system.20 The 2004 guidelines of the AAP 
recommend the use of 0.5-1.0 g/kg IVIg in neonates with alloimmune HDFN if total serum 
bilirubin (TSB) is rising despite intensive phototherapy or if TSB level is within 34-51 µmol/L 
(2-3 mg/dL) of exchange level.17 This recommendation was also based on limited evidence. 
Although results of the Cochrane review in 2002 showed a significant reduction in the need 
for ET in infants treated with IVIg, the applicability of the results was limited because none 
of three included studies was of high quality. The Cochrane authors concluded that further 
well-designed trials were required before routine use of IVIg could be recommended. We 
therefore performed a double-blind placebo-controlled RCT on the prophylactic use of IVIg 
in red cell alloimmune HDFN. We demonstrated that IVIg does not reduce the need for and 
number of ETs and top-up transfusions nor the duration of phototherapy and maximum 
bilirubin levels (Chapter 5). 
Hereafter, we updated the Cochrane review (Chapter 6) and included fourteen (quasi-) RCTs 
of which only two were of high quality.21-35 Meta-analysis of all fourteen trials, comprising 
942 infants, showed a reduction in the need for and number of ETs in infants treated 
with IVIg combined with phototherapy compared to infants treated with phototherapy 
only. However, analysis of the only two high quality studies showed no reduction in the 
need for and number of ETs when IVIg was combined with intensive phototherapy. Eight 
studies measured the effect of IVIg on top-up transfusions for late anemia and found no 
difference in the need for or number of top-up transfusions. Based on the evidence from 
high quality trials (without selection bias, performance bias, detection bias, attrition bias 
and reporting bias) that IVIg is ineffective in preventing ET or top-up transfusion, routine 
use in alloimmune HDN should be discouraged. However, since there is some evidence that 
IVIg reduces hemolysis (in laboratory studies)36,37, future high quality studies are needed to 
determine whether IVIg has limited role in some infants with alloimmune HDN, for example 
when ET can not be performed promptly or without unusually high risk. 
Summary and general discussion
211
Alloimmunizations other than Rh D
Anti-Kell and anti-c are after anti-D the most important red cell antibodies causing severe 
HDFN necessitating IUT.38 In Kell HDFN antibody titer is not well-correlated with disease 
severity. Kell antibodies are, after anti-D, the most frequent antibodies causing HDFN.39 Kell 
HDFN probably has a different manifestation than Rh HDFN. Because the Kell antigen is 
expressed earlier on cells of the erythropoietic lineage Kell antibodies can cause destruction 
of progenitor cells (which are not yet hemoglobinized) in addition to hemolysis of 
erythrocytes.40-43 Similar as for Rh HDFN, neonates with Kell hemolytic disease may require 
top up transfusions up to several months after birth. However, it was not known whether 
incidence and severity of anemia differs between both types. In Chapter 7 we therefore 
compared a group of near-term neonates with Kell HDFN with neonates with Rh D HDFN. 
We found that neonates with Kell HDFN required less phototherapy (2.4 versus 4.1 days) 
and ETs (6% versus 62%). The need for top-up transfusions was not significantly different 
between Kell HDFN and Rh D HDFN (62% versus 72%). The median number of days after 
birth until first top-up transfusion was also not significantly different (16 days versus 17.5 
days). Our results show that infants with Kell HDFN require a different management in the 
early neonatal period (less phototherapy and less ET because of less formation of bilirubin 
as breakdown product of hemoglobin), but a similar follow up management as infants with 
Rh D HDFN. 
In Chapter 8 we performed a similar study and compared postnatal outcome between 
infants with Rh c HDFN and infants with Rh D HDFN. In this study we excluded cases 
with multiple clinical significant antibodies because it is known that disease can be more 
severe when multiple antibodies are present.44 We found a trend of a slightly more severe 
antenatal course of Rh c HDFN reflected by an earlier and higher need for IUT (61% versus 
41%). Postnatal course was not significantly different between infants with Rh c and Rh D 
HDFN in terms of phototherapy duration (mean days 4.8 and 4.5), need for ET (50% versus 
46%) and need for top-up transfusions (62% versus 78%). Therefore, also for Rh c HDFN a 
similar follow up management is justified. In this study we also investigated if antibody titer 
at birth was correlated with postnatal transfusion requirements. For Rh D HDFN it is known 
that antibody titer is correlated to postnatal anemia.45 In our study we also found a positive 
correlation between anti-D titer at birth and need for and number of top-up transfusions. 
Whether antibody titer in Rh c HDFN is correlated to postnatal transfusion requirements 
was not known. We found a positive correlation between antibody titer at birth and need 




Treatment of anemia mainly consists of top-up transfusions. International guidelines 
for top-up transfusions in neonates (with HDFN) are lacking. As a consequence, studies 
on transfusion requirements are difficult to compare due to differences in transfusion 
thresholds, volumes, products and different outcome measures. In our center we transfuse 
15 ml/kg ABO and Rh type specific, leukocyte-depleted RBCs which are negative for the 
antigen to which maternal antibodies are directed. Irradiated products are used in infants 
treated with IUT and/or born <32 weeks of gestation and/or birth weight <1500 gram. 
Transfusion triggers at our center include a hemoglobin level <5 mmol/L (8 g/dL) or <6 
mmol/L (9.6 g/dL) when clinical symptoms of anemia are present (need for extra oxygen, 
poor feeding, tachycardia, tachypnea). 
Supplements to support erythropoiesis which are applied in infants with HDFN include folic 
acid, iron and vitamin E (tocopherol). Folic acid is essential for proliferation of erythroblasts 
during their differentiation but also for de novo synthesis of the RNA and DNA; hence every 
growing cell requires folic acid.46 Gandy and Jacobson et al. demonstrated that 2.5-5 mg/
day folic acid supplementation had a beneficial effect on growth, but not on hemoglobin 
level in infants with alloimmune HDFN.9,10 Although evidence is lacking, in our center folic 
acid is supplemented to infants with alloimmune HDFN in a dose of 0.05 mg/day orally 
during the first three months of life.
Supplementation of iron is not routine practice in our center and the motivation for this is 
dealt with later in this chapter. 
Vitamin E (tocopherol) is occasionally supplemented in neonates with alloimmune HDFN. 
This antioxidant reduces oxidative stress to the RBC membrane and vitamin E deficiency 
can therefore lead to a shorter life span of RBCs.47 Although infants with alloimmune HDFN 
have lower vitamin E levels compared to healthy controls, administration of large amount 
of vitamin E analogue in three neonates with Rh D HDFN showed no beneficial effects.48,49 In 
our center, vitamin E is not supplemented to neonates with alloimmune HDFN.
Recombinant human erythropoietin (rhEPO) is used, often combined with supplements to 
support erythropoiesis, to treat (late) anemia in HDFN due to red cell alloimmunization. In 
Table 2 of Chapter 2 an overview is provided of studies/case reports of administration of 
rhEPO in infants with alloimmune HDFN. Only one small randomized placebo controlled 
trial has been performed in 20 neonates (≥35 weeks’ gestation) with Rh HDFN showing a 
significantly lower number of top-up transfusions in the rhEPO treated group.50   
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Associated hematological morbidity
Thrombocytopenia and coagulation disorders
Thrombocytopenia was first reported in 1955 in three neonates with alloimmune HDFN.51 
In 1970, Nielsen showed that neonates with alloimmune HDFN had a decreasing platelet 
count and an increasing clot-promoting activity (measured by the thromboplastin activation 
test in plasma) at birth associated with increase of disease severity.51 In 1979, a report was 
published by Hey and Jones on coagulation failure in Rh alloimmunization.52 They found 
very low vitamin-K dependent coagulation factor levels in cord blood of seven infants with 
severe disease probably caused by liver damage in utero. Five severely diseased infants died 
of pulmonary or cerebral hemorrhages. In addition, they demonstrated a strong correlation 
between platelet count and hemoglobin level at birth. Infants with a cord blood hemoglobin 
level of <10 g/dL (6.2 mmol/L) had a platelet count <150 × 109/L.52
The exact etiology of thrombocytopenia in alloimmune HDFN is still unknown, but several 
mechanisms have been suggested including increased immunological destruction and/or 
bilirubin toxicity53, sequestration of platelets due to hypersplenism52, dilution due to platelet 
poor (intrauterine) erythrocyte transfusions54, increased consumption (disseminated 
intravascular coagulation)55 and decreased production. Koenig et al. suggested a decreased 
platelet production in favor of increased erythrocyte production.56 In their study group of 
20 neonates with Rh HDFN, eleven neonates with hydrops (severe disease) or who were 
treated with ET (moderate disease) had thrombocytopenia and none of the nine neonates 
without hydrops or ET had thrombocytopenia. The thrombocytopenic neonates did not 
have an increased platelet volume. In a severely affected neonate, they also demonstrated 
that the in vitro maturation of multipotent progenitor cells was altered, with a greater 
proportion of normoblasts, and fewer neutrofils and megakaryocytes. The significant 
higher incidence of thrombocytopenia in hydropic (more severely affected) fetuses 
and the negative correlation between reticulocyte and platelet count that Saade et al. 
demonstrated, also supports the decreased platelet production theory.57
Because IUT has improved significantly over the years, severe hemolytic disease with 
hydrops has become less common nowadays. In a recent large study (Chapter 9) we 
demonstrated that 26% (94/362) and 6% (20/362) of neonates with alloimmune HDFN had 
thrombocytopenia (platelet count <150 × 109/L) and severe thrombocytopenia (platelet 
count <50 × 109/L) at birth, respectively. Risk factors that were independently associated 
with thrombocytopenia included treatment with IUT, being small for gestational age and a 
lower gestational age at birth. Although fetal hydrops was not significant at the 5% level, 
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the relative low p-value (p = 0.083) is suggestive of a possible independent association with 
thrombocytopenia at birth. Only one neonate had clinical signs of bleeding at birth. This 
hydropic premature infant with a platelet count of 53 × 109/L at birth had an intraventricular 
hemorrhage (IVH) grade 2 on day one.
In our center a concentrated platelet transfusion in a dose of 20 × 109/kg is given if: 1) 
platelet count is <20 × 109/L in clinically stable neonates; 2) platelet count is <50 × 109/L  in 
neonates with a manifest bleeding, those undergoing a procedure with a risk of bleeding 
and in clinically unstable neonates weighing <1500 grams and of <32 weeks of gestation, 3) 
platelet count is <100 × 109/L before ET (halfway the ET a platelet transfusion is performed). 
However, the causal relationship between thrombocytopenia and IVH in preterm infants 
is controversial.58-60 Moreover, platelet transfusion are also occasionally associated with 
adverse effects such as transfusion reactions and transmission of infectious agents.61,62 
In addition, the role of platelet transfusions in preventing bleeding is still unclear in 
neonates.63 
Cholestasis
Few studies, mostly case-reports, have reported on the occurrence of conjugated 
hyperbilirubinemia, i.e. cholestasis, in alloimmune HDFN.64-67 Cholestasis in neonates 
with alloimmune HDFN has been associated with iron overload due to IUTs.49,65,68,69 
Other suggested etiologic mechanisms include overload of pigment causing stasis and 
blocking of bile canaliculi; liver necrosis caused by hypoxia due to anemia; and pressure 
by extramedullary hematopoiesis in the liver caused by anemia leading to damage of 
intrahepatic canaliculi.70 In Chapter 10 we evaluated the incidence, potential risk factors, 
management and outcome of cholestasis in 313 neonates with alloimmune HDFN due to 
various anti-RBC antibody specificities. Cholestasis occurred in 13% and was independently 
associated with IUT treatment and Rh D antibodies. However, 88% of cholestatic neonates 
had both Rh D HDFN and were treated with IUT, preventing reliable distinction between 
both risk factors. Extensive tests to rule out other causes of cholestasis were all negative. 
However, they were not performed in all neonates with cholestasis. In almost half of the 
patients cholestasis resolved spontaneously within 1 week to 3 months after birth. In the 
other half of the patients, measurements of bilirubin and liver enzymes were not monitored 
until they reached normal values. Median maximum ferritin levels during admission were 
significantly higher in cholestatic neonates than in the non-cholestatic neonates (1191 
(range: 489-73000) μg/L and 657 (range: 86-10195) μg/L, p = <0.001). In addition, maximum 
ferritin level and treatment with IUT were positively correlated (r = 0.565, p = <0.001). One 
cholestatic patient with severe hyperferritinemia was treated with iron chelation therapy. 
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Iron overload
Ferritin reflects total body iron stores and age-appropriate levels are used to determine 
iron deficiency and iron overload. In healthy term newborns median ferritin levels at birth 
of 134-141 μg/L have been reported.71,72 Mean ferritin levels at birth have been reported 
to range from 101 μg/L to 183 μg/L.73,74 After birth, ferritin levels rise to a mean level of 
226-356 μg/L and than decrease progressively over the following months to a mean level 
around 30 μg/L at the age of 6 months.71,74,75 Although it is known that ferritin levels in 
the fetal period and at birth can be highly elevated in neonates with alloimmune HDFN, 
the course of ferritin levels in the following months after birth was not known.49,68,69 We 
therefore prospectively collected data on the iron status of 35 neonates with alloimmune 
HDFN treated with or without IUT (Chapter 11). We found that iron overload occurred in 
70% (23/33) of neonates with alloimmune HDFN at birth, 50% (10/20) at the age of one 
month, 42% (5/12) at the age of two months and 18% (2/11) at the age of three months. 
We found no cases of iron deficiency at birth and only one term infant had iron deficiency 
at three months of age based on the for this study defined criterion for iron deficiency (<40 
μg/L). Whether this infant, who received one IUT and no postnatal transfusions, would 
have benefitted from iron supplementation is not clear. In our cohort, none of the infants 
received iron supplementation. We recommend to measure iron status before starting 
iron supplementation in infants with alloimmune HDFN because iron deficiency as well as 
iron overload can have detrimental effects. Iron deficiency and overload have both been 
associated with neurodevelopmental impairment.72 Iron overload can also lead to damage 
to the liver, heart and endocrine organs and increase susceptibility to infection.72 In adults 
with hereditary hemochromatosis ferritin levels >1000 μg/L have been associated with 
increased risk for liver cirrhosis.76 To assess the long term outcome of iron overload and 
deficiency in infants with alloimmune HDFN more research is warranted.
Leukocytopenia
As shown in Chapter 4, leukocytopenia is a common complication after ET with leukocyte-
depleted donor blood. However, Koenig et al. demonstrated that neutropenia was also 
present before ET in four hydropic neonates with Rh HDFN. They also showed that erythroid 
progenitors were increased and granulocyte-macrophage progenitors were decreased in 
two severely affected neonates.56 Segal et al. described two hydropic neonates with Rh 
HDFN and neutropenia who were successfully treated with recombinant human granulocyte 
colony-stimulating factor.77 These scarce data are insufficient to be conclusive on the 




In conclusion, this thesis focuses on several aspects related to the hematological 
outcome of infants with HDFN due to RBC alloimmunization, including pathogenesis and 
management of the disease. The presence of leukocytopenia and thrombocytopenia 
support the mechanism of suppression of thrombopoiesis and granulopoiesis in favor of 
the increased erythropoiesis stimulated by anemia and hypoxia. In addition to the problems 
caused by a shortage of platelets and white and red blood cells, the excess of the RBC 
metabolites bilirubin and iron also contribute to the morbidity of the disease. Based on our 
systematic review we can also conclude that there is a lack of high level evidence promoting 
the use of IVIG. Irrespective of the controversy concerning the use of IVIg, our data show 
that intensive follow-up is indicated in both Rh D and non-Rh D HDFN and raised awareness 
about the associated morbidity is of paramount importance. 
Although a few questions are answered in this thesis, it yielded much more questions 
to answer. In the next and final chapter, some of these future research questions are 
discussed.
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In 1932 Diamond et al. reported that hemolysis of fetal and neonatal red blood cells 
(RBCs) resulted in extramedullary hematopoiesis causing hepatosplenomegaly and a high 
proportion of erythroblasts in the circulation.1 Since this description of the pathophysiologic 
mechanism of alloimmune HDFN, then called erythroblastosis fetalis, numerous discoveries 
in prenatal and postnatal care have led to a significant decrease in perinatal morbidity 
and mortality.2 However, currently there are still several aspects of the pathogenesis, 
management and outcome of alloimmune HDFN that require further investigation. 
Pathogenesis
The cause of late hyporegenerative anemia is still unclear. The following mechanisms 
have been suggested: intramedullary destruction of RBC precursors and of circulating 
reticulocytes by RBC antibodies, bone marrow suppression from IUTs, and inappropriate 
low erythropoietin production for the degree of anemia. 3-6 Burk et al. showed anti-D 
antibody bound to Rh D positive erythrocytes in the bone marrow in an infant with a high 
persistent antibody titer.7 When antibody titer was fallen to 1:64 at eleven weeks, the 
first evidence of peripheral reticulocyte survival was observed.7 Late hyporegenerative 
anemia was already described before the introduction of IUT in 1963 and thereafter was 
also observed in infants who were not treated with IUT.6 Dallacasa et al. reported that 
reticulocyte counts, hemoglobin and erythropoietin (EPO) levels were similar in IUT and 
non-IUT treated neonates with Rh D alloimmune HDFN.8 In contrast, in a study by De 
Boer et al. the percentage of neonates requiring top-up transfusions was significantly 
higher for IUT-treated neonates than non-IUT-treated neonates with Rh HDFN.9 Studies 
that measured EPO-levels conclude differently on whether EPO-levels are appropriate for 
the degree of anemia or not.3,5,6 Several small studies and casuistic reports suggest that 
neonates with alloimmune HDFN may benefit from treatment with recombinant human 
erythropoietin (rhEPO) to reduce the risk of delayed anemia and subsequent need for 
top-up transfusions.10-15 However, other authors found that rhEPO may be less effective 
than expected.8,16 Pessler et al. suggested that rhEPO might be ineffective when antibody 
titers are high.16 This theory from Pessler sounds plausible since RhEPO in these neonates 
will produce erythrocytes that can be covered by circulating antibodies and subsequently 
destructed. 
Future randomized controlled trials on the effectiveness of rhEPO in preventing late anemia 





Several pharmacological antenatal management options for alloimmune HDFN deserve 
further study, including phenobarbital, IVIg and corticosteroids.
Phenobarbital
Antenatal maternal administration of phenobarbital (30 mg 3 times a day for 7-10 days) 
significantly reduced the need for ET in neonates with HDFN due to RBC alloimmunization 
in a recent retrospective study by Trevett et al.17 In neonates with and without antenatal 
maternal administration of phenobarbital, ET was performed in 9% and 52%, respectively 
(p=<0.01). Phenobarbital has been shown to improve the capability of the neonatal liver 
to conjugate and eliminate bilirubin. Because of the immaturity of the hepatic conjugation 
pathways, premature infants are at greater risk of requiring ET for hyperbilirubinemia. 
Mainly premature infants were included in the study by Trevett et al. (mean gestational 
age in ET and no-ET group 33.0 and 35.4 weeks, respectively). Although the effect of 
phenobarbital remained significant in reducing the need for ET after Trevett et al. adjusted 
for gestational age, antenatal maternal administration of phenobarbital might be more 
effective in premature infants with alloimmune HDFN.17  
IVIg 
Several case series and retrospective studies show that antenatal maternal administration 
of IVIg improves perinatal outcome in Rh D and Kell HDFN.18-30 Only Chitkara et al. 
concluded after studying the effect of maternal IVIg in 5 cases with alloimmune HDFN, 
that this treatment does not appear useful in Rh D HDFN.31 Suggested mechanism of 
action of maternal administration of IVIg include: decrease of maternal antibodies by 
suppression of production or enhanced clearance, competitive inhibition of anti-D transport 
to the fetus and the inhibition of phagocytosis of fetal antibody-coated red cells by the 
fetal reticuloendothelial system. Maternal administration of IVIg can not compete with 
the excellent outcome of IUT treatment but may play an additional role in early hydrops 
that developed before the 18th week and less eligible for IUT. Fetal administration of IVIG 
is another option. A great advantage of fetal administration compared with maternal 
administration is the lower cost since IVIg is dosed per kilogram of body weight. For that 
reason fetal infusion of IVIg has also been studied.32-34 Although the case report of Alonso et 
al. and the case series of Kriplani et al. showed promising results32,34, a small RCT including 
20 fetuses with severe Rh D HDFN by Dooren et al. showed no significant differences in the 
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transfusion requirements or clinical outcome. However the dose used in this trial was too 
low to reach reliable conclusions on the effect.33
Corticosteroids
Labor is often induced in pregnancies that are complicated by red cell alloimmunization 
because of the risks of an additional necessary IUT. Late preterm (34 0/7 to 36 6/7 weeks 
of gestation) and early term (37 0/7 to 38 6/7 weeks of gestation) births are therefore no 
exception. Recent studies show that late preterm and early term births have a higher rate 
of morbidity, especially relating to respiratory function and long-term neurodevelopmental 
outcome, than infants born at 39 weeks of gestation.35,36 In line with this, it should be 
evaluated if there is a role for maternal administration of corticosteroids to prevent 
respiratory complications at birth in infants with alloimmune HDFN. A Cochrane review 
published in 2006 showed that antenatal corticosteroids significantly reduced the rate of 
respiratory distress syndrome in neonates (without HDFN) born between 33 0/7 and 34 6/7 
weeks of gestation (RR 0.53, 95% CI 0.31 to 0.91, 2 RCTs, 434 infants), but not in neonates 
born between 35 0/7 and 36 6/7 weeks of gestation (RR 0.61, 95% CI 0.11 to 3.26, 1 RCT, 
189 infants).37 In 2011 a randomized placebo-controlled trial by Porto et al. showed that 
12 mg Betamethasone for two consecutive days at 34 0/7 to 36 6/7 weeks of non-HDFN 
pregnancy does not reduce the incidence of respiratory disorders in neonates.38 However, 
the risk of jaundice requiring phototherapy was significantly lower in the group treated with 
antenatal corticosteroids (RR 0.63, 95% CI 0.44 to 0.91).38 This finding makes it especially 
interesting to study the effectiveness of antenatal corticosteroids in neonates with 
alloimmune HDFN who nearly all require phototherapy.
Intrauterine transfusions
Although IUTs are performed since the 1960s, there are still some aspects to be taken into 
consideration for future research in alloimmune HDFN. In our center, IUTs are performed 
mainly intravascular to treat fetal anemia. However, a combination of intravascular and 
intraperitoneal IUT might achieve a more stable fetal Ht and a longer interval between 
transfusions.39-41 This topic deserves further study in a randomized controlled trial. 
Another technical aspect of IUT that requires further investigation is the effect of analgesia 
on the fetal hormonal and hemodynamic stress response in case of intrahepatic vein 
needling.42
Further research is also required to evaluate the benefits and harms associated with 





Recently, an RCT that compared two-stage single-volume ET (TSSV-ET) with single-
stage double-volume ET (SSDV-ET) in full-term neonates with HDFN due to Rh or ABO 
incompatibility showed promising results.44 The mean rebound bilirubin level (measured 
3 hours after ET) was significantly lower in the TSSV-ET group compared to the SSDV-ET 
group (12.7 ± 1.1 mg/dL versus 17.3 ± 1.7 mg/dL, p=<0.001). Also the need for repeated ET 
was significantly lower in the TSSV-ET group compared to the SSDV-ET group (13.5% versus 
32.7%, p=<0.05). In addition, complications of ET (sepsis, NEC, pulmonary hemorrhage) and 
mortality were not significantly different between both groups. Authors suggested that the 
beneficial effect of TSSV-ET lies in lowering rebound bilirubin because extravascular bilirubin 
has more time to distribute to the intravascular space.44
Likewise, antibodies also have a longer period to distribute between the extravascular and 
intravascular space and consequently a lower antibody titer and duration and severity of 
late anemia could be expected. However, the authors did not measure the number of top-
up transfusions or antibody titers. 
Future RCTs should preferably include a more homogenous group of neonates (only Rh 
HDFN or ABO HDFN) and should also measure duration of phototherapy and the number op 
top-up transfusions to evaluate all possible benefits of TSSV-ET compared to SSDV-ET.
IVIg
Based on the results of the Cochrane review in Chapter 6 it can be concluded that the 
effectiveness of neonatal administration of IVIg in alloimmune HDN is still controversial. 
Future research into the role of neonatal administration of IVIg in alloimmune HDN may 
particularly be warranted in infants for whom ET is considered to be high risk or not 
available. 
Prophylactic antibiotics
In Chapter 4 we demonstrated that leukocytopenia and sepsis are common complications 
of ET. Whether ET-related removal of leukocytes may play a role in the higher incidence of 
sepsis after ET deserves further study. However, it might be more interesting to evaluate the 
role of prophylactic antibiotics to prevent sepsis after ET in alloimmune HDFN because the 
higher incidence of sepsis is probably caused by manipulating the umbilical venous catheter 
during ET. A recent Cochrane review on the use of prophylactic antibiotics to reduce 
morbidity and mortality in neonates with umbilical venous catheters only included one 
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study which was of poor quality.45 This quasi-RCT, performed in 1984, included 23 infants 
who required ET for hyperbilirubinemia and 6 infants who required partial ET for hematocrit 
> 0.70.46 Although 5 of 15 infants given antibiotics and 5 of 14 control infants having positive 
blood cultures three days after catheterization, all positive blood cultures were considered 
contaminated due to lack of clinical and hematological evidence of infection.
Top-up transfusion and medicaments for late anemia
The optimal transfusion trigger for top-up transfusions in alloimmune HDN should be 
taken into consideration for future research. Guidelines for RBC transfusions in neonates 
vary greatly between and within countries. Possible advantages of restrictive transfusion 
guidelines are reduction of total transfusions and donor exposure. However, some studies 
reported worse short-term neurological or long-term neurodevelopmental outcome 
in those treated with restrictive transfusion guidelines compared to liberal transfusion 
guidelines.47,48   
As previously mentioned in this chapter, RCTs to evaluate the use of rhEPO to prevent late 
anemia and consequently top-up transfusions are required. RhEPO has been increasingly 
used in neonates to prevent or reduce neonatal anemia without short or long-term adverse 
effects and might even work neuroprotective.14,49-52
Another benefit of rhEPO in alloimmune HDN could be lowering ferritin levels in neonates 
with iron overload/cholestasis. However, studies should monitor ferritin levels to prevent 
iron deficiency.
Folic acid and Vitamin E are often used in infants with alloimmune HDFN to support 
erythropoiesis.53 However, no high-quality studies are performed so far to evaluate the 
efficacy of those supplements in reducing the severity of anemia. Further well-designed 
studies are required.
Long term outcome
There is lack of long-term follow-up studies in alloimmune HDFN. The neurodevelopmental 
outcome in IUT treated infants with alloimmune HDFN has recently been reported.54 
However, studies that evaluate long term effects on the immune system and liver function 
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Hemolytische ziekte van de foetus en de pasgeborene (HZFP) is een aandoening waarbij 
rode bloedcellen van de foetus/pasgeborene worden afgebroken door antistoffen 
(afweerstoffen) die van de moeder afkomstig zijn. 
Op de rode bloedcellen zitten eiwitten (bloedgroepantigenen) die de bloedgroep bepalen. 
Deze bloedgroepantigenen zijn niet bij alle mensen hetzelfde. Een voorbeeld van een 
dergelijk bloedgroepantigeen is rhesus-D. Als de rode bloedcellen van een moeder dit 
bloedgroepantigeen niet bevatten (rhesus-D-negatief) en die van haar foetus wel (rhesus-
D-positief), dan kan de moeder antistoffen (rhesus-D-antistoffen) gaan maken tegen de 
bloedcellen van haar kind. Dit proces, dat zwangerschapsimmunisatie genoemd wordt, 
kan ontstaan als bloedcellen van de foetus in de bloedbaan van de moeder terecht 
komen. Dit gebeurt meestal tijdens de bevalling, maar kan ook in de laatste drie maanden 
van de zwangerschap ontstaan. Als tijdens een zwangerschap of de bevalling rhesus-D-
antistoffen zijn gevormd, is het afweersysteem van de moeder geactiveerd. Bij een volgende 
zwangerschap van een rhesus-D-positief kind reageert het afweersysteem van de moeder 
snel met het aanmaken van rhesus-D-antistoffen als bloed van de foetus in de bloedbaan 
van de moeder terecht komt. Deze antistoffen kunnen via de placenta bij de foetus terecht 
komen en daar voor afbraak van de rode bloedcellen (hemolyse) van de foetus zorgen. Dit 
kan leiden tot bloedarmoede (anemie) bij de foetus. Soms is de bloedarmoede zo ernstig 
dat één of meerdere zogenaamde intra-uteriene bloedtransfusies (IUTs) nodig zijn. Deze  
IUTs worden in de foetus zelf toegediend via de navelstreng of een lever vene.
Ook na de geboorte kan anemie een probleem zijn en daarnaast kan het kind geel gaan 
zien (icterus) en ziek worden van de ophoping van bilirubine, een afbraakproduct van de 
rode bloedcellen, in het bloed en in de weefsels. Het teveel aan bilirubine in het bloed 
(hyperbilirubinemie) moet behandeld worden omdat het schadelijk kan zijn voor de 
hersenen. Bilirubine wordt in de lever omgezet in een wateroplosbare vorm die via de gal 
en urine kan worden uitgescheden. Deze omzetting wordt conjugatie genoemd. Bij ernstige 
hyperbilirubinemie kan de lever niet al het bilirubine omzetten en kan het ongeconjugeerde 
bilirubine, dat de bloed-hersen-barrière kan passeren, zich afzetten in het hersenweefsel 
en tot ernstige hersenschade (kernicterus) met blijvende neurologische verschijnselen en 
gehoorverlies leiden en zelfs tot overlijden.
De behandeling van hyperbilirubinemie begint met intensieve fototherapie, waarbij het 
ongeconjugeerde bilirubine onder invloed van licht wordt omgezet in een wateroplosbare 
vorm. Als het bilirubine in het bloed ondanks de fototherapie verder blijft stijgen, kan een 
wisseltransfusie noodzakelijk zijn. Bij een wisseltransfusie wordt het bloed van het kind 
vervangen door donorbloed door steeds kleine hoeveelheden bloed van het kind af te 
nemen en hier donorbloed voor terug te geven via een katheter in de navel. In totaal wordt 
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meestal tweemaal het circulerend bloedvolume van de pasgeborene gewisseld (160 ml/kg). 
Met een wisseltransfusie worden bilirubine en antistoffen verwijderd en wordt eventuele 
anemie behandeld. 
De antistoffen kunnen na de geboorte nog een aantal maanden in het bloed van het kind 
aanwezig zijn en voor afbraak van rode bloedcellen zorgen. Rode bloedceltransfusies (top-
up transfusies) bij kinderen met HZFP kunnen tot ongeveer drie maanden na de geboorte 
noodzakelijk zijn. 
Naast bloedarmoede kunnen de volgende hematologische problemen voorkomen bij HZFP: 
te laag aantal bloedplaatjes (trombocytopenie) en witte bloedcellen (leukocytopenie), 
stollingsstoornissen en ijzerstapeling. 
In Hoofdstuk 2 wordt een samenvatting van de literatuur gegeven van de hematologische 
problemen die bij HZFP kunnen voorkomen. Tevens worden de behandelingsopties van deze 
problemen besproken. 
Deel 1 Wisseltransfusies
In Hoofdstuk 3 beschreven wij het effect van de verandering in onze richtlijn fototherapie 
en wisseltransfusies op de bloedtransfusiebehoefte van kinderen met HZFP. In december 
2005 zijn naar aanleiding van aanbevelingen van de American Academy of Pediatrics de 
wisseltransfusie-criteria in ons centrum aangepast. Door deze aanpassing hoefde veel 
minder vaak een wisseltransfusie uitgevoerd  te worden. Voor deze studie hebben wij het 
aantal wisseltransfusies en top-up transfusies vergeleken tussen een groep (bijna) voldragen 
pasgeborenen met HZFP die volgens de oude richtlijn werden behandeld (groep 1, n=156) 
met pasgeborenen met HZFP die volgens de nieuwe richtlijn werden behandeld (groep 2, 
n=27). Het percentage pasgeborenen bij wie een wisseltransfusie werd uitgevoerd daalde 
van 66% (103/156) in groep 1 naar 26% (7/27) in groep 2. Het percentage pasgeborenen 
aan wie een top-up transfusie werd gegeven steeg echter van 68% (105/154) in groep 1 
naar 81% (22/27) in groep 2. Het aantal top-up transfusies was significant hoger in groep 
2 dan in groep 1. Wij hebben hiermee aangetoond dat de nieuwe richtlijn heeft geleid tot 
sterke vermindering van het aantal wisseltransfusies, maar ook een toename van het aantal 
top-up transfusies. 
In Hoofdstuk 4 rapporteerden wij de resultaten van een studie naar de complicaties 
van wisseltransfusies bij pasgeborenen met HZFP. Een wisseltransfusie is een risicovolle, 
invasieve procedure waarbij katheters in de bloedbaan (meestal in de navelstrengader) 
worden gebracht. Bijwerkingen die beschreven zijn omvatten onder andere: infecties, 
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elektrolytstoornissen, hematologische complicaties en cardiorespiratoire complicaties. Wij 
hebben bij in totaal 347 pasgeborenen met HZFP gekeken naar het aantal complicaties ten 
gevolge van wisseltransfusies. Daartoe hebben wij alle complicaties geregistreerd van alle 
pasgeborenen met HZFP die ten minste één wisseltransfusie hebben ondergaan (ET-groep, 
n=134) en vergeleken met degenen die geen wisseltransfusie hebben ondergaan (niet-
ET-groep, n=213). Vergelijking tussen ET-groep en niet-ET-groep liet zien dat behandeling 
met wisseltransfusie onafhankelijk geassocieerd is met: klinisch beeld van sepsis 
(bloedvergiftiging) met positieve bloedkweek (8% in ET-groep versus 1% in niet-ET-groep), 
leukocytopenie (88% versus 23%), ernstige trombocytopenie (bloedplaatjes <50 x 109/L) 
(63% versus 8%), hypocalciëmie (te laag calciumgehalte in het bloed) (22% versus 1%) en 
hypernatriëmie (te hoog natriumgehalte in het bloed) (8% versus 0%). Deze complicaties 
waren allemaal van voorbijgaande aard en neonatale sterfte kwam niet voor in de ET-groep. 
Uit deze studie kunnen wij dus opmaken dat permanente ziekte en sterfte ten gevolge van 
wisseltransfusies bij pasgeborenen met HZFP in ervaren handen tot een minimum beperkt 
kan worden.
Deel 2 Intraveneus immunoglobulinen
Omdat een wisseltransfusie een invasieve, risicovolle procedure is, wordt naar alternatieve 
behandelingen voor hyperbilirubinemie gezocht. Eén van deze alternatieven is intraveneus 
immunoglobulinen (IVIg). In de Amerikaanse richtlijn uit 2004 wordt geadviseerd om 
IVIg toe te dienen aan pasgeborenen met HZFP als fototherapie niet voldoende is om de 
hyperbilirubinemie te behandelen. Deze richtlijn was echter gebaseerd op kleine studies 
met kwalitatieve beperkingen. De Cochrane review uit 2002 die het effect van IVIg op het 
aantal wisseltransfusies onderzocht, concludeerde dat meer studies (van hoge kwaliteit) 
noodzakelijk waren om een uitspraak over het effect van IVIg te kunnen doen.
In Hoofdstuk 5 hebben wij in het Leids Universitair Medisch Centrum met een 
gerandomiseerde dubbelblinde placebo-gecontroleerde studie (LIVIN-studie) onderzocht 
of het vlak na de geboorte  geven van IVIg  (0.75 g/kg) het aantal wisseltransfusies kan 
verminderen bij pasgeborenen met HZFP door rhesus-D- of rhesus-c-antistoffen. In totaal 
kregen 41 pasgeborenen IVIg en 39 pasgeborenen een placebo (glucose 5% oplossing 
via het infuus). Het percentage pasgeborenen dat ten minste één wisseltransfusie nodig 
had, was niet verschillend tussen de IVIg-groep en placebogroep (17% versus 15% 
respectievelijk). Ook de duur van de fototherapie (4.7 versus 5.1 dagen), de gemiddelde 
maximale bilirubine waarde tijdens opname (14.8 versus 14.1 mg/dL) en het percentage 
pasgeborenen dat ten minste één top-up transfusie in de eerste drie maanden na de 
Nederlandse samenvatting
239
geboorte nodig had (83% versus 87%) was niet verschillend tussen beide groepen. Deze 
bevindingen ondersteunen het standaard gebruik van IVIg bij het falen van fototherapie 
niet.
In Hoofdstuk 6 beschreven wij de resultaten van de update van de Cochrane review uit 
2002 die het effect van IVIg op het aantal en de noodzaak voor wisseltransfusies onderzocht 
bij pasgeborenen met HZFP. Voor dit onderzoek (meta-analyse) hebben we de resultaten 
van veertien (quasi-) gerandomiseerde studies met een controlegroep samengevoegd om 
een betrouwbaardere uitspraak te kunnen doen over het effect van IVIg. Slechts twee van 
de veertien studies (waaronder de LIVIN-studie) waren van hoge kwaliteit. Meta-analyse 
van alle veertien onderzoeken, met in totaal 942 kinderen, toonde een vermindering in het 
aantal en de noodzaak voor wisseltransfusies bij pasgeborenen die met IVIg en fototherapie 
behandeld werden vergeleken met pasgeborenen die met alleen fototherapie (en eventuele 
placebo) werden behandeld. Echter, analyse van de twee studies van hoge kwaliteit toonde 
geen vermindering van het aantal en de noodzaak voor wisseltransfusies wanneer IVIg werd 
gecombineerd met intensieve fototherapie. In acht studies werd het effect van IVIg op de 
top-up transfusiebehoefte voor late bloedarmoede onderzocht. Meta-analyse van deze 
studies toonde geen verschil in het aantal en de noodzaak voor top-up transfusies tussen 
pasgeborenen die met en zonder IVIg werden behandeld. Op basis van het bewijs van de 
twee studies van hoge kwaliteit kan geconcludeerd worden dat IVIg niet effectief is in het 
voorkomen van wisseltransfusies of top-up transfusies en moet routinematig gebruik van 
IVIg bij pasgeborenen met HZFP worden afgeraden. Aangezien er wel aanwijzingen zijn (in 
laboratoriumstudies) dat IVIg hemolyse vermindert, zijn toekomstige hoge kwaliteit studies 
nodig om te bepalen of IVIg een beperkte rol heeft bij een selecte groep pasgeborenen 
met HZFP, bijvoorbeeld wanneer een wisseltransfusie niet tijdig of zonder hoog risico op 
complicaties kan worden uitgevoerd.
Deel 3 Alloimmunisaties anders dan rhesus-D
Anti-Kell en anti-c zijn na anti-D de belangrijkste antistoffen die ernstige HZFP veroorzaken 
waarvoor IUT vaak noodzakelijk is. Anti-Kell is, na anti-D, ook de meest voorkomende 
antistof die HZFP in Nederland veroorzaakt. Kell HZFP heeft waarschijnlijk een andere 
pathogenese (ontstaanswijze van ziekte) dan rhesus-D HZFP. Kell HZFP lijkt meer een 
probleem van de aanmaak van rode bloedcellen dan van afbraak (hemolyse) van 
rode bloedcellen. Net zoals bij rhesus-D HZFP kunnen bij pasgeborenen met Kell HZFP 
bloedtransfusies noodzakelijk zijn tot enkele maanden na de geboorte. 
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In Hoofdstuk 7 hebben we bekeken of de incidentie en ernst van anemie verschilt tussen 
pasgeborenen met rhesus-D en Kell HZFP. Wij vonden dat pasgeborenen met Kell HZFP 
minder fototherapie (2.4 versus 4.1 dagen) en wisseltransfusies (6% versus 62%) nodig 
hadden dan pasgeborenen met rhesus-D HZFP. De noodzaak van en het aantal top-up 
transfusies en het aantal dagen na de geboorte tot de eerste top-up transfusie waren niet 
significant verschillend tussen beide groepen. Onze resultaten laten zien dat kinderen met 
Kell HDFN een ander beleid vlak na de geboorte vereisen (minder fototherapie en minder 
wisseltransfusies), maar hetzelfde follow-up beleid als kinderen met rhesus-D HZFP.
In Hoofdstuk 8 hebben we in een vergelijkbare studie als Hoofdstuk 7 de uitkomsten 
vergeleken tussen kinderen met rhesus-c HZFP en rhesus-D HZFP. We vonden dat kinderen 
met rhesus-c HZFP gemiddeld eerder en vaker een IUT nodig hadden dan kinderen 
met rhesus-D HZFP (61% versus 41%). Het beloop na de geboorte was niet significant 
verschillend tussen de kinderen met rhesus-c en rhesus-D HZFP in termen van duur van 
fototherapie (gemiddeld 4.8 en 4.5 dagen), noodzaak voor een wisseltransfusie (50% 
versus 46%) en de noodzaak van top-up transfusies (62% versus 78%). Daarom is ook 
voor rhesus-c HZFP hetzelfde follow-up beleid als rhesus-D HZFP gerechtvaardigd. In deze 
studie hebben we ook onderzocht of de antistoftiter bij de geboorte gecorreleerd is met 
de transfusiebehoeften na de geboorte. We vonden een positieve correlatie tussen anti-
D-titer bij de geboorte en de noodzaak van en het aantal top-up transfusies. Daarnaast 
vonden we een positieve correlatie tussen anti-c-titer bij de geboorte en de noodzaak voor 
wisseltransfusie. 
Deel 4 Geassocieerde hematologische problemen
In Hoofdstuk 9 hebben we gekeken naar de incidentie en ernst van trombocytopenie bij 
de geboorte en de risicofactoren voor het krijgen hiervan onderzocht bij pasgeborenen 
met HZFP. Wij vonden dat 26% (94/362) trombocytopenie (bloedplaatjesgehalte <150 x 
109/L) en 6% (20/362) ernstige trombocytopenie (bloedplaatjesgehalte <50 x 109/L) bij de 
geboorte had. Eén pasgeborene met trombocytopenie had klinische symptomen van een 
bloeding (intraventriculaire bloeding graad 2) bij de geboorte. Zeer waarschijnlijk hebben 
de prematuriteit (te vroeg geboren zijn) van deze pasgeborene en hydrops (vochtophoping 
in organen/huid bij ernstige HZFP) ook meegespeeld in het ontwikkelen van de bloeding 
in de hersenen. We hebben drie risicofactoren voor het ontstaan van trombocytopenie bij 
de geboorte bij kinderen met HZFP gevonden: behandeling met IUT, dysmaturiteit (te laag 
geboortegewicht voor de zwangerschapsduur) en prematuriteit. 
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In Hoofdstuk 10 hebben we de incidentie, potentiële risicofactoren, het behandelbeleid 
en de uitkomsten van cholestase (verstoring van de galafvoer) bij pasgeborenen met 
HZFP bekeken. Cholestase is een ziekte van de lever waarbij het geconjugeerde bilirubine 
in het bloed te hoog is. De oorzaak van cholestase bij HZFP is niet precies bekend, maar 
lijkt samen te hangen met ijzerstapeling in de lever ten gevolge van (intra-uteriene) 
rode bloedceltransfusies. Cholestase kwam voor bij 13% (41/313) en was onafhankelijk 
geassocieerd met IUT behandeling en rhesus-D type immunisatie. Echter, 88% van de 
pasgeborenen met cholestase had zowel rhesus-D type immunisatie en werd behandeld 
met IUT, wat een betrouwbaar onderscheid tussen beide risicofactoren niet mogelijk maakt. 
Uitgebreide tests om andere oorzaken van cholestase uit te sluiten waren allen negatief 
(oorzaak niet aangetoond). Echter, ze werden niet bij alle pasgeborenen met cholestase 
uitgevoerd. In bijna de helft van de patiënten met cholestase herstelde dit spontaan 
binnen 1 week tot 3 maanden na de geboorte. In de andere helft van de patiënten werden 
bilirubine en leverenzymen in het bloed niet gecontroleerd tot zij normale waarden 
hadden bereikt. Eén patiënt met cholestase en ernstige ijzerstapeling werd behandeld met 
ontijzeringstherapie. Grotere vervolgstudies zijn nodig om het beloop en de oorzaak van 
cholestase bij kinderen met HZFP vast te stellen.  
In Hoofdstuk 11 hebben wij het beloop van de ijzerstatus in de eerste drie levensmaanden 
in het bloed bij kinderen met HZFP bestudeerd. We vonden ijzerstapeling (gedefinieerd als 
te hoog ferritine gehalte in het bloed voor de leeftijd) bij 70% (23/33) van de pasgeborenen 
bij de geboorte, bij 50% (10/20) op de leeftijd van één maand, bij 42% (5/12) op de leeftijd 
van twee maanden en bij 18% (2/11) op de leeftijd van drie maanden. IJzerdeficiëntie 
kwam niet voor in ons cohort, behalve bij één voldragen pasgeborene op de leeftijd van 
drie maanden op basis van het voor dit onderzoek bepaald criterium voor ijzerdeficiëntie 
(ferritine gehalte bloed <40 ug/L). Of dit kind, dat één IUT en geen postnatale transfusies 
heeft gehad, baat zou hebben gehad bij ijzersuppletie is niet duidelijk. In ons cohort 
kregen geen van de kinderen ijzersuppletie. Wij raden aan de ijzerstatus te meten voor het 
starten van ijzersuppletie bij kinderen met HZFP, omdat zowel ijzergebrek als ijzerstapeling 
nadelige effecten kunnen hebben. Om de lange termijn uitkomsten van ijzerstapeling en 
ijzerdeficiëntie bij kinderen met HZFP in kaart te brengen, is meer onderzoek nodig.
Conclusie 
Dit proefschrift richt zich op een aantal aspecten van de hematologische uitkomst van 
zuigelingen met HZFP als gevolg van zwangerschapsimmunisatie, inclusief de ontstaanswijze 
en het behandelbeleid van de ziekte. De aanwezigheid van trombocytopenie en 
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leukocytopenie ondersteunen het mechanisme van onderdrukking van de aanmaak van 
bloedplaatjes en witte bloedcellen door een verhoogde aanmaak van rode bloedcellen. 
Naast de problemen veroorzaakt door een tekort aan bloedplaatjes en witte en rode 
bloedcellen, draagt de overmaat van bilirubine en ijzer (metabolieten van rode bloedcellen) 
ook bij aan de morbiditeit van de ziekte. Op basis van onze systematische review kunnen 
we ook concluderen dat er onvoldoende bewijs is voor het gebruik van IVIg bij deze ziekte. 
Ongeacht de controverse over het gebruik van IVIg, blijkt uit ons onderzoek dat intensieve 
follow-up is aangewezen in zowel rhesus-D als niet-rhesus-D HZFP en bewustwording over 
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AAP  American Academy of Pediatrics
ADCC  Antibody Dependent Cellular Cytotoxicity
ALT  Alanine aminotransferase 
AST  Aspartate aminotransferase 
CI  Confidence interval
EPO  Erythropoietin
ET(s)  Exchange transfusions
FNAIT  Fetal/neonatal alloimmune thrombocytopenia
γGT  Gamma-glutamyl transpeptidase
Hb  Hemoglobin 
HELLP  (syndrome of) Hemolysis, Elevated Liver enzymes, Low Platelet counts
HDFN  Hemolytic disease of the fetus/newborn
HDN  Hemolytic disease of the newborn/neonate
Ht   Hematocrit
IgG  Immunoglobulin G
IQR  Interquartile range
ITP  Immune thrombocytopenic purpura
IUT(s)   Intrauterine transfusion(s)
IVIg  Intravenous immunoglobulin
LDH  Lactate dehydrogenase
LIVIN  Leiden’s IVIg trial in Rhesus disease of the Neonate
LUMC  Leiden University Medical Center
MCA  Middle cerebral artery
MD  Mean difference
MRI  Magnetic resonance imaging
NICU  Neonatal intensive care unit
NEC  Necrotizing enterocolitis
NNT  Number needed to treat
OR  Odds ratio
PIH  Pregnancy induced hypertension
PVT  Portal vein thrombosis
RBC  Red blood cell




rhEPO  Recombinant human erythropoietin
RR  Relative risk/risk ratio
SD  Standard deviation
SGA  Small for gestational age
TORCH  Toxoplasma gondii, Rubella virus, Cytomegalovirus, Herpes Simplex virus
TIBC  Total iron binding capacity
TSB  Total serum bilirubin
UVC  Umbilical venous catheter
